PT J
AU Kasymjanova, G
   Grossman, M
   Tran, T
   Jagoe, RT
   Cohen, V
   Pepe, C
   Small, D
   Agulnik, J
AF Kasymjanova, G
   Grossman, M
   Tran, T
   Jagoe, R T
   Cohen, V
   Pepe, C
   Small, D
   Agulnik, J
TI The potential role for acupuncture in treating symptoms in patients with lung
SO Current oncology (Toronto, Ont.)
LA English
DT Journal Article
DE Acupuncture; Edmonton Symptom Assessment System; esas; integrative oncology clinics; lung cancer; narcotics; pain
AB BACKGROUND: Most lung cancer patients experience multiple symptoms related either  to the disease or its treatment. The commonly reported symptoms are pain,  depression, anxiety, nausea, and poor well-being. The aim of the present study  was to evaluate the effect of acupuncture as a potential treatment modality in  symptomatic lung cancer patients. METHODS: This prospective observational study  enrolled 33 lung cancer patients from the Peter Brojde Lung Cancer Centre between  August 2010 and May 2012. All patients received 45-minute sessions of  acupuncture, 1-2 times weekly for a minimum of 4 sessions. Symptom severity was  assessed using the Edmonton Symptom Assessment System (esas) before and after  completion of acupuncture. RESULTS: The study cohort included 30 patients with  non-small- cell lung cancer and 3 with small-cell lung cancer. Mean age was 62  years (range: 36-88 years); 17 of the patients were women. Most of the patients  had advanced-stage cancer (73%) and good performance status (Eastern Cooperative  Oncology Group 0-1: 88%). Of these patients, 67% received anticancer treatment  (chemotherapy or radiotherapy, or both) with acupuncture. Of the remaining 10  patients, 8 received acupuncture after a complete surgical resection of their  tumour, and because of their advanced age, 2 received acupuncture and best  supportive care. The median number of acupuncture sessions was 7 (interquartile  range: 4-13 sessions). Statistically significant improvements in pain, appetite,  nausea, nervousness, and well-being were observed. A clinically important  improvement (2 points on the esas) was reported by 61% of patients for pain and  by 33% for well-being. A significant positive correlation between improved  well-being and the number of acupuncture sessions was observed. This correlation  remained significant even after controlling for treatment and narcotic use.  Receiver operating characteristic analysis demonstrated that a minimum of 6  acupuncture sessions are required for a 70% chance of a clinically important  improvement in well-being. CONCLUSIONS: The present study is the first to  demonstrate that acupuncture may be an effective approach for improving  symptoms-in particular, pain and well-being-in lung cancer patients. Acupuncture  is a safe and minimally invasive procedure, and it is potentially useful even in  patients undergoing anticancer treatment.
C1 Peter Brojde Lung Cancer Centre, Montreal, QC. 
   Jewish General Hospital, Montreal, QC.
NR 0
TC 0
SN 1718-772
EI 1198-005
J9 Curr Oncol
PD JUN 6
PY 2013
VL 20
IS 3
BP 152
EP 7
DI 10.3747/co.20.1312
PG -145
UT PubMed:23737683
PM 23737683
DA 2013-06-06
ER

PT J
AU Lu, WD
   Rosenthal, DS
AF Lu, Weidong
   Rosenthal, David S.
TI Acupuncture for Cancer Pain and Related Symptoms
SO CURRENT PAIN AND HEADACHE REPORTS
LA English
DT Review
DE Acupuncture; Acupuncture protocol; Aromatase inhibitor-associated joint pain; Cancer pain; Chemotherapy-induced neuropathy; Clinical practice; Clinical trials; Electroacupuncture; Evidence; Neck dissection-related pain; Oncology acupuncture; Opioid-induced constipation; Opioid-induced pruritus; Postoperative cancer pain; Postoperative nausea and vomiting; Postsurgical gastroparesis syndrome
ID low-back-pain; integrative oncology; controlled-trial; complementary therapy; postoperative nausea; electroacupuncture; management; placebo; outpatients; expression
AB Cancer pain is one of most prevalent symptoms in patients with cancer. Acupuncture and related techniques have been suggested for the management of cancer pain. The National Comprehensive Cancer Network guidelines for adult cancer pain recommends acupuncture, as one of several integrative interventions, in conjunction with pharmacologic intervention as needed. This review presents the latest available evidence regarding the use of acupuncture for cancer pain. It also provides "actionable" acupuncture protocols for specific cancer pain conditions and related symptoms in order to provide more clinically relevant solutions for clinicians and cancer patients with pain. These conditions include postoperative cancer pain, postoperative nausea and vomiting, postsurgical gastroparesis syndrome, opioid-induced constipation, opioid-induced pruritus, chemotherapy-induced neuropathy, aromatase inhibitor-associated joint pain, and neck dissection-related pain and dysfunction.
C1 [Lu, Weidong; Rosenthal, David S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard Medical School
RP Lu, WD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies, 44 Binney St, Boston, MA 02115 USA.
EM weidong_lu@dfci.harvard.edu
FU National Center for Complementary and Alternative Medicine (NCCAM) [1K01 AT004415]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Anderson KO, 2002, CANCER, V94, P2295, DOI 10.1002/cncr.10414
   Unknown -, 2012, APPRAISAL OF CLINICAL PRACTICE GUIDELINES, V0, P0
   Arce DA, 2002, AM FAM PHYSICIAN, V65, P2283
   Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1
   Cassileth B, 2006, ONCOLOGY-NY, V20, P1302
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   ECKHAUSER FE, 1988, ANN SURG, V208, P345, DOI 10.1097/00000658-198809000-00012
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Fisch MJ, 2012, J CLIN ONCOL, V30, P1980, DOI 10.1200/JCO.2011.39.2381
   Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482
   Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761
   Green CR, 2003, J PAIN, V4, P29, DOI 10.1054/jpai.2003.5
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Han JS, 2011, PAIN, V152, PS41, DOI 10.1016/j.pain.2010.10.012
   HAN JS, 1982, ADV BIOCHEM PSYCHOPH, V33, P369
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Jiang YH, 2010, CHIN J INTEGR MED, V16, P71, DOI 10.1007/s11655-010-0070-7
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kaptchuk TJ, 2011, PHILOS T R SOC B, V366, P1849, DOI 10.1098/rstb.2010.0385
   Kautio AL, 2011, SUPPORT CARE CANCER, V19, P1991, DOI 10.1007/s00520-010-1043-2
   Kong J, 2007, REV NEUROSCIENCE, V18, P173
   Lee A, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub3
   Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4
   Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203
   Lin LW, 2009, J ALTERN COMPLEM MED, V15, P1335, DOI 10.1089/acm.2008.0373
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Merskey H, 2012, CLASSIFICATION OF CHRONIC PAIN, VSecond, P209
   Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036
   Pettersson PH, 2012, J CLIN NURS, V21, P1799, DOI 10.1111/j.1365-2702.2012.04114.x
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Rosenthal David S, 2005, HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM, V0, P491
   Running A, 2012, CURR PAIN HEADACHE R, V16, P325, DOI 10.1007/s11916-012-0275-x
   Sagar Stephen M, 2006, J SOC INTEGR ONCOL, V4, P27
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Sun Bao-Mu, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P641
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Xu M, 2012, J NEUROSURG ANESTH, V24, P312, DOI 10.1097/ANA.0b013e31825eb5ef
   Zhang Feng-Li, 2009, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V29, P922
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/710750
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 54
TC 60
Z9 71
U1 5
U2 99
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1531-3433
EI 1534-3081
J9 CURR PAIN HEADACHE R
JI Curr. Pain Headache Rep.
PD MAR 15
PY 2013
VL 17
IS 3
BP 
EP 
DI 10.1007/s11916-013-0321-3
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 099OD
UT WOS:000315630200006
PM 23338773
DA 2026-01-16
ER

PT J
AU Mao, JJ
   Xie, SX
   Farrar, JT
   Stricker, CT
   Bowman, MA
   Bruner, D
   DeMichele, A
AF Mao, Jun J
   Xie, Sharon X
   Farrar, John T
   Stricker, Carrie T
   Bowman, Marjorie A
   Bruner, Deborah
   DeMichele, Angela
TI A randomised trial of electro-acupuncture for arthralgia related to aromatase
SO European journal of cancer (Oxford, England : 1990)
LA English
DT Journal Article
DE Acupuncture; Adverse effects; Aromatase inhibitors; Breast neoplasm; Clinical trial; Joint pain; Musculoskeletal
AB BACKGROUND: Arthralgia is a common and debilitating side-effect experienced by  breast cancer patients receiving aromatase inhibitors (AIs) and often results in  premature drug discontinuation. METHODS: We conducted a randomised controlled  trial of electro-acupuncture (EA) as compared to waitlist control (WLC) and sham  acupuncture (SA) in postmenopausal women with breast cancer who self-reported  arthralgia attributable to AIs. Acupuncturists performed 10 EA/SA treatments over  8 weeks using a manualised protocol with 2 Hz electro-stimulation delivered by a  TENS unit. Acupuncturists administered SA using Streitberger (non-penetrating)  needles at non-traditional acupuncture points without electro-stimulation. The  primary end-point was pain severity by Brief Pain Inventory (BPI) between EA and  WLC at Week 8; durability of response at Week 12 and comparison of EA to SA were  secondary aims. FINDINGS: Of the 67 randomly assigned patients, mean reduction in  pain severity was greater in the EA group than in the WLC group at Week 8 (-2.2  versus -0.2, p=0.0004) and at Week 12 (-2.4 versus -0.2, p<0.0001). Pain-related  interference measured by BPI also improved in the EA group compared to the WLC  group at both Week 8 (-2.0 versus 0.2, p=0.0006) and Week 12 (-2.1 versus -0.1,  p=0.0034). SA produced a magnitude of change in pain severity and pain-related  interference at Week 8 (-2.3, -1.5 respectively) and Week 12 (-1.7, -1.3  respectively) similar to that of EA. Participants in both EA and SA groups  reported few minor adverse events. INTERPRETATIONS: Compared to usual care, EA  produced clinically important and durable improvement in arthralgia related to  AIs in breast cancer patients, and SA had a similar effect. Both EA and SA were  safe.
C1 Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, PA, United States
   Center for ClinicalEpidemiology and Biostatistics and Department of Biostatistics and Epidemiology,Perelman School of Medicine at the University of Pennsylvania, PA, United States;Abramson Cancer Center, Perelman School of Medicine at the University ofPennsylvania, PA, United States. 
   Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University ofPennsylvania, PA, United States.
   Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University ofPennsylvania, PA, United States
   Abramson Cancer Center, Perelman School ofMedicine at the University of Pennsylvania, PA, United States.
   Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, PA, United States.
   Wright State University School of Medicine, United States.
   Emory University School of Nursing, United States.
   Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University ofPennsylvania, PA, United States
   Abramson Cancer Center, Perelman School ofMedicine at the University of Pennsylvania, PA, United States.
EM jun.mao@uphs.upenn.edu
NR 0
TC 0
SN 1879-085
EI 0959-804
J9 Eur J Cancer
PD NOV 12
PY 2013
VL 50
IS 2
BP 267
EP 76
DI 10.1016/j.ejca.2013.09.022
PG -191
WC Acupuncture Points; Adult; Aged; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Double-Blind Method; Electroacupuncture; methods; Female; Humans; Middle Aged; Pain Measurement; methods; Time Factors; Treatment Outcome; Waiting Lists
UT PubMed:24210070
PM 24210070
DA 2013-11-12
ER

PT J
AU Noble, S
   Williamson, IJ
   Brewster, AE
   Ionescu, AA
   Kulatilake, N
AF Noble, S.
   Williamson, I. J.
   Brewster, A. E.
   Ionescu, A. A.
   Kulatilake, N.
TI The role of acupuncture in the management of post-thoracotomy pain: description and evaluation of an acupuncture service in lung cancer survivorship
SO LUNG CANCER
LA English
DT Meeting Abstract
C1 [Noble, S.] Cardiff Univ, Cardiff CF10 3AX, S Glam, Wales.
   [Williamson, I. J.; Ionescu, A. A.] Royal Gwent Hosp, Newport, Gwent, Wales.
   [Brewster, A. E.] Velindre Hosp, Cardiff, S Glam, Wales.
   [Kulatilake, N.] Univ Hosp Wales, Cardiff, S Glam, Wales.
C3 Cardiff University; Royal Gwent Hospital; Velindre Cancer Centre; Cardiff University
NR 0
TC 1
Z9 2
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0169-5002
EI 
J9 LUNG CANCER
JI Lung Cancer
PD JAN 15
PY 2013
VL 79
IS 
BP S39
EP S40
DI 10.1016/S0169-5002(13)70114-4
PG 2
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 094BW
UT WOS:000315239000115
DA 2026-01-16
ER

PT J
AU Paley, C
AF Paley, Carole
TI Acupuncture for the treatment of cancer pain: a systematic review. Response to
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Letter
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD JAN 12
PY 2013
VL 21
IS 5
BP 1217
EP 1217
DI 10.1007/s00520-012-1704-4
PG 0
WC Acupuncture Therapy; methods; Humans; Pain; etiology; Pain Management; methods
UT PubMed:23306936
PM 23306936
DA 2013-01-12
ER

PT J
AU Liu, JP
   Han, M
   Li, XX
   Mu, YJ
   Lewith, G
   Wang, YY
   Witt, CM
   Yang, GY
   Manheimer, E
   Snellingen, T
   Berman, B
   Gluud, C
AF Liu, Jian-Ping
   Han, Mei
   Li, Xin-Xue
   Mu, Yu-Jie
   Lewith, George
   Wang, Yu-Yi
   Witt, Claudia M
   Yang, Guo-Yan
   Manheimer, Eric
   Snellingen, Torkel
   Berman, Brian
   Gluud, Christian
TI Prospective registration, bias risk and outcome-reporting bias in randomised
SO BMJ open
LA English
DT Journal Article
AB BACKGROUND: Clinical trials on Traditional Chinese Medicine (TCM) should be  registered in a publicly accessible international trial register and report on  all outcomes. We systematically assessed and evaluated TCM trials in registries  with their subsequent publications. OBJECTIVE: To describe the characteristics of  TCM trials, estimate bias risk and outcome-reporting bias in clinical trials.  DATA SOURCES AND STUDY SELECTION: Fifteen trial registries were searched from  their inception to July 2012 to identify randomised trials on TCM including  Chinese herbs, acupuncture and/or moxibustion, cupping, tuina, qigong, etc. DATA  EXTRACTION: We extracted data including TCM specialty and treated  disease/conditions from the registries and searched for subsequent publications  in PubMed and Chinese databases. We compared information in the registries of  completed trials with any publications focusing on study design, sample size,  randomisation, bias risk including reporting bias from the register protocol.  RESULTS: 1096 registered randomised trials were identified evaluating TCM, of  which 505 were completed studies (46.1%). The most frequent conditions were pain  (13.3%), musculoskeletal (11.7%), nervous (8.7%), digestive (7.1%), circulatory  (6.5%), respiratory (6.3%), mental and behavioural disorders (6.2%) and cancer  (6.0%). The trial register data identified parallel, phase II/III randomised  trials with sample size estimations and blinding, but limited information about  randomisation (sequence generation and allocation concealment). Comparing trial  registration data of 115 completed trials (22.8%) with their subsequent 136  publications, inconsistencies were identified in one or more of the following:  sample size (11%), outcome assessor blinding (37.5%), primary outcomes (29%) and  safety (28%) reporting. CONCLUSIONS: Increasing numbers of clinical trials  investigating a variety of TCM interventions have been registered in  international trial registries. The study design of registered TCM trials has  improved in estimating sample size, use of blinding and placebos. However,  selective outcome reporting is widespread and similar to conventional medicine  and therefore study conclusions should be interpreted with caution.
C1 Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD JUL 19
PY 2013
VL 3
IS 7
BP 
EP 
DI 10.1136/bmjopen-2013-002968
PG 0
UT PubMed:23864210
PM 23864210
DA 2013-07-19
ER

PT J
AU Bauml, J
   Basal, C
   Mao, JJ
AF Bauml, Joshua
   Basal, Coby
   Mao, Jun J
TI Treatment of post-mastectomy pain syndrome with acupuncture: a case report.
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE Oncology
AB Post-mastectomy pain syndrome (PMPS) is a common and severe neuropathic pain  syndrome arising after breast surgery. Since few effective allopathic treatments  exist for PMPS, many patients may seek assistance from complementary and  alternative medicine. Here, we report a case of a woman with severe and  persistent PMPS who was successfully treated with acupuncture.
C1 Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, , Philadelphia, Pennsylvania, USA.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD NOV 19
PY 2013
VL 32
IS 2
BP 183
EP 5
DI 10.1136/acupmed-2013-010459
PG -178
WC Acupuncture Therapy; Breast Neoplasms; surgery; Female; Humans; Mastectomy; adverse effects; Middle Aged; Pain, Postoperative; etiology; Treatment Outcome
UT PubMed:24240772
PM 24240772
DA 2013-11-19
ER

PT J
AU Oh, B
   Kimble, B
   Costa, DSJ
   Davis, E
   McLean, A
   Orme, K
   Beith, J
AF Oh, B.
   Kimble, B.
   Costa, D. S. J.
   Davis, E.
   McLean, A.
   Orme, K.
   Beith, J.
TI Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE COMPLEMENTARY MEDICINE; PAIN MANAGEMENT; PAIN RESEARCH; THERAPEUTICS
ID low-back-pain; alternative medicine; placebo acupuncture; american-society; controlled-trial; complementary; electroacupuncture; chemotherapy; multicenter; management
AB Background Aromatase inhibitors (AIs) are recommended as adjuvant hormone treatment for postmenopausal women with early breast cancer. A substantial proportion of women taking AIs experience joint pain and stiffness. Studies have suggested that acupuncture may be effective in treating joint pain. Objective A pilot study was conducted to evaluate the feasibility, safety and efficacy of using acupuncture to treat AI-induced arthralgia. Methods A total of 32 patients were randomised to receive either sham or real electroacupuncture (EA) twice weekly for 6weeks. Outcomes of joint pain, stiffness and physical function were measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), overall pain severity and interference with the BPI-SF and quality of life (QOL) with the Functional Assessment of Cancer Therapy-General (FACT-G) instrument. Hand strength was assessed by a grip test, and a serum marker of inflammation (C reactive protein (CRP)) was also measured. All assessments were performed at baseline, 6weeks and 12weeks, except for blood samples at baseline and 6weeks only. Results No serious adverse events were reported during or after acupuncture treatments. There were no significant differences in outcome measures. However, positive trends were observed in stiffness and physical function at week 12 in favour of real EA. Conclusions Findings suggest that acupuncture is feasible and safe in patients with breast cancer with joint pain caused by AI. A larger study with adequately powered to confirm these results and detect clinically relevant effects is needed.
C1 [Oh, B.; McLean, A.; Beith, J.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [Oh, B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Kimble, B.; Orme, K.; Beith, J.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Sydney, NSW, Australia.
   [Costa, D. S. J.; Davis, E.] Univ Sydney, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW 2006, Australia.
C3 University of Sydney; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard Medical School; University of Sydney; NSW Health; Royal Prince Alfred Hospital; University of Sydney
RP Davis, E (corresponding author), Univ Sydney, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW 2006, Australia.
EM esther.davis@sydney.edu.au
FU Cancer Institute NSW Innovative Grant; Sydney South West Area Health Service, NSW Department of Health
CR AIHW, 2012, AIHW CANC SER, V74, P0
   Unknown -, 2012, BREAST CANCER STATISTICS, V0, P0
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Beith JM, 2011, MED ACUPUNCT, V23, P151, DOI 10.1089/acu.2011.0798
   Beith JM, 2012, MED ACUPUNCT, V24, P241, DOI 10.1089/acu.2012.0876
   Bellamy N, 2002, WOMAC OSTEOARTHRITIS INDEX USER GUIDE, V0, P0
   Boon Heather S, 2007, BMC WOMENS HEALTH, V7, P4, DOI 10.1186/1472-6874-7-4
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   Cassileth BR, 2011, ACUPUNCT MED, V29, P170, DOI 10.1136/aim.2011.004069
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Cole Tracey, 2006, BR J NURS, V15, P969
   Coleman RE, 2008, CANCER TREAT REV, V34, P275, DOI 10.1016/j.ctrv.2007.10.004
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655
   Hershman DL, 2008, J CLIN ONCOL, V26, P3120, DOI 10.1200/JCO.2008.16.7684
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126
   Jacobson JS, 2000, J CLIN ONCOL, V18, P668, DOI 10.1200/JCO.2000.18.3.668
   Johnston MF, 2011, EVIDENCE BASED COMPL, V2011, P0
   Kaptchuk TJ, 2001, JAMA-J AM MED ASSOC, V285, P1015, DOI 10.1001/jama.285.8.1015
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kerr DP, 2003, CLIN J PAIN, V19, P364, DOI 10.1097/00002508-200311000-00004
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Mendoza T, 2006, EUR J PAIN, V10, P353, DOI 10.1016/j.ejpain.2005.06.002
   Navo MA, 2004, J CLIN ONCOL, V22, P671, DOI 10.1200/JCO.2004.04.162
   Oh B, 2010, ASIA-PAC J CLIN ONCO, V6, P342, DOI 10.1111/j.1743-7563.2010.01329.x
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   So EWS, 2009, HUM REPROD, V24, P341, DOI 10.1093/humrep/den380
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Vas J, 2012, PAIN, V153, P1883, DOI 10.1016/j.pain.2012.05.033
   Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121
   Wolfe F, 1999, ANN RHEUM DIS, V58, P563, DOI 10.1136/ard.58.9.563
   World Health Organization, 2008, WHO STANDARD ACUPUNCTURE POINT LOCATIONS IN THE WESTERN PACIFIC REGION, V1st ed., P0
NR 41
TC 57
Z9 66
U1 0
U2 43
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD SEP 15
PY 2013
VL 31
IS 3
BP 264
EP 271
DI 10.1136/acupmed-2012-010309
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 208YU
UT WOS:000323719800002
PM 23722951
DA 2026-01-16
ER

PT J
AU Garcia, MK
   Driver, L
   Haddad, R
   Lee, R
   Palmer, JL
   Wei, Q
   Frenkel, M
   Cohen, L
AF Garcia, M Kay
   Driver, Larry
   Haddad, Robin
   Lee, Richard
   Palmer, J Lynn
   Wei, Qi
   Frenkel, Moshe
   Cohen, Lorenzo
TI Acupuncture for treatment of uncontrolled pain in cancer patients: a pragmatic
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; cancer; complementary medicine; integrative medicine; pain; symptom management
AB PURPOSE: Pain control is an ongoing challenge in the oncology setting. Prior to  implementing a large randomized trial at our institution, we investigated the  feasibility, safety, and initial efficacy of acupuncture for uncontrolled pain  among cancer patients. HYPOTHESES: Our hypotheses were that the acupuncture  treatments provided would be ( : ) feasible, ( : ) safe, and ( : ) a beneficial  adjunct to pain management. STUDY DESIGN: This was a single arm, nonrandomized  pragmatic pilot study. METHODS: Participants experiencing pain ≥4 on a 0 to 10  numeric rating scale received a maximum of 10 treatments on an individualized  basis. Recruitment, attrition, compliance, and adverse events (AEs) were  assessed. Pain (Brief Pain Inventory-Short Form), quality of life (MD Anderson  Symptom Inventory [MDASI]), and patient satisfaction were assessed at baseline  and at the end of treatment. RESULTS: Of 115 patients screened, 52 (45%) were  eligible and agreed to participate. Eleven (21%) were lost to follow-up, leaving  41 who completed all study procedures. No AEs were reported. Mean pain SEVERIT:  was 6.0 ± 1.3 at baseline and 3.8 ± 2.0 at follow-up ( : < .0001). Pain  INTERFERENC: was 6.2 ± 2.3 at baseline and 4.3 ± 2.8 at follow-up ( : < .0011).  On the MDASI, the mean symptom SEVERIT: was 4.6 ± 1.8 at baseline and 3.2 ± 1.9  at follow-up ( : < .0001), and mean symptom INTERFERENC: was 5.8 ± 2.4 at  baseline and 4.1 ± 2.9 at follow-up ( : < .002). Prescribed pain medications  decreased across the course of the study. Patient satisfaction was high: 87%  reported that their expectations were met "very well" or "extremely well"; 90%  said they were likely to participate again; 95% said they were likely to  recommend acupuncture to others; and 90% reported they found the service to be  "useful" or "very useful." CONCLUSIONS: Acupuncture was feasible, safe, and a  helpful treatment adjunct for cancer patients experiencing uncontrolled pain in  this study. Randomized placebo-controlled trials are needed to confirm these  results.
C1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
NR 0
TC 0
SN 1552-695
EI 
J9 Integr Cancer Ther
PD NOV 28
PY 2013
VL 13
IS 2
BP 133
EP 40
DI 10.1177/1534735413510558
PG -93
WC Acupuncture Therapy; methods; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Neoplasms; complications; Pain; physiopathology; Pain Management; methods; Pilot Projects
UT PubMed:24282103
PM 24282103
DA 2013-11-28
ER

PT J
AU Smeester, BA
   Al-Gizawiy, M
   O'Brien, EE
   Ericson, ME
   Triemstra, JL
   Beitz, AJ
AF Smeester, Branden A.
   Al-Gizawiy, Mona
   O'Brien, Elaine E.
   Ericson, Marna E.
   Triemstra, Jennifer L.
   Beitz, Alvin J.
TI The Effect of Electroacupuncture on Osteosarcoma Tumor Growth and Metastasis: Analysis of Different Treatment Regimens
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID necrosis-factor-alpha; peripheral-nerve; factor receptor; t-cells; acupuncture; model; pain; inhibition; expression; reduction
AB Osteosarcoma is the most common malignant bone tumor found in children and adolescents and is associated with many complications including cancer pain and metastasis. While cancer patients often seek complementary and alternative medicine (CAM) approaches to treat cancer pain and fatigue or the side effects of chemotherapy and treatment, there is little known about the effect of acupuncture treatment on tumor growth and metastasis. Here we evaluate the effects of six different electroacupuncture (EA) regimens on osteosarcoma tumor growth and metastasis in both male and female mice. The most significant positive effects were observed when EA was applied to the ST-36 acupoint twice weekly (EA-2X/3) beginning at postimplantation day 3 (PID 3). Twice weekly treatment produced robust reductions in tumor growth. Conversely, when EA was applied twice weekly (EA2X/7), starting at PID 7, there was a significant increase in tumor growth. We further demonstrate that EA-2X/3 treatment elicits significant reductions in tumor lymphatics, vasculature, and innervation. Lastly, EA-2X/3 treatment produced a marked reduction in pulmonary metastasis, thus providing evidence for EA's potential antimetastatic capabilities. Collectively, EA-2X/3 treatment was found to reduce both bone tumor growth and lung metastasis, which may be mediated in part through reductions in tumor-associated vasculature, lymphatics, and innervation.
C1 [Smeester, Branden A.] Univ Minnesota, Coll Pharm, Dept Med Chem, Minneapolis, MN 55455 USA.
   [Al-Gizawiy, Mona] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA.
   [O'Brien, Elaine E.; Triemstra, Jennifer L.] Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA.
   [Ericson, Marna E.] Univ Minnesota, Dept Dermatol, Minneapolis, MN 55455 USA.
   [Ericson, Marna E.] Univ Minnesota, Ctr Drug Design, Minneapolis, MN 55455 USA.
   [Beitz, Alvin J.] Univ Minnesota, Dept Vet & Biomed Sci, St Paul, MN 55108 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities; Medical College of Wisconsin; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities
RP Beitz, AJ (corresponding author), Univ Minnesota, Dept Vet & Biomed Sci, Room 205 Vet Med Bldg,1971 Commonwealth Ave, St Paul, MN 55108 USA.
EM beitz001@umn.edu
FU National Cancer Institute at NIH [5R01/CA084233]
CR Al-Salihi MA, 2007, CELL SIGNAL, V19, P1956, DOI 10.1016/j.cellsig.2007.05.003
   Cassileth Barrie, 2007, CURR PAIN HEADACHE REP, V11, P265, DOI 10.1007/s11916-007-0202-8
   Chen Y-F, 2011, EVID-BASED COMPL ALT, V2011, P0
   Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Cohen I, 2002, SEMIN ONCOL, V29, P563, DOI 10.1053/sonc.2002.50005
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Gelderblom H, 2011, EUR J CANCER, V47, P895, DOI 10.1016/j.ejca.2010.11.036
   Huang C, 2008, NEUROCHEM RES, V33, P2107, DOI 10.1007/s11064-008-9721-x
   Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547
   Kim S, 2011, EXP CELL RES, V317, P2650, DOI 10.1016/j.yexcr.2011.08.023
   Lai Min, 2008, ZHONGGUO ZHEN JIU, V28, P607
   Lawenda BD, 2013, CANCER-AM CANCER SOC, V119, P2362, DOI 10.1002/cncr.28090
   Li SG, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0057604
   Liu L J, 1995, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V15, P615
   Lund I, 2010, CHINESE MED, V5, P0
   Lund I, 2008, ACUPUNCT MED, V26, P33, DOI 10.1136/aim.26.1.33
   Lynch JL, 2008, PAIN, V136, P293, DOI 10.1016/j.pain.2007.07.007
   Ma Jingxi, 2008, J TRADIT CHIN MED, V28, P217
   Makrilia N, 2009, EUR J INTERN MED, V20, P663, DOI 10.1016/j.ejim.2009.07.009
   Mao Qing-Ju, 2012, ZHEN CI YAN JIU, V37, P476
   McDonald JL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/591796
   Meng ZQ, 2012, EUR J CANCER, V48, P1692, DOI 10.1016/j.ejca.2011.12.030
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Omura Y, 2007, ACUPUNCTURE ELECTRO, V32, P31, DOI 10.3727/036012907815844174
   Östman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002
   Ouyang BS, 2011, CHIN J INTEGR MED, V17, P505, DOI 10.1007/s11655-011-0783-2
   Pacharinsak C, 2008, COMPARATIVE MED, V58, P220
   Paley CA, 2011, PHYSIOTHERAPY, V97, P256, DOI 10.1016/j.physio.2010.08.008
   Park SI, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/464586
   Qiu WQ, 2010, BRAIN RES, V1362, P56, DOI 10.1016/j.brainres.2010.09.040
   Regan J M, 2000, CANCER CONTROL, V7, P111
   Robotin M, 2012, COMPLEMENT THER MED, V20, P345, DOI 10.1016/j.ctim.2012.04.001
   Shen AD, 2012, J SURG ONCOL, V105, P830, DOI 10.1002/jso.23012
   Smeester BA, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/671386
   Smith Mary Elizabeth, 2012, SEMIN ONCOL NURS, V28, P64, DOI 10.1016/j.soncn.2011.11.007
   Sueyoshi T, 2012, CANCER LETT, V316, P23, DOI 10.1016/j.canlet.2011.10.013
   Tsubaki M, 2012, TOXICOL APPL PHARM, V259, P402, DOI 10.1016/j.taap.2012.01.024
   Väyrynen JP, 2012, VIRCHOWS ARCH, V460, P455, DOI 10.1007/s00428-012-1232-0
   Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21-23-09355.2001
   Wang K, 2009, ANESTH ANALG, V109, P1666, DOI 10.1213/ANE.0b013e3181b5a234
   Wardle JL, 2013, ACUPUNCT MED, V31, P45, DOI 10.1136/acupmed-2012-010244
   Williams AM, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-47
   WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2
   Xu WT, 2009, CANCER LETT, V281, P32, DOI 10.1016/j.canlet.2009.02.022
   Zhang D, 2011, EVID-BASED COMPL ALT, V2011, P0
   Zhang J, 2010, J PAIN, V11, P1250, DOI 10.1016/j.jpain.2010.02.013
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
NR 49
TC 15
Z9 19
U1 0
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2013
VL 2013
IS 
BP 
EP 
DI 10.1155/2013/387169
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 246OH
UT WOS:000326547800001
PM 24228059
DA 2026-01-16
ER

PT J
AU Towler, P
   Molassiotis, A
   Brearley, SG
AF Towler, P.
   Molassiotis, A.
   Brearley, S. G.
TI What is the evidence for the use of acupuncture as an intervention for symptom management in cancer supportive and palliative care: an integrative overview of reviews
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Acupuncture; Cancer; Symptom management; Complex intervention
ID breast-cancer; complex interventions; prostate-cancer; hot flashes; men; xerostomia; hospice; flushes; relief; design
AB This study aims to systematically appraise the evidence for the use of acupuncture for symptom management in cancer and supportive care and to identify recommendations for clinical practice and future research. A systematic search was carried out to identify reviews of the use of acupuncture in cancer supportive and palliative care, using MEDLINE, EMBASE, CINAHL, Web of Science, Cochrane Library, British Nursing Index, Index to Theses, Dissertations and Theses (via Proquest) and NHS evidence. Search terms included: acupuncture, cancer and symptoms. Data were extracted for analysis. Reviews were assessed for quality using a five-item checklist but were not excluded from the review on grounds of quality, in order to include a comprehensive scope of the subject. Seventeen reviews were included in the review. Evidence was found for the use of acupuncture for treatment-related nausea and vomiting. Benefit was reported for other cancer-related symptoms, including pain, fatigue, hot flushes, xerostomia, dyspnoea and anxiety. Reviewers found a paucity of rigorous trials and heterogeneity of populations, interventions, controls and outcome measures, which challenge the process of systematic review and meta-analysis. Acupuncture should be considered for symptom management where there are limited treatment options, using current peer-reviewed guidelines and clinical reasoning. Much of the primary research reported in reviews is innovative and indicates potential benefit for people with cancer-related symptoms. The complexity of acupuncture as an intervention needs to be acknowledged in future research designs and when reviewing research findings. An iterative approach using adequate interventions, appropriate outcome measures and adherence to reporting standards is required to evaluate the efficacy of acupuncture in cancer supportive and palliative care.
C1 [Towler, P.] Univ Manchester, Manchester, Lancs, England.
   [Molassiotis, A.] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester, Lancs, England.
   [Brearley, S. G.] Univ Lancaster, Fac Hlth & Med, Lancaster, England.
C3 University of Manchester; University of Manchester; Lancaster University
RP Brearley, SG (corresponding author), Univ Lancaster, Fac Hlth & Med, Lancaster, England.
EM sarah.brearley@lancaster.ac.uk
FU Cancer Experiences Collaborative; National Cancer Research Institute
CR Barsevick AM, 2006, J PAIN SYMPTOM MANAG, V31, P85, DOI 10.1016/j.jpainsymman.2005.05.015
   Beer TM, 2010, UROLOGY, V76, P1182, DOI 10.1016/j.urology.2010.03.033
   BLOM M, 1992, ORAL SURG ORAL MED O, V73, P293, DOI 10.1016/0030-4220(92)90124-9
   Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Cohen Andrea J, 2005, INTEGR CANCER THER, V4, P131, DOI 10.1177/1534735405276419
   Collins JA, 2005, HUM REPROD UPDATE, V11, P103, DOI 10.1093/humupd/dmh058
   Craig P, 2008, BMJ-BRIT MED J, V337, P0, DOI 10.1136/bmj.a1655
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng G, 2010, OXFORD TXB PALLIATIV, V0, P0
   Dijkers MPJM, 2009, AM J PHYS MED REHAB, V88, P423, DOI 10.1097/PHM.0b013e31819c59c6
   Dos Santos S, 2010, MED ACUPUNCT, V22, P81, DOI 10.1089/acu.2009.0730
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.03.010
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Filshie J, 1996, PALLIATIVE MED, V10, P145, DOI 10.1177/026921639601000209
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Finnegan-John J, 2013, INTEGR CANCER THER, V12, P276, DOI 10.1177/1534735413485816
   Frisk J, 2009, EUR UROL, V55, P156, DOI 10.1016/j.eururo.2008.02.002
   Hammar M, 1999, J UROLOGY, V161, P853, DOI 10.1016/S0022-5347(01)61789-0
   Hopkins Hollis Anne Seton, 2010, ONCOL NURS FORUM, V37, PE344, DOI 10.1188/10.ONF.E344-E348
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee MS, 2009, SUPPORT CARE CANCER, V17, P763, DOI 10.1007/s00520-009-0589-3
   Lee MS, 2009, BREAST CANCER RES TR, V115, P497, DOI 10.1007/s10549-008-0230-z
   Leng G, 1999, PALLIATIVE MED, V13, P163, DOI 10.1191/026921699676243035
   Linde K, 2007, ACUPUNCTURE RESEARCH STRATEGIES FOR ESTABLISHING AN EVIDENCE BASE, V0, P199
   Lu Weidong, 2007, J SOC INTEGR ONCOL, V5, P1, DOI 10.2310/7200.2006.035
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Lundeberg T, 2009, ACUPUNCT MED, V27, P31, DOI 10.1136/aim.2008.000133
   MacPherson H, 2010, ACUPUNCT MED, V28, P83, DOI 10.1136/aim.2009.001370
   Matheson L, 2011, DOING YOUR LITERATURE REVIEW: TRADITIONAL AND SYSTEMATIC TECHNIQUES, V0, P0
   Meidell L, 2009, INT J PALLIAT NURS, V15, P12, DOI 10.12968/ijpn.2009.15.1.37947
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   ORegan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   OSullivan EM, 2010, ACUPUNCT MED, V28, P191, DOI 10.1136/aim.2010.002733
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Paterson C, 2010, EUROPEAN JOURNAL OF ORIENTAL MEDICINE, V6, P36
   Pomeranz B, 2001, CLINICAL ACUPUNCTURE, V0, P1
   Sagar SM, 2008, CURR TREAT OPTION ON, V9, P117, DOI 10.1007/s11864-008-0063-3
   Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515
   Simmons B, 2010, J ADV NURS, V66, P1151, DOI 10.1111/j.1365-2648.2010.05262.x
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   White A, 2009, ACUPUNCT MED, V27, P0
NR 48
TC 64
Z9 74
U1 0
U2 88
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD OCT 15
PY 2013
VL 21
IS 10
BP 2913
EP 2923
DI 10.1007/s00520-013-1882-8
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 214DB
UT WOS:000324109900031
PM 23868190
DA 2026-01-16
ER

PT J
AU Liu, JP
   Han, M
   Li, XX
   Mu, YJ
   Lewith, G
   Wang, YY
   Witt, CM
   Yang, GY
   Manheimer, E
   Snellingen, T
   Berman, B
   Gluud, C
AF Liu, Jian-Ping
   Han, Mei
   Li, Xin-Xue
   Mu, Yu-Jie
   Lewith, George
   Wang, Yu-Yi
   Witt, Claudia M.
   Yang, Guo-Yan
   Manheimer, Eric
   Snellingen, Torkel
   Berman, Brian
   Gluud, Christian
TI Prospective registration, bias risk and outcome-reporting bias in randomised clinical trials of traditional Chinese medicine: an empirical methodological study
SO BMJ OPEN
LA English
DT Article
ID quality
AB Background Clinical trials on Traditional Chinese Medicine (TCM) should be registered in a publicly accessible international trial register and report on all outcomes. We systematically assessed and evaluated TCM trials in registries with their subsequent publications. Objective To describe the characteristics of TCM trials, estimate bias risk and outcome-reporting bias in clinical trials. Data sources and study selection Fifteen trial registries were searched from their inception to July 2012 to identify randomised trials on TCM including Chinese herbs, acupuncture and/or moxibustion, cupping, tuina, qigong, etc. Data extraction We extracted data including TCM specialty and treated disease/conditions from the registries and searched for subsequent publications in PubMed and Chinese databases. We compared information in the registries of completed trials with any publications focusing on study design, sample size, randomisation, bias risk including reporting bias from the register protocol. Results 1096 registered randomised trials were identified evaluating TCM, of which 505 were completed studies (46.1%). The most frequent conditions were pain (13.3%), musculoskeletal (11.7%), nervous (8.7%), digestive (7.1%), circulatory (6.5%), respiratory (6.3%), mental and behavioural disorders (6.2%) and cancer (6.0%). The trial register data identified parallel, phase II/III randomised trials with sample size estimations and blinding, but limited information about randomisation (sequence generation and allocation concealment). Comparing trial registration data of 115 completed trials (22.8%) with their subsequent 136 publications, inconsistencies were identified in one or more of the following: sample size (11%), outcome assessor blinding (37.5%), primary outcomes (29%) and safety (28%) reporting. Conclusions Increasing numbers of clinical trials investigating a variety of TCM interventions have been registered in international trial registries. The study design of registered TCM trials has improved in estimating sample size, use of blinding and placebos. However, selective outcome reporting is widespread and similar to conventional medicine and therefore study conclusions should be interpreted with caution.
C1 [Liu, Jian-Ping; Han, Mei; Li, Xin-Xue; Mu, Yu-Jie; Wang, Yu-Yi; Yang, Guo-Yan; Snellingen, Torkel] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.
   [Lewith, George] Univ Southampton, Ctr Complementary Med Res, Southampton, Hants, England.
   [Witt, Claudia M.] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany.
   [Manheimer, Eric; Berman, Brian] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA.
   [Gluud, Christian] Copenhagen Univ Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark.
C3 Beijing University of Chinese Medicine; University of Southampton; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University System of Maryland; University of Maryland Baltimore; Rigshospitalet; University of Copenhagen; Copenhagen University Hospital
RP Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.
EM Liujp@bucm.edu.cn
FU NCCAM of NIH, USA; Ministry of Science and Technology, China [R24 AT001293, 2011-CXTD-09, 2011ZX09302-006-01-03(5)]; National Center for Complementary and Integrative Health [R24AT001293] Funding Source: NIH RePORTER
CR Abaid LN, 2007, OBSTET GYNECOL, V109, P1434, DOI 10.1097/01.AOG.0000266557.11064.2a
   Unknown -, 2005, BMJ-BRIT MED J, V0, P0
   Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457
   Dickersin K, 2003, JAMA-J AM MED ASSOC, V290, P516, DOI 10.1001/jama.290.4.516
   He J, 2011, TRIALS, V12, P0, DOI 10.1186/1745-6215-12-122
   Higgins JP, 2011, COCHRANE HDB SYSTEMA, V0, P0, DOI DOI 10.1007/S12119-019-09598-3
   Mathieu S, 2009, JAMA-J AM MED ASSOC, V302, P977, DOI 10.1001/jama.2009.1242
   Reveiz L, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0012484
   Savovic J, 2012, ANN INTERN MED, V157, P429, DOI 10.7326/0003-4819-157-6-201209180-00537
   Tang JL, 1999, BMJ-BRIT MED J, V319, P160, DOI 10.1136/bmj.319.7203.160
   Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5
   Viergever RF, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014701
   Wang G, 2007, CLIN THER, V29, P1456, DOI 10.1016/j.clinthera.2007.07.023
   Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD
NR 16
TC 48
Z9 51
U1 1
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUN 15
PY 2013
VL 3
IS 7
BP 
EP 
DI 10.1136/bmjopen-2013-002968
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 291CO
UT WOS:000329805500049
PM 23864210
DA 2026-01-16
ER

PT J
AU Ogawa, K
   Ogawa, M
   Nishijima, K
   Tsuda, M
   Nishimura, G
AF Ogawa, Keiko
   Ogawa, Masao
   Nishijima, Koji
   Tsuda, Masaki
   Nishimura, Genichi
TI Efficacy of Contact Needle Therapy for Chemotherapy-Induced Peripheral Neuropathy
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID acupuncture; pain; electroacupuncture
AB Cancer chemotherapy-induced peripheral neuropathy (CIPN) often results in discontinuation of treatment with potentially useful anticancer drugs and may deteriorate the patient's quality of life. This study investigated the effect of contact needle therapy (CNT) on CIPN caused by responsible chemotherapeutic agents as taxanes and oxaliplatin. Six patients with CIPN were treated with CNT. The severity of CIPN was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 4 and FACT/GOG-Ntx before and after CNT. After the treatment, all of the patients showed some improvement. Four patients showed apparent improvement in breakthrough pain. One of the cases had difficulty in walking because of CIPN in lower extremities, but after 2 times of CNT, he could walk without pain and could continue the chemotherapy. Although its putative mechanisms remain elusive, CNT has strong potential as an adjunctive therapy in CIPN. Well-designed clinical trials with adequate sample size and power are necessary to confirm the findings of this study.
C1 [Ogawa, Keiko] Kanazawa Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Clin Japanese Oriental Kampo Med, Kanazawa, Ishikawa 9208641, Japan.
   [Ogawa, Masao] Kanazawa Med Univ Hosp, Dept Anesthesiol, Uchinada, Ishikawa 9200265, Japan.
   [Nishijima, Koji; Nishimura, Genichi] Japanese Red Cross Kanazawa Hosp, Dept Surg, Kanazawa, Ishikawa 9218162, Japan.
   [Tsuda, Masaki] Mukeido Acupuncture & Moxibust Off, Toyama 9398081, Japan.
C3 Kanazawa University; Kanazawa Medical University
RP Ogawa, K (corresponding author), Kanazawa Univ Hosp, Dept Otorhinolaryngol & Head & Neck Surg, Clin Japanese Oriental Kampo Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.
EM ikkandoo@gmail.com
CR Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Colson Kathleen, 2004, CLIN J ONCOL NURS, V8, P473, DOI 10.1188/04.CJON.473-480
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Galantino MLA, 1999, J ALTERN COMPLEM MED, V5, P135, DOI 10.1089/acm.1999.5.135
   Goodnick PJ, 2000, AM J PSYCHIAT, V157, P1342, DOI 10.1176/appi.ajp.157.8.1342-a
   HAN JS, 1982, ADV BIOCHEM PSYCHOPH, V33, P369
   Hayashi K, 2010, KAMPO MED, V61, P198
   Kaley TJ, 2009, BRIT J HAEMATOL, V145, P3, DOI 10.1111/j.1365-2141.2008.07558.x
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Litscher G, 2002, LASER MED SCI, V17, P19, DOI 10.1007/s10103-002-8262-9
   LOMONACO M, 1992, J NEUROL, V239, P199, DOI 10.1007/BF00839140
   Ma SX, 2000, BRAIN RES, V855, P124, DOI 10.1016/S0006-8993(99)02379-3
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Pasetto LM, 2006, CRIT REV ONCOL HEMAT, V59, P159, DOI 10.1016/j.critrevonc.2006.01.001
   Phillips KD, 2004, J ALTERN COMPLEM MED, V10, P449, DOI 10.1089/1075553041323678
   Quan D, 2002, PRINCIPLES PRACTICE, V0, P545
   ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590
   Sioka C, 2009, CANCER CHEMOTH PHARM, V63, P761, DOI 10.1007/s00280-008-0876-6
   SJOLUND B, 1977, ACTA PHYSIOL SCAND, V100, P382, DOI 10.1111/j.1748-1716.1977.tb05964.x
   Smith F W Jr, 1992, PROBL VET MED, V4, P34
   Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004
   Weiss RB, 2005, CANC PRINCIPLES PRAC, V0, P2602
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   World Health Organization, 2008, WHO STANDARD ACUPUNCTURE POINT LOCATIONS IN THE WESTERN PACIFIC REGION, V1st ed., P0
NR 29
TC 13
Z9 22
U1 0
U2 19
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2013
VL 2013
IS 
BP 
EP 
DI 10.1155/2013/928129
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 158HP
UT WOS:000319960400001
PM 23762168
DA 2026-01-16
ER

PT J
AU Yang, JR
   Zhang, JP
   Yu, JC
   Han, JX
AF Yang, Jun-Rion
   Zhang, Jian-Ping
   Yu, Jian-Chun
   Han, Jing-Xian
TI [Lumbar disc herniation treated with qi pathway intervention and spinal
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
AB OBJECTIVE: To compare the efficacy difference in the treatment of lumbar disc  herniation (LDH) between the comprehensive therapy of qi pathway intervention and  the spinal adjustment and the conventional therapy of acupuncture and Tuina and  explore the analgesic mechanism. METHODS: Seventy-one cases were randomized into  a comprehensive therapy group (36 cases) and a conventional therapy group (35  cases). In the comprehensive therapy group, the acupoints in the region of  abdominal qi pathway were selected and stimulated manually with both hands. In  combination, the spinal adjustment therapy was applied. In the conventional  therapy group, Shenshu (BL 23), Dachangshu (BL 25), Huantiao (GB 30) and Chengfu  (BL 36) on the affected side were selected and stimulated with the conventional  needling technique. Additionally, the routine Tuina therapy was applied. Before  and after treatment, the visual analogue scale (VAS), Oswestry disability index  (ODI) questionnaire, the health related quality of life (SF-36) questionnaire and  the level of serum tumor necrosis factor (TNF-alpha) were adopted to determine  analgesic effect and clinical efficacy. RESULTS: In the comprehensive therapy  group, the curative and effective rate was 91.7% (33/36), which was apparently  superior to 77.1% (27/35) in the conventional therapy group (P < 0.05). The  analgesic effect in the first 10 treatments in the comprehensive therapy group  was apparently superior to that in the conventional therapy group (P < 0.05). ODI  after treatment was improved significantly in both groups (both P < 0.05), in  which the result in the comprehensive therapy group was superior to that in the  conventional therapy group (P < 0.05). After treatment, the SF-36 values of gener  al health, bodily pain, physiological functioning, social functioning and  emotional functioning in the comprehensive therapy group were superior to that in  the conventional therapy group (all P < 0.05). After 15 treatments, the level of  serum TNF-alpha in the comprehensive therapy group was lowered as compared with  that before treatment and lower apparently than that in the conventional therapy  group (P < 0.05); after 30 treatments, it was also lower than that in  conventional therapy group (P < 0.05). CONCLUSION: In the guide of the theory of  qi pathway, the comprehensive therapy of acupuncture and spinal adjustment  intervention achieves the quick and good efficacy on LDH as compared with the  conventional acupuncture and Tuina and improves the quality of life for the  patients to certain extent. The analgesic effect of this therapy is relevant with  the decrease of serum TNF-alpha.
C1 Department of Acupuncture and Moxibustion, Affiliated HOsiptal of Tongren Occupation Technical College, Tongren 554300, Guizhou Province, China.yangjunxiong_320@163.com
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUL 4
PY 2013
VL 33
IS 4
BP 289
EP 93
DI 
PG -196
WC Acupuncture Points; Acupuncture Therapy; Adult; Aged; Female; Humans; Intervertebral Disc Displacement; blood; Male; Manipulation, Spinal; Middle Aged; Qi; Treatment Outcome; Tumor Necrosis Factor-alpha; blood; Young Adult
UT PubMed:23819224
PM 23819224
DA 2013-07-04
ER

PT J
AU Jeong, JH
   Song, JY
   Jo, HG
   Kim, JM
   Yoon, SS
   Park, C
   Kim, S
   Roh, SS
   Lee, BH
   Yang, CH
   Kim, HY
AF Jeong, Jong-Ho
   Song, Joo-Young
   Jo, Hyo-Gwon
   Kim, Ji-Min
   Yoon, Samuel-S.
   Park, Chul
   Kim, Seunghyun
   Roh, Seong-Soo
   Lee, Bong Hyo
   Yang, Chae Ha
   Kim, Hee Young
TI Simple Acupoints Prescription Flow Chart Based on Meridian Theory: A Retrospective Study in 102 Dogs
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID intervertebral-disk disease; acupuncture pretreatment; myocardial-ischemia; manual acupuncture; electroacupuncture; rats; nausea; acupressure; cancer; gv01
AB To help the clinicians prescribe acupoints easily and effectively, we developed one simple flow chart to select acupoints. This study aimed to evaluate the usefulness of flow chart to select acupoints in dogs. Total 102 dogs showing intervertebral disc disease (IVDD) (n = 12), vomiting (n = 11), diarrhea (n = 2), abdominal pain (n = 5), cough (n = 66), or epilepsy (n = 6) received acupuncture treatment according to the chart, and its outcomes were evaluated as regards clinical symptoms, duration, treatment numbers, and recovery time. Dogs (8/8) with IVDD from grades I to III recovered over periods of 5 days to 6 weeks after 1-12 treatments, while 1/4 dogs with grade IV recovered over 7 weeks after 15 treatments. Vomiting dogs with acute/subacute (n = 8) and chronic symptoms (n = 3) required about 1 and 7 treatments to recover fully, respectively. All dogs (n = 5) with abdominal pain showed fast relief within 24 hours after acupuncture. Two diarrhea cases recovered over 2-9 days after 1-2 treatments. Fifty-four of 66 coughing dogs were recovered by 1-2 treatments. And 5 of 6 epilepsy dogs under a regular acupuncture treatment had no epileptic episode during followup of 12 months. These results suggest that this flow chart can help the clinicians prescribe acupoints effectively.
C1 [Jeong, Jong-Ho] Boo Young Anim Hosp, Namyangju Si 472080, Gyeonggi Do, South Korea.
   [Song, Joo-Young] Sarang Anim Hosp, Seoul 152053, South Korea.
   [Jo, Hyo-Gwon] Jakjeon 24 Hour Anim Hosp, Incheonsi 407060, Gyeonggi Do, South Korea.
   [Kim, Ji-Min] Jun Anim Hosp, Anyangsi 431088, Gyeonggi Do, South Korea.
   [Yoon, Samuel-S.] Twin City Anim Hosp, Fitchburg, MA 01420 USA.
   [Park, Chul] Chonbuk Natl Univ, Dept Vet Internal Med, Coll Vet Med, Jeonju Si 561756, Jeollabuk Do, South Korea.
   [Kim, Seunghyun; Roh, Seong-Soo; Lee, Bong Hyo; Yang, Chae Ha] Daegu Haany Univ, Coll Korean Med, Taegu 706828, South Korea.
   [Kim, Hee Young] Daegu Haany Univ, Dept Physiol, Coll Korean Med, Taegu 706828, South Korea.
C3 Jeonbuk National University; Daegu Haany University; Daegu Haany University
RP Kim, HY (corresponding author), Daegu Haany Univ, Dept Physiol, Coll Korean Med, Taegu 706828, South Korea.
EM hykim@dhu.ac.kr
FU National Research Foundation of Korea (NRF); Korea Government (MEST) [20120009400]; International Veterinary Acupuncture Society (IVAS) via the Grady Young Memorial Scholarship program
CR AlSadi M, 1997, ANAESTHESIA, V52, P658, DOI 10.1111/j.1365-2044.1997.143-az0147.x
   An Y, 2002, ALL GUIDE ACUPUNCTUR, V0, P0
   Aschkenazi SO, 2009, ALTERNATIVE THERAPIE, V0, P0
   Buchli R, 1975, VET MED SMALL ANIMAL, V70, P0
   Cabyoglu MT, 2006, INT J NEUROSCI, V116, P115, DOI 10.1080/00207450500341472
   CAI WY, 1992, AM J CHINESE MED, V20, P331, DOI 10.1142/S0192415X92000369
   Carlsson CPO, 2000, J PAIN SYMPTOM MANAG, V20, P273, DOI 10.1016/S0885-3924(00)00185-8
   CHANG PL, 1993, AM J CHINESE MED, V21, P231, DOI 10.1142/S0192415X93000261
   Chung IM, 2008, NEUROSCI LETT, V439, P18, DOI 10.1016/j.neulet.2008.04.100
   Coates JR, 2000, VET CLIN N AM-SMALL, V30, P77, DOI 10.1016/S0195-5616(00)50004-7
   Coeytaux RR, 2006, J ALTERN COMPLEM MED, V12, P863, DOI 10.1089/acm.2006.12.863
   COFFIN B, 1994, GASTROENTEROLOGY, V107, P1636, DOI 10.1016/0016-5085(94)90802-8
   Cui KM, 2005, NEUROSCI LETT, V376, P20, DOI 10.1016/j.neulet.2004.11.018
   Dent HE, 2003, COMPLEMENT THER MED, V11, P72, DOI 10.1016/S0965-2299(03)00058-X
   Durkes T E, 1992, PROBL VET MED, V4, P207
   Freire AO, 2007, SLEEP MED, V8, P43, DOI 10.1016/j.sleep.2006.04.009
   Gao JH, 2007, LIFE SCI, V80, P1484, DOI 10.1016/j.lfs.2007.01.019
   Gao JH, 2006, J PHYSIOL SCI, V56, P275, DOI 10.2170/physiolsci.RP006606
   Gardani G, 2006, MINERVA MED, V97, P391
   Gardani G, 2007, MINERVA MED, V98, P665
   Giamberardino MA, 1999, EUR J PAIN, V3, P77, DOI 10.1053/eujp.1999.0117
   Glinski MH, 2001, VET ACUPUNCTURE ANCI, V0, P113
   Hayashi AM, 2007, JAVMA-J AM VET MED A, V231, P913, DOI 10.2460/javma.231.6.913
   Hayashi AM, 2007, J VET SCI, V8, P95, DOI 10.4142/jvs.2007.8.1.95
   HWANG YC, 1988, AM J VET RES, V49, P1641
   Iwa M, 2006, AM J PHYSIOL-GASTR L, V290, PG285, DOI 10.1152/ajpgi.00068.2005
   Iwa M, 2006, NEUROSCI LETT, V399, P6, DOI 10.1016/j.neulet.2005.11.069
   Jaggar DH, 2002, VET ACUPUNCTURE ANCI, V0, P3
   Jang Jae Young, 2006, KOREAN JOURNAL OF ACUPUNCTURE, V23, P27
   Jang KJ, 1996, J KOREA ACUPUNCTURE, V13, P384
   Janssens L A, 1992, PROBL VET MED, V4, P107
   Janssens LA, 2002, VET ACUPUNCTURE ANCI, V0, P193
   JANSSENS LAA, 1989, VET REC, V124, P283, DOI 10.1136/vr.124.11.283-b
   Jeong HC, 1996, J KOREAN ACUPUNCTURE, V13, P292
   Jeong SeongMok Jeong SeongMok, 2004, JOURNAL OF VETERINARY CLINICS, V21, P49
   JIANG R, 1990, JOURNAL OF TRADITIONAL CHINESE MEDICINE, V10, P20
   Kang SB, 2000, ACUPUNCTURE MOXIBUST, V0, P0
   Karst M, 2001, CEPHALALGIA, V21, P637, DOI 10.1046/j.1468-2982.2001.00198.x
   Kim H, 2004, CANINE ACUPUNCTURE, V0, P0
   Kim HY, 2007, J PHYSIOL SCI, V57, P253, DOI 10.2170/physiolsci.SC001607
   Kim HY, 2006, J PHYSIOL SCI, V56, P317, DOI 10.2170/physiolsci.SC001606
   Kim HY, 2005, JPN J PHYSIOL, V55, P205, DOI 10.2170/jjphysiol.S647
   Kim YooSu Kim YooSu, 2005, JOURNAL OF VETERINARY CLINICS, V22, P202
   KLIDE AM, 1987, ACUPUNCTURE ELECTRO, V12, P71, DOI 10.3727/036012987816358931
   Kline KL, 2002, CLIN TECH SMALL AN P, V17, P25, DOI 10.1053/svms.2002.29075
   Kuruvilla A, 2007, MED ACUPUNCT, V19, P137, DOI 10.1089/acu.2007.0514
   인창식, 2002, JOURNAL OF ACUPUNCTURE RESEARCH, V19, P42
   Lee BH, 2005, J KOREAN ACUPUNCTURE, V22, P101
   Lee CH, 2003, J KOREAN ACUPUNCTURE, V20, P168
   Lee GS, 1998, J KOREAN ACAD MED GI, V2, P103
   Lin JG, 1996, CHINESE MED J-PEKING, V109, P482
   Litscher G, 2010, EVID-BASED COMPL ALT, V7, P151, DOI 10.1093/ecam/nen034
   Lubbe AM, 1990, J S AFRICAN VET ASS, V61, P0
   Luo D, 2008, DIGEST DIS SCI, V53, P689, DOI 10.1007/s10620-007-9929-7
   Maciocia G, 1989, THE FOUNDATIONS OF CHINESE MEDICINE: A COMPREHENSIVE TEXT FOR ACUPUNCTURISTS AND HERBALISTS, V0, P0
   Mayor DF, 2008, DTSCH Z AKUPUNKT, V51, P26, DOI 10.1016/j.dza.2008.05.006
   Morey SS, 1998, AM FAM PHYSICIAN, V57, P2545
   Nystrom E, 2008, ACUPUNCT MED, V26, P27, DOI 10.1136/aim.26.1.27
   PANZER RB, 1994, AM J CHINESE MED, V22, P11, DOI 10.1142/S0192415X94000036
   Park Eun-sung, 2003, J VET SCI, V4, P125
   Peuker Elmar, 2004, ACUPUNCT MED, V22, P40
   PHILP T, 1988, BRIT J UROL, V61, P490, DOI 10.1111/j.1464-410X.1988.tb05086.x
   Qi LZ, 2005, J ACUPUNCTURE TUINA, V3, P3
   Qin-Feng H, 2005, J ACUPUNCTURE TUINA, V3, P7
   Scavelli T D, 1989, PROBL VET MED, V1, P402
   Schwartz C, 1992, PROBL VET MED, V4, P136
   Schwartz C, 2001, VETERINARY ACUPUNCTURE: ANCIENT ART TO MODERN MEDICINE, V2A, P149
   Shiotani A, 2004, NEUROGASTROENT MOTIL, V16, P293, DOI 10.1111/j.1365-2982.2004.00504.x
   Steiss JE, 2001, VETERINARY ACUPUNCTURE: ANCIENT ART TO MODERN MEDICINE, V2A, P27
   STILL J, 1990, J S AFR VET ASSOC, V61, P102
   Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6
   Tatewaki M, 2005, AM J PHYSIOL-REG I, V288, PR401, DOI 10.1152/ajpregu.00344.2004
   Tian L, 2003, WORLD J GASTROENTERO, V9, P1028
   Tsou MT, 2004, AM J CHINESE MED, V32, P951, DOI 10.1142/S0192415X04002557
   VANNIEKERK J, 1988, J S AFR VET ASSOC, V59, P5
   Wang SB, 2008, WORLD J GASTROENTERO, V14, P6496, DOI 10.3748/wjg.14.6496
   Xie H, 2007, ACUPUNCTURE INTERNAL, V0, P0
   Xing JH, 2004, ALTERN THER HEALTH M, V10, P38
   Xu S, 1995, J TRADIT CHIN MED, V15, P189
   Yi Wei-Min, 2008, ZHONGGUO ZHEN JIU, V28, P653
   Zhang SY, 2005, J ACUPUNCTURE TUINA, V3, P24
   ZWOLFER W, 1993, AM J CHINESE MED, V21, P113, DOI 10.1142/S0192415X93000145
NR 82
TC 2
Z9 3
U1 1
U2 32
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2013
VL 2013
IS 
BP 
EP 
DI 10.1155/2013/129315
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 157UD
UT WOS:000319923800001
PM 23762103
DA 2026-01-16
ER

PT J
AU Ju, ZY
   Cui, HS
   Guo, XH
   Yang, HY
   He, JS
   Wang, K
AF Ju, Ziyong
   Cui, Huashun
   Guo, Xiaohui
   Yang, Huayuan
   He, Jinsen
   Wang, Ke
TI Molecular mechanisms underlying the effects of acupuncture on neuropathic pain
SO NEURAL REGENERATION RESEARCH
LA English
DT Article
DE neural regeneration; acupuncture; neuropathic pain; chronic constriction injury; electroacupuncture; spinal dorsal horn; ephrin-B/EphB signaling; nerve repair; grants-supported paper; neuroregeneration
ID spinal nerve ligation; randomized controlled-trial; activated protein-kinase; dorsal-root ganglion; bone cancer pain; manual acupuncture; cord-injury; frequency electroacupuncture; clinical-applications; cell-proliferation
AB Acupuncture has been used to treat neuropathic pain for a long time, but its mechanisms of action remain unknown. In this study, we observed the effects of electroacupuncture and manual acupuncture on neuropathic pain and on ephrin-B/EphB signaling in rats models of chronic constriction injury-induced neuropathic pain. The results showed that manual acupuncture and electroacupuncture significantly reduced mechanical hypersensitivity following chronic constriction injury, especially electroacupuncture treatment. Real-time PCR results revealed that ephrin-B1/B3 and EphB1/B2 mRNA expression levels were significantly increased in the spinal dorsal horns of chronic constriction injury rats. Electroacupuncture and manual acupuncture suppressed the high expression of ephrin-B1 mRNA, and elevated EphB3/B4 mRNA expression. Electroacupuncture significantly enhanced the mRNA expression of ephrin-B3 and EphB3/B6 in the dorsal horns of neuropathic pain rats. Western blot results revealed that electroacupuncture in particular, and manual acupuncture, significantly up-regulated ephrin-B3 protein levels in rat spinal dorsal horns. The results of this study suggest that acupuncture could activate ephrin-B/EphB signaling in neuropathic pain rats and improve neurological function.
C1 [Ju, Ziyong; Guo, Xiaohui; Yang, Huayuan; He, Jinsen] Shanghai Univ Tradit Chinese Med, Coll Acumox & Tuina, Shanghai 201203, Peoples R China.
   [Cui, Huashun] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Acupuncture, Shanghai 201203, Peoples R China.
   [Wang, Ke] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Cardiothorac Surg, Shanghai 201203, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP He, JS (corresponding author), Shanghai Univ Tradit Chinese Med, Coll Acumox & Tuina, Shanghai 201203, Peoples R China.
EM hejinsen@citiz.net; wangke8430@163.com
FU China Postdoctoral Science Foundation [20100480643]; Program of Shanghai Municipal Education Commission [2011JW13]
CR Ahn CB, 2011, J ACUPUNCT MERIDIAN, V4, P29, DOI 10.1016/S2005-2901(11)60005-8
   Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408
   BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6
   Bridges D, 2001, BRIT J ANAESTH, V87, P12, DOI 10.1093/bja/87.1.12
   Bush JO, 2012, SEMIN CELL DEV BIOL, V23, P26, DOI 10.1016/j.semcdb.2011.10.018
   Cabyoglu MT, 2006, INT J NEUROSCI, V116, P115, DOI 10.1080/00207450500341472
   Cao JL, 2008, PAIN, V139, P617, DOI 10.1016/j.pain.2008.06.023
   Cavenagh J, 2006, INTERN MED J, V36, P251, DOI 10.1111/j.1445-5994.2006.01046.x
   Chen Y, 2008, NEURON GLIA BIOL, V4, P211, DOI 10.1017/S1740925X09990287
   Chiu HHE, 2011, J ALTERN COMPLEM MED, V17, P915, DOI 10.1089/acm.2010.0082
   Choi DC, 2012, EXP NEUROL, V236, P268, DOI 10.1016/j.expneurol.2012.05.014
   Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003
   Chumley MJ, 2007, J NEUROSCI, V27, P13481, DOI 10.1523/JNEUROSCI.4158-07.2007
   Cidral FJ, 2011, NEUROSCIENCE, V193, P370, DOI 10.1016/j.neuroscience.2011.07.076
   Dong Y, 2011, NEUROSCI LETT, V496, P163, DOI 10.1016/j.neulet.2011.04.008
   Dray A, 2008, BRIT J ANAESTH, V101, P48, DOI 10.1093/bja/aen107
   Du J, 2007, CURR PHARM DESIGN, V13, P2507
   Feng Y, 2012, EXP PHYSIOL, V97, P651, DOI 10.1113/expphysiol.2011.063131
   Fornasari D, 2012, CLIN DRUG INVEST, V32, P45, DOI 10.2165/11630070-000000000-00000
   Fume C, 2009, BIOCHIM BIOPHYS ACTA, V1793, P231
   Galea MP, 2012, CLIN NEUROL NEUROSUR, V114, P483, DOI 10.1016/j.clineuro.2012.01.009
   Garg G, 2012, CHIN J INTEGR MED, V18, P565, DOI 10.1007/s11655-012-1188-6
   Guan XH, 2010, PHARMACOL BIOCHEM BE, V95, P315, DOI 10.1016/j.pbb.2010.02.007
   Han Mei, 2011, SHENGLI XUEBAO, V63, P106
   Hantoushzadeh S, 2007, AUST NZ J OBSTET GYN, V47, P26, DOI 10.1111/j.1479-828X.2006.00674.x
   Hruska M, 2012, MOL CELL NEUROSCI, V50, P35, DOI 10.1016/j.mcn.2012.03.004
   Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040
   Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011
   Jin SX, 2003, J NEUROSCI, V23, P4017
   Kang BR, 2007, AM J CHINESE MED, V35, P987, DOI 10.1142/S0192415X07005454
   Kim SK, 2005, EXP NEUROL, V195, P430, DOI 10.1016/j.expneurol.2005.06.018
   Klein R, 2009, NAT NEUROSCI, V12, P15, DOI 10.1038/nn.2231
   Lau WK, 2010, NEUROSCIENCE, V170, P655, DOI 10.1016/j.neuroscience.2010.07.031
   Li W, 2011, J NEUROSCI, V31, P8441, DOI 10.1523/JNEUROSCI.6343-10.2011
   Liu S, 2011, CANCER RES, V71, P4392, DOI 10.1158/0008-5472.CAN-10-3870
   Liu X, 2006, J NEUROSCI, V26, P3087, DOI 10.1523/JNEUROSCI.4797-05.2006
   Liu Z, 2011, CURR MED CHEM, V18, P5165, DOI 10.2174/092986711797636144
   Manni L, 2011, ARCH ITAL BIOL, V149, P247, DOI 10.4449/aib.v149i2.1365
   McClelland AC, 2010, P NATL ACAD SCI USA, V107, P8830, DOI 10.1073/pnas.0910644107
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Mischoulon D, 2012, J AFFECT DISORDERS, V141, P469, DOI 10.1016/j.jad.2012.03.023
   Muir D, 2010, EXP NEUROL, V223, P102, DOI 10.1016/j.expneurol.2009.05.038
   Norrbrink C, 2011, ACUPUNCT MED, V29, P108, DOI 10.1136/aim.2010.003269
   Obata K, 2004, J NEUROSCI, V24, P10211, DOI 10.1523/JNEUROSCI.3388-04.2004
   Obata K, 2004, LIFE SCI, V74, P2643, DOI 10.1016/j.lfs.2004.01.007
   Orikawa Y, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-72
   Park JH, 2009, J PHYSIOL SCI, V59, P291, DOI 10.1007/s12576-009-0035-9
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Ricard J, 2006, MOL CELL NEUROSCI, V31, P713, DOI 10.1016/j.mcn.2006.01.002
   Ruan JP, 2010, ANESTHESIOLOGY, V112, P1234, DOI 10.1097/ALN.0b013e3181d3e0df
   Ryu JW, 2008, BRAIN RES BULL, V75, P687, DOI 10.1016/j.brainresbull.2007.11.005
   Salvucci O, 2012, ADV CANCER RES, V114, P21, DOI 10.1016/B978-0-12-386503-8.00002-8
   Sator-Katzenschlager SM, 2004, ANESTH ANALG, V98, P1359, DOI 10.1213/01.ANE.0000107941.16173.F7
   Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x
   Sentürk A, 2011, NATURE, V472, P356, DOI 10.1038/nature09874
   Shi GX, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-42
   Shukla S, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-45
   Sloniowski S, 2012, SEMIN CELL DEV BIOL, V23, P75, DOI 10.1016/j.semcdb.2011.10.020
   Smith BH, 2012, CURR PAIN HEADACHE R, V16, P191, DOI 10.1007/s11916-012-0256-0
   Song XJ, 2008, EUR J PAIN, V12, P1031, DOI 10.1016/j.ejpain.2008.01.011
   Sun RQ, 2004, EXP NEUROL, V187, P23, DOI 10.1016/j.expneurol.2003.12.011
   The Ministry of Science and Technology of the Peoples Republic of China, 2006, GUID SUGG CAR US LAB, V0, P0
   Udina E, 2011, ANN ANAT, V193, P347, DOI 10.1016/j.aanat.2011.02.012
   Wang K, 2012, J NEUROSCI RES, V90, P1464, DOI 10.1002/jnr.23028
   Wang LP, 2011, PAIN, V152, P1864, DOI 10.1016/j.pain.2011.04.006
   Wang LN, 2006, BRAIN RES, V1120, P46, DOI 10.1016/j.brainres.2006.08.077
   Xiong J, 2012, CHIN J INTEGR MED, V18, P7, DOI 10.1007/s11655-011-0857-1
   Xu KD, 2010, CHINESE MED J-PEKING, V123, P1176, DOI 10.3760/cma.j.issn.0366-6999.2010.09.014
   Xu NJ, 2012, SEMIN CELL DEV BIOL, V23, P58, DOI 10.1016/j.semcdb.2011.10.024
   Yang JL, 2011, BRAIN BEHAV IMMUN, V25, P1452, DOI 10.1016/j.bbi.2011.05.012
   Zhang Y, 2011, NEUROCHEM RES, V36, P1785, DOI 10.1007/s11064-011-0495-1
   Zhang YH, 2011, J CRANIOFAC SURG, V22, P1626, DOI 10.1097/SCS.0b013e31822e5f07
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 74
TC 14
Z9 21
U1 0
U2 41
PU SHENYANG EDITORIAL DEPT NEURAL REGENERATION RES
PI SHENYANG
PA PO BOX 1234, SHENYANG, LIAONING 110004, PEOPLES R CHINA
SN 1673-5374
EI 
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD SEP 15
PY 2013
VL 8
IS 25
BP 2350
EP 2359
DI 10.3969/j.issn.1673-5374.2013.25.006
PG 10
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA 229CL
UT WOS:000325239300006
PM 25206545
DA 2026-01-16
ER

PT J
AU Posadzki, P
   Moon, TW
   Choi, TY
   Park, TY
   Lee, MS
   Ernst, E
AF Posadzki, Paul
   Moon, Tae-Woong
   Choi, Tae-Young
   Park, Tae-Yong
   Lee, Myeong Soo
   Ernst, Edzard
TI Acupuncture for cancer-related fatigue: a systematic review of randomized clinical trials
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Acupuncture; Cancer; Fatigue; Systematic review; Effectiveness
ID management; pain
AB Managing cancer-related fatigue (CRF) is an important element of the palliative care of cancer patients. The aim of this systematic review was to critically evaluate the effectiveness of acupuncture (AT) or electroacupuncture (EA) for CRF. Fourteen databases were searched from their respective inception to November 2012. Randomized clinical trials (RCTs) of AT or EA for the treatment of CRF were considered for inclusion. The risk of bias/methodological quality was assessed using the method suggested by the Cochrane Collaboration. Seven RCTs met the eligibility criteria. Most were small pilot studies with serious methodological flaws. Four of the RCTs showed effectiveness of AT or AT in addition to usual care (UC) over sham AT, UC, enhanced UC, or no intervention for alleviating CRF. Three RCTs showed no effect of AT/EA over sham treatment. Overall, the quantity and quality of RCTs included in the analysis were too low to draw meaningful conclusions. Even in the positive trials, it remained unclear whether the observed outcome was due to specific effects of AT/EA or nonspecific effects of care. Further research is required to investigate whether AT/EA demonstrates specific effects on CRF.
C1 [Posadzki, Paul; Moon, Tae-Woong; Choi, Tae-Young; Park, Tae-Yong; Lee, Myeong Soo] Korea Inst Oriental Med, KM Hlth Technol Res Grp, Div Med Res, Taejon 305811, South Korea.
   [Posadzki, Paul; Lee, Myeong Soo; Ernst, Edzard] Univ Exeter, Peninsula Med Sch, Exeter, Devon, England.
C3 Korea Institute of Oriental Medicine (KIOM); University of Exeter
RP Posadzki, P (corresponding author), Univ Exeter, Peninsula Med Sch, Exeter, Devon, England.
EM paul.posadzki@pcmd.ac.uk
FU KIOM [K12130, C12080]
CR Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Ben-Aharon I, 2008, J CLIN ONCOL, V26, P2396, DOI 10.1200/JCO.2007.15.5796
   Brown LF, 2009, PSYCHOSOMATICS, V50, P440, DOI 10.1176/appi.psy.50.5.440
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   DENG G, 2010, J SOC INTEGR ONCOL, V8, P171
   DONOVAN KA, 2012, PSYCHO-ONCOLOGY, V0, P0, DOI DOI 10.1002/P0N.3085
   EDZARD E, 2012, FOCUS ALTERNAT COMPL, V17, P15
   Ernst E, 2005, POSTGRAD MED J, V81, P203, DOI 10.1136/pgmj.2004.026807
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.03.010
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Hofman M, 2007, ONCOLOGIST, V12, P4, DOI 10.1634/theoncologist.12-S1-4
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-49
   Kuchinski Anne-Marie, 2009, MEDSURG NURS, V18, P174
   Lee MS, 2009, SUPPORT CARE CANCER, V17, P763, DOI 10.1007/s00520-009-0589-3
   Minton O, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006704.pub2
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   OH D, 2009, THESIS KYUNG HEE U, V0, P0
   Oh HS, 2011, WORLDV EVID-BASED NU, V8, P191, DOI 10.1111/j.1741-6787.2011.00214.x
   Richardson PG, 2010, J NATL COMPR CANC NE, V8, P0
   Saligan LN, 2012, BRAIN BEHAV IMMUN, V26, P830, DOI 10.1016/j.bbi.2012.05.004
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Stone JAM, 2010, CURR TREAT OPTION ON, V11, P118, DOI 10.1007/s11864-010-0128-y
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wanchai A, 2011, CLIN J ONCOL NURS, V15, P203, DOI 10.1188/11.CJON.203-214
NR 25
TC 42
Z9 51
U1 0
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUL 15
PY 2013
VL 21
IS 7
BP 2067
EP 2073
DI 10.1007/s00520-013-1765-z
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 155ME
UT WOS:000319751500034
PM 23435597
DA 2026-01-16
ER

PT J
AU Lu, LM
   Liao, MX
   Zeng, JC
   He, J
AF Lu, Liming
   Liao, Muxi
   Zeng, Jingchun
   He, Jun
TI Quality of reporting and its correlates among randomized controlled trials on acupuncture for cancer pain: application of the CONSORT 2010 Statement and STRICTA
SO EXPERT REVIEW OF ANTICANCER THERAPY
LA English
DT Review
DE acupuncture; cancer pain; quality of reporting; randomized controlled trials; STRICTA; the CONSORT Statement
ID management; recommendations; impact
AB This study aims to analyze the quality of reporting and its correlates in randomized controlled trials (RCTs) on acupuncture for cancer pain. Quality of reporting for included papers was assessed against a subset of criteria adapted from the CONSORT 2010 statement and STRICTA. An overall quality score (OQS) and a combined key methodologic index score (MIS) was calculated for each trial. Factors associated with OQS and MIS were then identified. A total of 32 RCTs were included in the full text. The median OQS based on the CONSORT Statement and STRICTA was 4.0 and 0, respectively. The significant predictors for CONSORT OQS were year of publication and nationality of authors, for STRICTA it was nationality of authors and for MIS it was publication language. The quality of reporting in RCTs on acupuncture for cancer pain was poor. This indicates that RCTs on acupuncture for cancer pain need substantial improvement.
C1 [Lu, Liming] Sun Yat Sen Univ, Sch Publ Hlth, Fac Med Stat & Epidemiol, Guangzhou 510080, Guangdong, Peoples R China.
   [Liao, Muxi; He, Jun] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Acupuncture, Guangzhou 510405, Guangdong, Peoples R China.
   [Liao, Muxi] Guangzhou Univ Chinese Med, Guangzhou 510405, Guangdong, Peoples R China.
   [Zeng, Jingchun] People Hosp Pingyang, Dept Dermatol, Wenzhou 325400, Peoples R China.
C3 Sun Yat Sen University; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Liao, MX (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Acupuncture, Guangzhou 510405, Guangdong, Peoples R China.
EM liaomuxi1@163.com
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Allen JJB, 1998, PSYCHOL SCI, V9, P397, DOI 10.1111/1467-9280.00074
   Unknown -, 2005, BMJ-BRIT MED J, V0, P0
   Unknown -, 2011, EVID BASED COMPLEMEN, V0, P0
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Bradley N, 2005, J PAIN SYMPTOM MANAG, V30, P123, DOI 10.1016/j.jpainsymman.2005.02.015
   Cassileth Barrie, 2007, CURR PAIN HEADACHE REP, V11, P265, DOI 10.1007/s11916-007-0202-8
   Cata JP, 2006, MINERVA ANESTESIOL, V72, P151
   Cleary JF, 2007, J PALLIAT MED, V10, P1369, DOI 10.1089/jpm.2007.9842
   Di Maio M, 2004, BRIT J CANCER, V90, P2288, DOI 10.1038/sj.bjc.6601810
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.03.010
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   FILSHIE J, 1990, ACUPUNCT MED, V8, P38
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618
   GODFREY CM, 1978, J RHEUMATOL, V5, P121
   Hammerschlag R, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/183910
   HANSEN PE, 1985, CEPHALALGIA, V5, P137, DOI 10.1046/j.1468-2982.1985.0503137.x
   Harris JD, 2008, CLIN J PAIN, V24, PS8, DOI 10.1097/AJP.0b013e31816b58eb
   Hugh Macpherson, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P804
   Huwiler-Müntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801
   Hwang SS, 2004, J PAIN SYMPTOM MANAG, V28, P421, DOI 10.1016/j.jpainsymman.2004.02.023
   Keskinbora K, 2007, J PAIN SYMPTOM MANAG, V34, P183, DOI 10.1016/j.jpainsymman.2006.11.013
   Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4
   Laird B, 2008, EUR J CANCER, V44, P1078, DOI 10.1016/j.ejca.2008.03.022
   Pignon T, 2004, INT J RADIAT ONCOL, V60, P1204, DOI 10.1016/j.ijrobp.2004.04.040
   Prady SL, 2008, PLOS ONE, V3, P0, DOI 10.1371/journal.pone.0001577
   Prady SL, 2007, J ALTERN COMPLEM MED, V13, P939, DOI 10.1089/acm.2007.7186
   Rietman J, 2004, DISABIL REHABIL, V26, P78, DOI 10.1080/09638280310001629642
   SCHUG SA, 1992, DRUG SAFETY, V7, P200, DOI 10.2165/00002018-199207030-00005
   Schulz KF, 2010, EPIDEMIOL BIOSTAT PU, V7, P325
   SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Stjernsward J, 1996, J PAIN SYMPTOM MANAG, V12, P65, DOI 10.1016/0885-3924(96)00109-1
   Taylor KO, 2004, ANZ J SURG, V74, P314, DOI 10.1111/j.1445-1433.2004.02992.x
   Toulmonde M, 2011, J CLIN ONCOL, V29, P1204, DOI 10.1200/JCO.2010.30.9369
   Uetani K, 2009, INTERNAL MED, V48, P307, DOI 10.2169/internalmedicine.48.1358
   Vallerand AH, 2007, PAIN, V132, P82, DOI 10.1016/j.pain.2007.01.029
   White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489
   Wilson KG, 2004, CAN J PSYCHIAT, V49, P350, DOI 10.1177/070674370404900603
   Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD
NR 42
TC 23
Z9 25
U1 0
U2 23
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1473-7140
EI 1744-8328
J9 EXPERT REV ANTICANC
JI Expert Rev. Anticancer Ther
PD APR 15
PY 2013
VL 13
IS 4
BP 489
EP 498
DI 10.1586/ERA.13.27
PG 10
WC Oncology
SC Oncology
GA 133MD
UT WOS:000318141600017
PM 23560843
DA 2026-01-16
ER

PT J
AU Mao, JJ
   Xie, SR
   Farrar, JT
   Stricker, CT
   Bowman, M
   Bruner, D
   DeMichele, A
AF Mao, Jun J.
   Xie, Sharon
   Farrar, John T.
   Stricker, Carrie Tompkins
   Bowman, Marjorie
   Bruner, Deborah
   DeMichele, Angela
TI Electro-acupuncture for joint pain related to aromatase inhibitors among breast cancer survivors: A randomized placebo-controlled trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   Wright State Univ, Sch Med, Dayton, OH USA.
   Emory Univ, Neil Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA.
C3 University of Pennsylvania; University of Pennsylvania; University System of Ohio; Wright State University Dayton; Emory University
NR 0
TC 0
Z9 0
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
BP 
EP 
DI 
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603122
DA 2026-01-16
ER

PT J
AU Lu, L
   Liao, M
   Zeng, J
   He, J
AF Lu, Liming
   Liao, Muxi
   Zeng, Jingchun
   He, Jun
TI Quality of reporting and its correlates among randomized controlled trials on
SO Expert review of anticancer therapy
LA English
DT Review
AB This study aims to analyze the quality of reporting and its correlates in  randomized controlled trials (RCTs) on acupuncture for cancer pain. Quality of  reporting for included papers was assessed against a subset of criteria adapted  from the CONSORT 2010 statement and STRICTA. An overall quality score (OQS) and a  combined key methodologic index score (MIS) was calculated for each trial.  Factors associated with OQS and MIS were then identified. A total of 32 RCTs were  included in the full text. The median OQS based on the CONSORT Statement and  STRICTA was 4.0 and 0, respectively. The significant predictors for CONSORT OQS  were year of publication and nationality of authors, for STRICTA it was  nationality of authors and for MIS it was publication language. The quality of  reporting in RCTs on acupuncture for cancer pain was poor. This indicates that  RCTs on acupuncture for cancer pain need substantial improvement.
C1 Faculty of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.
NR 0
TC 0
SN 1744-832
EI 
J9 Expert Rev Anticancer Ther
PD APR 9
PY 2013
VL 13
IS 4
BP 489
EP 98
DI 10.1586/era.13.27
PG -391
WC Acupuncture Therapy; Humans; Neoplasms; complications; Outcome Assessment, Health Care; standards; Pain; etiology; Publishing; standards; Quality Improvement; Randomized Controlled Trials as Topic
UT PubMed:23560843
PM 23560843
DA 2013-04-09
ER

PT J
AU Feuvret, L
   Cuenca, X
   Lavaud, P
   Anane, S
   Colin, E
AF Feuvret, L
   Cuenca, X
   Lavaud, P
   Anane, S
   Colin, E
TI [Pain management in radiation oncology].
SO Cancer radiotherapie : journal de la Societe francaise de radiotherapie
LA fre
DT Journal Article
DE Anticipation; Douleurs; Pain; Plateau technique; Radiation department; Radiation therapy; Radiothérapie
AB The goal of this article is to propose some practical means of pain management in  radiation departments. Pain management in radiation oncology is difficult because  of the high proportion of painful patients, underestimation by medical teams, and  limited therapeutic options. Pain can cause mobilization difficulties, set-up  errors, treatment interruption. According to procedure steps, a preventive  attitude (for pre-radiation consultation) or an active attitude (for treatment)  to quickly relieve the patient can be planned. This work is a brain storming  about pain management. It is not a review about analgesic radiotherapy. The  practical situations apply to patients to whom radiotherapy is indicated.  Teamwork and anticipation are keywords to relieve patients. All proposed means  are not always available for different reasons (time, finance, staff, training).  The idea is to establish simple procedures that are appropriate to each center to  fluidify acts, to optimize time for a successful irradiation.
C1 Service d'oncologie radiothérapie, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
EM oic.feuvret@psl.aphp.fr
NR 0
TC 0
SN 1769-665
EI 
J9 Cancer Radiother
PD AUG 21
PY 2013
VL 17
IS 5-6
BP 523
EP 7
DI 10.1016/j.canrad.2013.05.006
PG -516
WC Acupuncture Therapy; Analgesics, Opioid; therapeutic use; Anti-Anxiety Agents; therapeutic use; Humans; Hypnosis; Muscle Relaxants, Central; therapeutic use; Neoplasms; psychology; Pain Management; methods; Patient Care Team; Physical Therapy Modalities; Radiotherapy; adverse effects
UT PubMed:23948427
PM 23948427
DA 2013-08-21
ER

PT J
AU Smeester, BA
   Al-Gizawiy, M
   Beitz, AJ
AF Smeester, Branden A
   Al-Gizawiy, Mona
   Beitz, Alvin J
TI Effects of different electroacupuncture scheduling regimens on murine bone
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB Previous studies have shown that electroacupuncture (EA) is able to reduce  hyperalgesia in rodent models of persistent pain, but very little is known about  the analgesic effects and potential sex differences of different EA treatment  regimens. In the present study, we examined the effects of five different EA  treatments on tumor-induced hyperalgesia in male and female mice. EA applied to  the ST-36 acupoint either twice weekly (EA-2X/3) beginning on postimplantation  day (PID) 3 or prophylactically three times prior to implantation produced the  most robust and longest lasting antinociceptive effects. EA treatment given once  per week beginning at PID 7 only produced an antinociceptive effect in female  animals. The analgesic effect of EA-2X/3 began earlier in males, but lasted  longer in females indicating sex differences in EA. We further demonstrate that  EA-2X/3 elicits a marked decrease in tumor-associated inflammation as evidenced  by a significant reduction in tumor-associated neutrophils at PID 7. Moreover,  EA-2X/3 produced a significant reduction in tumor-associated PGE(2) as measured  in microperfusate samples. Collectively, these data provide evidence that EA-2X/3  treatment reduces tumor-induced hyperalgesia, which is associated with a decrease  in tumor-associated inflammation and PGE(2) concentration at the tumor site  suggesting possible mechanisms by which EA reduces tumor nociception.
C1 Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108, USA.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD JAN 16
PY 2013
VL 2012
IS 
BP 671386
EP 671386
DI 10.1155/2012/671386
PG 0
UT PubMed:23320035
PM 23320035
DA 2013-01-16
ER

PT J
AU Bontoux, D
   Couturier, D
   Menkès, CJ
AF Bontoux, Daniel
   Couturier, Daniel
   Menkes, Charles-Joel
TI Place of alternative therapies in medical practice (acupuncture, hypnosis, osteopathy, tai-chi, etc.)
SO BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE
LA French
DT Article
DE COMPLEMENTARY THERAPIES; ACUPUNCTURE; HYPNOSIS; MANIPULATION, OSTEOPATHIC; TAI JI; QIGONG; PLACEBO EFFECT
ID low-back-pain; randomized controlled-trial; tension-type headache; spinal manipulation; cancer-chemotherapy; manual therapy; older-adults; osteoarthritis; fibromyalgia; knee
AB Do so-called alternative therapies have a place in the public hospital? The authors were prompted to examine this question following the appearance of these approaches in several public medical centers. Reviews and meta-analyses of controlled clinical trials show that acupuncture, manual osteopathic medicine and hypnosis (the alternative therapies most commonly used in Paris hospitals) are helpful in only a few situation, such as lower back pain, cervical pain, some headaches (acupuncture and spinal manipulations), nausea and vomiting due to cancer chemotherapy (acupuncture and hypnosis), and prevention of care-related pain in children (hypnosis). Tai-chi also appears to help prevent falls and to improve balance in elderly persons. However, these methods have few or no advantages over classical treatments or even placebo procedures. Despite these limitations, alternative therapies are widely appreciated by the public, and most French medical schools offer optional study modules. Public hospitals, particularly teaching hospitals and cancer care centers, cannot be criticized for allowing these practices a place in their care supply. The authors make several recommendations intended to ensure that hospitals which agree to these therapies are not considered to be endorsing them, but rather to be guaranteeing their proper use and their scientific evaluation in terms of patient benefit. These therapies are subsidiary to conventional treatments and cannot replace them.
CR Albuquerque FC, 2011, J NEUROSURG, V115, P1197, DOI 10.3171/2011.8.JNS111212
   Unknown -, 1900, DOI 10.1016/S1169-8330(02)00019-4, V0, P0
   Assendelft WJ, 2004, COCHRANE DB SYST REV, V1, P0, DOI 10.1002/14651858.CD000447.PUB2
   Auquier L, 2006, B ACAD NAT MED PARIS, V190, P221, DOI 10.1016/S0001-4079(19)33365-5
   Benedetti F, 2006, PAIN, V121, P133, DOI 10.1016/j.pain.2005.12.016
   Blakemore SJ, 2003, CURR OPIN NEUROBIOL, V13, P219, DOI 10.1016/S0959-4388(03)00043-6
   Brien S, 2011, RHEUMATOLOGY, V50, P1070, DOI 10.1093/rheumatology/keq234
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Bronfort G, 2012, ANN INTERN MED, V156, P1, DOI 10.7326/0003-4819-156-1-201201030-00002
   Bronfort Gert, 2010, CHIROPR OSTEOPAT, V18, P3, DOI 10.1186/1746-1340-18-3
   Chen SC, 2010, J ALTERN COMPLEM MED, V16, P1153, DOI 10.1089/acm.2009.0560
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Dagenais S, 2010, SPINE J, V10, P918, DOI 10.1016/j.spinee.2010.07.389
   Ernst E, 2009, RESP MED, V103, P1791, DOI 10.1016/j.rmed.2009.06.017
   Ernst E, 2009, INT J CLIN PRACT, V63, P1351, DOI 10.1111/j.1742-1241.2009.02133.x
   Fernández-de-las-Peñas C, 2006, CLIN J PAIN, V22, P278, DOI 10.1097/01.ajp.0000173017.64741.86
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Fu LM, 2009, J ALTERN COMPLEM MED, V15, P133, DOI 10.1089/acm.2008.0135
   Gillespie Lesley D, 2012, COCHRANE DATABASE SYST REV, V0, PPCD007146, DOI 10.1002/14651858.CD007146.pub2
   Guo X, 2008, J ALTERN COMPLEM MED, V14, P27, DOI 10.1089/acm.2007.7213
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Hall AM, 2011, ARTHRIT CARE RES, V63, P1576, DOI 10.1002/acr.20594
   Hróbjartsson A, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003974.pub3
   Hurwitz EL, 2008, SPINE, V33, PS123, DOI 10.1097/BRS.0b013e3181644b1d
   Irwin MR, 2008, SLEEP, V31, P1001
   Jäkel A, 2011, J AM OSTEOPATH ASSOC, V111, P685
   Kaminskyj Adrienne, 2010, J CAN CHIROPR ASSOC, V54, P24
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Langhorst J, 2010, RHEUMATOLOGY, V49, P778, DOI 10.1093/rheumatology/kep439
   Lee MS, 2007, J HYPERTENS, V25, P1525, DOI 10.1097/HJH.0b013e328092ee18
   Lee MS, 2010, J EVAL CLIN PRACT, V16, P818, DOI 10.1111/j.1365-2753.2009.01210.x
   Lee MS, 2009, COMPLEMENT THER MED, V17, P236, DOI 10.1016/j.ctim.2009.05.001
   Licciardone JC, 2003, SPINE, V28, P1355, DOI 10.1097/00007632-200307010-00002
   Linde K, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001218.pub2
   Liossi C, 2009, PAIN, V142, P255, DOI 10.1016/j.pain.2009.01.017
   Liu CZ, 2011, PAIN MED, V12, P300, DOI 10.1111/j.1526-4637.2010.01017.x
   Lystad RP, 2011, CHIROPR MAN THER, V19, P0, DOI 10.1186/2045-709X-19-21
   Manheimer E, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001977.pub2
   Maquet P, 1999, BIOL PSYCHIAT, V45, P327, DOI 10.1016/S0006-3223(97)00546-5
   Martin DP, 2006, MAYO CLIN PROC, V81, P749, DOI 10.4065/81.6.749
   Martin-Sanchez Eva, 2009, OPEN RHEUMATOL J, V3, P25, DOI 10.2174/1874312900903010025
   Mawdsley JE, 2008, AM J GASTROENTEROL, V103, P1460, DOI 10.1111/j.1572-0241.2008.01845.x
   Mayhew E, 2007, RHEUMATOLOGY, V46, P801, DOI 10.1093/rheumatology/kel406
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036
   Posadzki P, 2011, CEPHALALGIA, V31, P964, DOI 10.1177/0333102411405226
   Posadzki P, 2011, HEADACHE, V51, P1132, DOI 10.1111/j.1526-4610.2011.01932.x
   Proctor ML, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002119.pub3
   Rand D, 2011, AGE AGEING, V40, P297, DOI 10.1093/ageing/afr037
   Reid SA, 2005, MANUAL THER, V10, P4, DOI 10.1016/j.math.2004.03.006
   Reid SA, 2008, MANUAL THER, V13, P357, DOI 10.1016/j.math.2007.03.006
   Richardson J, 2007, EUR J CANCER CARE, V16, P402, DOI 10.1111/j.1365-2354.2006.00736.x
   Rodine Robert J, 2012, J CAN CHIROPR ASSOC, V56, P18
   Rubinstein SM, 2011, SPINE, V36, PE825, DOI 10.1097/BRS.0b013e3182197fe1
   Sirigu A, 2004, NAT NEUROSCI, V7, P80, DOI 10.1038/nn1160
   Smith CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009232
   Smith CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007854.pub2
   Standaert CJ, 2011, SPINE, V36, PS120, DOI 10.1097/BRS.0b013e31822ef878
   Still A, 1902, PHILOS MECH PRINCIPL, V0, P0
   Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225
   Thieme Kati, 2009, CURR RHEUMATOL REP, V11, P443
   Trinh KV, 2004, RHEUMATOLOGY, V43, P1085, DOI 10.1093/rheumatology/keh247
   Vas J, 2012, PAIN, V153, P1883, DOI 10.1016/j.pain.2012.05.033
   Walker BF, 2011, SPINE, V36, P230, DOI 10.1097/BRS.0b013e318202ac73
   Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611
   Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Yeh CH, 2012, J ALTERN COMPLEM MED, V18, P334, DOI 10.1089/acm.2011.0102
   Yeh Gloria Y, 2008, PREV CARDIOL, V11, P82
   Yeh GY, 2011, ARCH INTERN MED, V171, P750, DOI 10.1001/archinternmed.2011.150
   Yuan J, 2008, SPINE, V33, PE887, DOI 10.1097/BRS.0b013e318186b276
NR 89
TC 4
Z9 9
U1 3
U2 33
PU ELSEVIER MASSON SAS EDITEUR
PI ISSY LES  MOULINEAUX CEDEX
PA 62, RUE CAMILLE DESMOULINS, ISSY LES  MOULINEAUX CEDEX, 92442, FRANCE
SN 0001-4079
EI 2271-4820
J9 B ACAD NAT MED PARIS
JI Bull. Acad. Natl. Med.
PD MAR 15
PY 2013
VL 197
IS 3
BP 717
EP 757
DI 10.1016/S0001-4079(19)31565-1
PG 41
WC Medicine, General & Internal
SC General & Internal Medicine
GA AL8UH
UT WOS:000339414700019
DA 2026-01-16
ER

PT J
AU Lian, WL
   Pan, MQ
   Zhou, DH
   Zhang, ZJ
AF Lian, Wei-Ling
   Pan, Min-qi
   Zhou, Dai-han
   Zhang, Zhang-jin
TI Effectiveness of acupuncture for palliative care in cancer patients: a systematic
SO Chinese journal of integrative medicine
LA English
DT Journal Article
AB OBJECTIVE: To critically evaluate the currently available randomized clinical  trials regarding the effectiveness of acupuncture in palliative care for cancer  patients, hence, to provide sufficient evidences for the widespread use of  acupuncture in cancer treatment. METHODS: Two independent reviewers extracted  data from all of the randomized clinical trials (RCTs) that assessed the efficacy  of acupuncture in palliative care for cancer patients. Seven databases were  searched from their respective inception to December 2010. All eligible trials  identified were evaluated by two independent reviewers using the Jadad scale, and  data from the articles were validated and extracted. RESULTS: In total, 33 RCTs  met the inclusion criteria. The effects of acupuncture on different  cancer-related aspects were shown, including chemotherapy or radiotherapy-induced  side effects (13/33, 39.4%), cancer pain (6/33, 18.2%), post-operative urinary  retention (4/33, 12.1%), quality of life (2/33, 6.1%), vasomotor syndrome (2/33,  6.1%), post-operative gastrointestinal dysfunction (2/33, 6.1%), prevention of  prolonged postoperative ileus (2/33, 6.1%), joint symptoms (1/33, 3.0%), and  immunomodulation (1/33, 3.0%). CONCLUSIONS: The result of our systematic review  suggested that the effectiveness of acupuncture in palliative care for cancer  patients is promising, especially in reducing chemotherapy or radiotherapyinduced  side effects and cancer pain. Acupuncture may be an appropriate adjunctive  treatment for palliative care.
C1 School of Chinese Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China, 13902206571@139.com.
NR 0
TC 0
SN 1993-040
EI 
J9 Chin J Integr Med
PD DEC 18
PY 2013
VL 20
IS 2
BP 136
EP 47
DI 10.1007/s11655-013-1439-1
PG -89
WC Acupuncture Therapy; adverse effects; Drug Therapy; Humans; Neoplasms; surgery; Palliative Care; Postoperative Complications; etiology; Quality of Life; Radiotherapy; adverse effects; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:24338183
PM 24338183
DA 2013-12-18
ER

PT J
AU Lee, J
   Yoon, SW
AF Lee, Jinsoo
   Yoon, Seong Woo
TI Efficacy and Safety of Moxibustion for Relieving Pain in Patients With Metastatic
SO Integrative cancer therapies
LA English
DT Journal Article
DE cancer pain; metastatic cancer; moxibustion; sham moxibustion; true moxibustion
AB BACKGROUND: Moxibustion has been traditionally used to manage pain related to  chronic diseases, including cancer. This study aims to investigate the efficacy  and safety of moxibustion for relieving cancer pain in patients with metastatic  cancer. METHODS: A total of 16 patients were randomly divided into a true  moxibustion (TM) group or a sham moxibustion (SM) group. In both groups,  moxibustion was applied for 10 minutes, once daily for 7 consecutive days. In the  SM group, the moxa cone was removed earlier than in the TM group, so as not to  deliver heat stimulation completely into the skin. The changes of pain severity  using the Brief Pain Inventory (BPI) and quality of life measured by the  Functional Assessment of Cancer Therapy-General (FACT-G) were observed. A  blinding credibility test was done to validate the sham moxibustion procedure.  RESULTS: The total BPI score significantly decreased in the TM group compared  with the SM group (TM vs SM: -0.97 ± 1.05 vs 0.35 ± 0.60,P= .025). The 2 subsets  of BPI, pain intensity score and pain interference score, also significantly  decreased in the TM group (TM vs SM: intensity, -0.82 ± 0.93 vs 0.46 ± 0.87,P=  .020; interference, -1.12 ± 1.31 vs 0.24 ± 0.61,P= .047). Even after adjusting  for the values of opioid consumption, these results remained significant. FACT-G  did not significantly improve in the TM group. The blinding to sham moxibustion  was credible and no serious adverse events occurred. CONCLUSION: We suggest that  moxibustion could be a safe and potential modality for cancer-related pain in  patients with metastatic cancer. With the limitation of small sample size, a  larger and long-term follow-up study is necessary to determine more definitely  the efficacy of moxibustion.
C1 Kyung Hee University Korean Medicine Hospital at Gangdong, Seoul, Republic of Korea.
   Kyung Hee University Korean Medicine Hospital at Gangdong, Seoul, Republic of Korea stepano212@hanmail.net.
NR 0
TC 0
SN 1552-695
EI 
J9 Integr Cancer Ther
PD NOV 28
PY 2013
VL 13
IS 3
BP 211
EP 6
DI 10.1177/1534735413510025
PG -205
WC Adult; Aged; Analgesics, Opioid; administration & dosage; Female; Humans; Male; Middle Aged; Moxibustion; adverse effects; Neoplasm Metastasis; Neoplasms; complications; Pain; etiology; Pain Management; methods; Pain Measurement; Pilot Projects; Quality of Life; Single-Blind Method; Treatment Outcome
UT PubMed:24282101
PM 24282101
DA 2013-11-28
ER

PT J
AU Shi, J
   Ge, ZBZ
   Jin, Y
   Li, YD
   Zhou, J
AF Shi, J.
   Ge, Z. B. Z.
   Jin, Y.
   Li, Y. D.
   Zhou, J.
TI ACUPUNCTURE IMPROVES THE EFFECTS OF CHINESE HERBAL MEDICINE IN TREATING ENDOMETRIOSIS MODEL RATS
SO JOURNAL OF ANIMAL AND PLANT SCIENCES
LA English
DT Article
DE Chinese herbal medicine acupuncture; endometriosis
ID serum ca-125 levels; eutopic endometrium; pelvic pain; women; cyclooxygenase-2; epidemiology; expression; interleukin-18; prevalence; infertile
AB The present study was aimed to investigate whether acupuncture could significantly enhance the efficacy of Chinese herbal medicine (CHM) in treating endometriosis model rats. A total of 40 female Sprague-Dawley (SD) rats with body weight of 200 +/- 20 g were included. Operational transplantation was used with animal models. The rats were randomly divided into 5 groups: sham-operation control group (Group A), model group (Group B), CHM combined with acupuncture group (Group C), CHM group (Group D), Danazol group (Group E) with 8 rats in each group. During the treatment, two rats in Group B and one rat in Group E passed away. When the treatment ended, all the left rats were sacrificed. The samples of peritoneal fluids, serum and the ectopic endometrium were taken. The serum levels of cancer antigen 125 (CA-125) and interleukin 18(IL-18) in the peritoneal fluids were detected using enzyme-linked immune-sorbent assay. The cyclooxygenase-2 (COX-2) mRNA expression levels in the ectopic endometrium were measured by Real-time PCR. The results showed that in the rats from Groups A, C, D and E, the serum CA-125 levels, COX-2 mRNA expression in the ectopic endometrium and the IL-18 levels in the peritoneal fluids were significantly lower than those of Group B (P<0.05). The serum CA-125 levels and COX-2 mRNA expression in the ectopic endometrium of the rats in Group C were significantly lower than those of Group D (P<0.05), while there was no significant difference between Group C and E (P>0.05). The levels of IL-18 in the peritoneal fluids of the rats in Group C were markedly lower than those of Group D and E (P<0.05). It is then concluded that acupuncture treatment can improve the effects of CHM in treating endometriosis model rats.
C1 [Shi, J.; Jin, Y.; Li, Y. D.] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Ge, Z. B. Z.] Zhejiang Univ, Sir Run Shaw Hosp, Sch Med, Hangzhou 310016, Zhejiang, Peoples R China.
   [Zhou, J.] Zhejiang Gongshang Univ, Coll Food Sci & Biotechnol, Hangzhou 310012, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang Gongshang University
RP Zhou, J (corresponding author), Zhejiang Gongshang Univ, Coll Food Sci & Biotechnol, Hangzhou 310012, Zhejiang, Peoples R China.
EM juezhou2006@yahoo.com.cn
FU Zhejiang Administration of Traditional Chinese Medicine [2011ZA048, 2008YA023]; Health Department of Zhejiang Province [2011KYA053]; Zhejiang Provincial Education Department [Y201016894]; Science and Technology foundation of Overseas Scientists of Zhejiang Province [2011443]; Zhejiang Gongshang University [QY11-20]
CR Arici A, 2003, FERTIL STERIL, V80, P889, DOI 10.1016/S0015-0282(03)01122-1
   Ayaz L, 2011, FERTIL STERIL, V95, P298, DOI 10.1016/j.fertnstert.2010.07.1046
   Barbieri R L, 1987, CONTRIB GYNECOL OBSTET, V16, P103
   Brown J, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008475.pub2
   Chen FP, 1998, ACTA OBSTET GYN SCAN, V77, P665, DOI 10.1034/j.1600-0412.1998.770615.x
   Chen Ming, 2010, ZHONGGUO ZHEN JIU, V30, P725
   Chishima F, 2002, AM J REPROD IMMUNOL, V48, P50, DOI 10.1034/j.1600-0897.2002.01101.x
   Cho S, 2010, GYNECOL OBSTET INVES, V69, P93, DOI 10.1159/000261017
   Davis L, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001019.pub2
   Ramos IMD, 2012, REV ASSOC MED BRAS, V58, P26
   Ferrero S, 2010, EXPERT OPIN PHARMACO, V11, P1123, DOI 10.1517/14656561003685880
   Flower A, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006568.pub2
   Flower A, 2011, J ALTERN COMPLEM MED, V17, P691, DOI 10.1089/acm.2010.0073
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   GUILLEBAUD J, 1993, BRIT MED J, V306, P931, DOI 10.1136/bmj.306.6882.931
   Guo SW, 2006, GYNECOL OBSTET INVES, V62, P121, DOI 10.1159/000093019
   Guo SW, 2006, FERTIL STERIL, V86, P1584, DOI 10.1016/j.fertnstert.2006.04.040
   Lundeberg T, 2008, ACUPUNCT MED, V26, P94, DOI 10.1136/aim.26.2.94
   Machado DE, 2010, FERTIL STERIL, V93, P2674, DOI 10.1016/j.fertnstert.2009.11.037
   Matalliotakis IM, 2004, INT J FERTIL WOMEN M, V49, P75
   Matsuzaki S, 2004, FERTIL STERIL, V82, P1309, DOI 10.1016/j.fertnstert.2004.03.059
   Meissner K, 2010, FORSCH KOMPLEMENTMED, V17, P314, DOI 10.1159/000322890
   Ota H, 2001, HUM REPROD, V16, P561, DOI 10.1093/humrep/16.3.561
   OZAKSIT G, 1995, INT J GYNECOL OBSTET, V50, P269, DOI 10.1016/0020-7292(95)02456-M
   PARAZZINI F, 1993, BRIT MED J, V306, P930, DOI 10.1136/bmj.306.6882.930-b
   PATTON PE, 1986, FERTIL STERIL, V45, P770
   PITTAWAY DE, 1995, FERTIL STERIL, V64, P321, DOI 10.1016/S0015-0282(16)57730-9
   PRENTICE A, 1993, BRIT MED J, V306, P585, DOI 10.1136/bmj.306.6877.585-d
   PRENTICE A, 2000, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002122
   Sagsveen M, 2003, COCHRANE DB SYST REV, V0, P0
   Schnyer RN, 2008, J ALTERN COMPLEM MED, V14, P515, DOI 10.1089/acm.2007.0826
   SELAK V, 2001, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000068.PUB2
   Sharpe-Timms KL, 2004, FERTIL STERIL, V81, P1201, DOI 10.1016/j.fertnstert.2003.09.072
   Simoens S, 2007, HUM REPROD UPDATE, V13, P395, DOI 10.1093/humupd/dmm010
   Sinaii N, 2007, FERTIL STERIL, V87, P1277, DOI 10.1016/j.fertnstert.2006.11.051
   VESSEY MP, 1993, BRIT MED J, V306, P182, DOI 10.1136/bmj.306.6871.182
   Viganò P, 2004, BEST PRACT RES CL OB, V18, P177, DOI 10.1016/j.bpobgyn.2004.01.007
   Wang D Z, 1994, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V14, P112
   Wieser F, 2009, BIOL REPROD, V81, P371, DOI 10.1095/biolreprod.108.075069
   Xiang Dong-Fang, 2011, ZHONGGUO ZHEN JIU, V31, P113
   Zhang Yi, 2005, ZHONG NAN DA XUE XUE BAO YI XUE BAN, V30, P731
   Zhu X, 2011, COCHRANE DB SYST REV, V9, P0
NR 42
TC 2
Z9 2
U1 0
U2 11
PU PAKISTAN AGRICULTURAL SCIENTISTS FORUM
PI LAHORE
PA UNIV VETERINARY & ANIMAL SCIENCES, LAHORE, 00000, PAKISTAN
SN 1018-7081
EI 
J9 J ANIM PLANT SCI
JI J. Anim. Plant Sci.
PD JUN 15
PY 2013
VL 23
IS 1
BP 298
EP 303
DI 
PG 6
WC Agriculture, Multidisciplinary; Biology; Veterinary Sciences
SC Agriculture; Life Sciences & Biomedicine - Other Topics; Veterinary Sciences
GA 102NB
UT WOS:000315850200045
DA 2026-01-16
ER

PT J
AU Garcia, MK
   McQuade, J
   Haddad, R
   Patel, S
   Lee, R
   Yang, PY
   Palmer, JL
   Cohen, L
AF Garcia, M. Kay
   McQuade, Jennifer
   Haddad, Robin
   Patel, Sonya
   Lee, Richard
   Yang, Peiying
   Palmer, J. Lynn
   Cohen, Lorenzo
TI Systematic Review of Acupuncture in Cancer Care: A Synthesis of the Evidence
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID chemotherapy-induced nausea; randomized controlled-trial; prolonged postoperative ileus; breast-cancer; placebo-acupuncture; vasomotor symptoms; electroacupuncture; management; pain; women
AB Purpose Many cancer centers offer acupuncture services. To date, a comprehensive systematic review of acupuncture in cancer care has not been conducted. The purpose of this review was to evaluate the efficacy of acupuncture for symptom management in patients with cancer. Methods Medline, Embase, CINAHL, Cochrane (all databases), Scopus, and PubMed were searched from inception through December 2011 for prospective randomized clinical trials (RCT) evaluating acupuncture for symptom management in cancer care. Only studies involving needle insertion into acupuncture points were included. No language limitations were applied. Studies were assessed for risk of bias (ROB) according to Cochrane criteria. Outcomes by symptom were designated as positive, negative, or unclear. Results A total of 2,151 publications were screened. Of those, 41 RCTs involving eight symptoms (pain, nausea, hot flashes, fatigue, radiation-induced xerostomia, prolonged postoperative ileus, anxiety/mood disorders, and sleep disturbance) met all inclusion criteria. One positive trial of acupuncture for chemotherapy-induced nausea and vomiting had low ROB. Of the remaining studies, eight had unclear ROB (four positive, three negative, and one with unclear outcomes). Thirty-three studies had high ROB (19 positive, 11 negative, and three with both positive and negative outcomes depending on the symptom). Conclusion Acupuncture is an appropriate adjunctive treatment for chemotherapy-induced nausea/vomiting, but additional studies are needed. For other symptoms, efficacy remains undetermined owing to high ROB among studies. Future research should focus on standardizing comparison groups and treatment methods, be at least single-blinded, assess biologic mechanisms, have adequate statistical power, and involve multiple acupuncturists. J Clin Oncol 31:952-960. (C) 2013 by American Society of Clinical Oncology
C1 [Garcia, M. Kay; Haddad, Robin; Lee, Richard; Yang, Peiying; Palmer, J. Lynn; Cohen, Lorenzo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Garcia, M. Kay; Patel, Sonya] MHlth Multidisciplinary Pain Management Program, Houston, TX USA.
   [McQuade, Jennifer] Hosp Univ Penn, Philadelphia, PA 19104 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania
RP Cohen, L (corresponding author), Univ Texas MD Anderson Canc Ctr, Integrat Med Program, 1515 Holcombe Blvd,Unit 0462, Houston, TX 77030 USA.
EM lcohen@mdanderson.org
FU National Cancer Institute [CA121503, CA016672]; University of Texas MD Anderson Cancer Center; National Cancer Institute [P30CA016672] Funding Source: NIH RePORTER
CR Adams Mariama, 2007, INT SEMIN SURG ONCOL, V4, P10, DOI 10.1186/1477-7800-4-10
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Altman S, 1994, VET ACUPUNCTURE ANCI, V0, P95
   Unknown -, 2002, WHO TRADITIONAL MED, V0, P0
   Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Blom M, 1996, ORAL ONCOL, V32B, P182
   Cho JH, 2008, J ALTERN COMPLEM MED, V14, P523, DOI 10.1089/acm.2007.0793
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cui Rui, 2003, J TRADIT CHIN MED, V23, P57
   Dang W, 1998, J TRADIT CHIN MED, V18, P31
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Deng G, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-37
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Du YQ, 2011, WORLD CHIN J DIGESTOL, V19, P687
   DUNDEE JW, 1988, BRIT J CLIN PHARMACO, V25, P0
   DUNDEE JW, 1987, LANCET, V1, P1083
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Enblom A, 2011, ACUPUNCT MED, V29, P94, DOI 10.1136/aim.2010.003384
   Ernst E, 2006, J INTERN MED, V259, P125, DOI 10.1111/j.1365-2796.2005.01584.x
   Ernst E, 1997, BRIT MED J, V314, P1362
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Ernst G, 2003, COMPLEMENT THER MED, V11, P93, DOI 10.1016/S0965-2299(03)00004-9
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Feng Y, 2011, J TRADIT CHIN MED, V31, P199, DOI 10.1016/S0254-6272(11)60042-3
   Filshie J, 2001, ACUPUNCT MED, V19, P117
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8
   Garcia MK, 2008, MED ACUPUNCT, V20, P83, DOI 10.1089/acu.2008.0607
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   He Bi-mei, 2007, ZHONGGUO ZHEN JIU, V27, P369
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-49
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Lao Lixing, 2006, J SOC INTEGR ONCOL, V4, P13
   Lao LX, 2003, ALTERN THER HEALTH M, V9, P72
   LI QS, 1994, CHINESE MED J-PEKING, V107, P289
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   MacPherson H, 2001, ACUPUNCT MED, V19, P93
   MacPherson Hugh, 2005, ACUPUNCT MED, V23, P112
   MacPherson H, 2010, ACUPUNCT MED, V28, P83, DOI 10.1136/aim.2009.001370
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Melchart D, 2006, SUPPORT CARE CANCER, V14, P878, DOI 10.1007/s00520-006-0028-7
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   Mittleman E, 2000, J AM VET MED ASSOC, V217, P1201, DOI 10.2460/javma.2000.217.1201
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   National Acupuncture Foundation, 1997, CLEAN NEEDL TECHN MA, V0, P0
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Park Jongbae, 2002, ACUPUNCT MED, V20, P168
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   POULAIN P, 1997, ACUPUNCT MED, V15, P10
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Sun Bao-Mu, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P641
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   XIA Y, 1986, JOURNAL OF TRADITIONAL CHINESE MEDICINE, V6, P23
   Yang Yan, 2009, ZHONGGUO ZHEN JIU, V29, P955
   Yin Shuang-hong, 2009, ZHONGGUO ZHEN JIU, V29, P459
NR 67
TC 229
Z9 266
U1 2
U2 117
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 1
PY 2013
VL 31
IS 7
BP 952
EP 960
DI 10.1200/JCO.2012.43.5818
PG 9
WC Oncology
SC Oncology
GA 097AU
UT WOS:000315447200026
PM 23341529
DA 2026-01-16
ER

PT J
AU Dyer, L
   Venton, K
   Forrester, M
AF Dyer, Lisa
   Venton, Kate
   Forrester, Max
TI Home electroacupuncture for persistent postsurgical pain: a patient's report
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE Oral & Maxillofacial Surgery; Pain Management; Acupuncture
ID cancer-related fatigue; acupuncture
AB A 30-year-woman presented with iatrogenic myofascial facial pain of 12months' duration after surgical treatment for bilateral temporomandibular joint dysfunction. Limited response to manual acupuncture was followed by a trial of electroacupuncture. Response to electroacupuncture was limited in duration and one option was to teach her partner to perform electroacupuncture at home. The patient and partner, trained in beauty therapy, embraced this idea and it proved equally effective as therapist-provided acupuncture. We describe this case report from the perspective of the patient, caregiver or acupuncture partner and therapist. Home electroacupuncture seems to be safe, acceptable and practicable as a maintenance treatment for patients with persistent postsurgical pain of myofascial origin.
C1 [Forrester, Max] Taunton & Somerset NHS Fdn Trust, Dept Orthopaed, Musgrove Pk Hosp, Taunton TA1 5DA, Somerset, England.
C3 Musgrove Park Hospital
RP Forrester, M (corresponding author), Taunton & Somerset NHS Fdn Trust, Dept Orthopaed, Musgrove Pk Hosp, Taunton TA1 5DA, Somerset, England.
EM maxforrester@yahoo.co.uk
CR Adler Z, 2012, BMC COMPLEMENT. ALTERN. MED., V12, PP125, DOI 10.1186/1472-6882-12-S1-P125
   Unknown -, 2010, TRANSP OUTC FRAM NHS, V0, P0
   Auras S, 2010, INT J QUAL HEALTH C, V22, P132, DOI 10.1093/intqhc/mzq006
   Bishop, 2008, J ACUPUNCT ASS CHART, V0, P51
   Campbell Anthony, 2004, ACUPUNCT MED, V22, P141
   Carrubba R W, 1974, J HIST MED ALLIED SCI, V29, P371
   Cheville AM, 2006, FOCUS ALTERN COMP S1, V11, P0
   Cole-King A, 2001, PSYCHOSOM MED, V63, P216, DOI 10.1097/00006842-200103000-00004
   Cummings M, 2008, J ACUPUNCT ASS CHART, V0, P47
   Davies S, 2011, J PERS DISORD, V25, P741, DOI 10.1521/pedi.2011.25.6.741
   Department of Health, 2010, EQ EXC LIB NHS, V0, P0
   Department of Health, 2008, HIGH QUAL CAR ALL NH, V0, P0
   Fagan Nigel, 2003, ACUPUNCT MED, V21, P28
   Filshie J, 2001, ACUPUNCT MED, V19, P117
   Filshie J, 2006, ACUPUNCT MED, V24, P94
   Filshie Jacqueline, 2005, ACUPUNCT MED, V23, P171
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Filshie J, 2011, ACUPUNCT MED, V29, P166, DOI 10.1136/acupmed-2011-010063
   Foell J, 2011, ACUPUNCT MED, V29, P61, DOI 10.1136/aim.2010.003715
   Fremont AM, 2001, J GEN INTERN MED, V16, P800, DOI 10.1046/j.1525-1497.2001.10102.x
   KAPLAN SH, 1989, MED CARE, V27, PS110, DOI 10.1097/00005650-198903001-00010
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   NHS Confederation, 2011, FEEL BETT IMPR PAT E, V0, P0
   Orpen Michele, 2004, ACUPUNCT MED, V22, P137
   Ovretveit J, 2009, DOES IMPROVING QUALI, V0, P0
   Pain Management Service, 2007, CLIN GUID HOM AC PAT, V0, P0
   Sandberg M, 2006, ACUPUNCT MED, V24, P91
   Schulz R, 2008, AM J NURS, V108, P23, DOI 10.1097/01.NAJ.0000336406.45248.4c
   Teig Silje, 2006, ACUPUNCT MED, V24, P80
   Yamashita H, 2001, COMPLEMENT THER MED, V9, P98, DOI 10.1054/ctim.2001.0446
NR 32
TC 5
Z9 5
U1 1
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD DEC 15
PY 2013
VL 31
IS 4
BP 425
EP 429
DI 10.1136/acupmed-2013-010421
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 266BI
UT WOS:000327996900013
PM 23969146
DA 2026-01-16
ER

PT J
AU Lee, DG
   Lee, SH
   Hwang, SW
   Kim, ES
   Eoh, W
AF Lee, Dong-Geun
   Lee, Sun-Ho
   Hwang, Sang-Won
   Kim, Eun-Sang
   Eoh, Whan
TI Myositis ossificans in the paraspinal muscles of the neck after acupuncture: a case report
SO SPINE JOURNAL
LA English
DT Article
DE Myositis ossificans; Acupuncture; Cervical spine
ID traumatica; mimicking; bone
AB BACKGROUND CONTEXT: Although traumatic myositis ossificans (MO) has been reported occasionally, MO of paraspinal muscles has been rarely seen in the cervical spine after minor injury. This is difficult to distinguish from benign and malignant soft lesions in cases of a lack of definite trauma history. PURPOSE: We report a case of MO in the cervical paraspinal muscle after acupuncture and describe methods for diagnosis and proper treatment, including classification, etiology, and radiologic and histologic features. STUDY DESIGN: Case report. METHODS: A 26-year-old woman complained of posterior neck pain that had began 2 months earlier and neck swelling after acupuncture. No abnormal finding existed on the X-ray except soft tissue swelling. Magnetic resonance imaging was evaluated because of constant neck pain. To obtain more accurate assessment, computed tomography-guided biopsy was performed and a diagnosis of MO was made. RESULTS: The patient was conservatively treated through rest and analgesics. Posterior neck pain and swelling improved for a several months. The hyperdensity was comparable with the bony density, and the size of the calcified lesion on X-ray diminished until the last follow-up. CONCLUSIONS: Myositis ossificans that can occur after acupuncture should be recognized as a possible cause of persistent neck pain and swelling despite no definite trauma after thorough evaluation of the neoplasm and infection. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Lee, Dong-Geun; Lee, Sun-Ho; Hwang, Sang-Won; Kim, Eun-Sang; Eoh, Whan] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, Seoul 135710, South Korea.
   [Hwang, Sang-Won] Eulji Univ, Sch Med, Taejon 301746, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Eulji University
RP Lee, SH (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurosurg, 50 Ilwon Dong, Seoul 135710, South Korea.
EM sobotta72@hotmail.com
CR ACKERMAN LV, 1958, J BONE JOINT SURG AM, V40, P279, DOI 10.2106/00004623-195840020-00004
   Aneiros-Fernandez Jose, 2010, J CLIN MED RES, V2, P142, DOI 10.4021/jocmr2010.05.364w
   Baysal T, 1999, EUR RADIOL, V9, P662, DOI 10.1007/s003300050728
   Findlay I, 2010, SPINE, V35, PE1525, DOI 10.1097/BRS.0b013e3181ec066b
   Gould CF, 2007, CURR PROBL DIAGN RAD, V36, P124, DOI 10.1067/j.cpradiol.2007.01.001
   Gunduz B, 2007, INT J REHABIL RES, V30, P87, DOI 10.1097/MRR.0b013e3280146f85
   Kokkosis AA, 2009, PEDIATR RADIOL, V39, P409, DOI 10.1007/s00247-009-1165-1
   LELLO GE, 1986, J MAXILLOFAC SURG, V14, P231, DOI 10.1016/S0301-0503(86)80295-8
   Lin TY, 2011, HEAD NECK-J SCI SPEC, V33, P753, DOI 10.1002/hed.21329
   McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256-005-0958-z
   Meara RS, 2009, CYTOPATHOLOGY, V20, P121, DOI 10.1111/j.1365-2303.2007.00538.x
   Saussez S, 2006, EUR ARCH OTO-RHINO-L, V263, P331, DOI 10.1007/s00405-005-0997-z
   Shin SJ, 2011, CLIN ORTHOP SURG, V3, P81, DOI 10.4055/cios.2011.3.1.81
   Yazici M, 2002, J PEDIATR SURG, V37, P1621, DOI 10.1053/jpsu.2002.36196
NR 14
TC 8
Z9 10
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1529-9430
EI 1878-1632
J9 SPINE J
JI Spine Journal
PD JUL 15
PY 2013
VL 13
IS 7
BP E9
EP E12
DI 10.1016/j.spinee.2013.02.012
PG 4
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 179BG
UT WOS:000321491100003
PM 23523436
DA 2026-01-16
ER

PT J
AU Zhuang, Y
   Xing, JJ
   Li, J
   Zeng, BY
   Liang, FR
AF Zhuang, Yi
   Xing, Jing-jing
   Li, Juan
   Zeng, Bai-Yun
   Liang, Fan-rong
TI History of Acupuncture Research
SO NEUROBIOLOGY OF ACUPUNCTURE
LA English
DT Review; Book Chapter
ID induced polycystic ovary; controlled-trial; electroacupuncture stimulation; migraine prophylaxis; opioid receptors; neuropathic pain; randomized-trial; breast-cancer; double-blind; opiate
AB The acupuncture has been practiced in China for more than 3000 years and was spread to Europe and American from the sixteenth to the nineteenth century. The history of acupuncture research was initiated in the eighteenth century and developed rapidly since then. In the past, physicians tried hard to apply acupuncture into clinical practice, while scientists were focused on the possible characteristics of acupoints and meridians. In the modern time, scientists have strived hard to evaluate the real effectiveness of acupuncture and the underlying physiological and biological mechanisms of acupuncture. Reviewing research history from past to present, we are delighted to witness this wonderful development. Accumulated evidences that acupuncture is beneficial in various conditions significantly enhanced our understanding the mechanisms of acupuncture treatment. However, there is still no conclusive evidence in acupuncture clinical studies. The clinical research still needs great improving, while the basic research results need to be appropriately transformed into clinical outcomes. Based on current achievements, we believe that although the challenges and difficulties exist, a more collaborative, innovative, and integrated approach will help us to achieve further progress in future acupuncture research.
C1 [Zhuang, Yi; Xing, Jing-jing; Li, Juan; Liang, Fan-rong] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
   [Zeng, Bai-Yun] Kings Coll London, Sch Biomed Sci, Inst Pharmaceut Sci, Neurodegenerat Dis Res Grp, London WC2R 2LS, England.
C3 Chengdu University of Traditional Chinese Medicine; University of London; King's College London
RP Liang, FR (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
EM acuresearch@126.com
CR Unknown -, 1998, SCIENTIFIC FOUNDATIONS OF ACUPUNCTURE MOXIBUSTION, V0, P0
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Bivins R, 2001, ACUPUNCT MED, V19, P2
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Brinkhaus B, 2013, ANN INTERN MED, V158, P225, DOI 10.7326/0003-4819-158-4-201302190-00002
   CAHN AM, 1978, LANCET, V1, P182
   CASSEDY JH, 1974, B NEW YORK ACAD MED, V50, P892
   Ceniceros S, 1998, SOUTH MED J, V91, P1121, DOI 10.1097/00007611-199812000-00005
   Chae Y, 2006, J PHYSIOL SCI, V56, P425, DOI 10.2170/physiolsci.RP010206
   Chao DM, 1999, AM J PHYSIOL-HEART C, V276, PH2127, DOI 10.1152/ajpheart.1999.276.6.H2127
   CHEIN EYM, 1973, JAMA-J AM MED ASSOC, V224, P1533, DOI 10.1001/jama.1973.03220250055029
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   DARRAS JC, 1992, AM J ACUPUNCTURE, V20, P245
   De Morant GS, 1994, CHINESE ACUPUNCTURE: LACUPONCTURE CHINOISE, V0, P0
   Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9
   DIMOND EG, 1971, J AMER MED ASSOC, V218, P1558, DOI 10.1001/jama.218.10.1558
   DIMOND EG, 1971, J AMER MED ASSOC, V218, P1552, DOI 10.1001/jama.218.10.1552
   Fang JL, 2004, NEURORADIOLOGY, V46, P359, DOI 10.1007/s00234-003-1125-7
   Fanti L, 2003, AM J GASTROENTEROL, V98, P312, DOI 10.1016/S0002-9270(02)05899-9
   FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831
   Flachskampf FA, 2007, CIRCULATION, V115, P3121, DOI 10.1161/CIRCULATIONAHA.106.661140
   Foster NE, 2007, BMJ-BRIT MED J, V335, P436, DOI 10.1136/bmj.39280.509803.BE
   FUNG KP, 1986, LANCET, V2, P1419
   GAW AC, 1975, NEW ENGL J MED, V293, P375, DOI 10.1056/NEJM197508212930803
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Guo HF, 1996, MOL BRAIN RES, V43, P167, DOI 10.1016/S0169-328X(96)00171-4
   Guo JC, 2004, ACUPUNCTURE ELECTRO, V29, P173, DOI 10.3727/036012904815901434
   Hammerschlag R, 2000, CLIN ACUPUNCTURE ORI, V1-3, P133
   HAN J, 1979, CHINESE MED J-PEKING, V92, P625
   HAN JS, 1985, NEUROPEPTIDES, V5, P399, DOI 10.1016/0143-4179(85)90038-1
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Hsieh JC, 2001, NEUROSCI LETT, V307, P105, DOI 10.1016/S0304-3940(01)01952-8
   HU SQ, 1992, GASTROENTEROLOGY, V102, P1854, DOI 10.1016/0016-5085(92)90305-I
   HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F
   JOBST K, 1986, LANCET, V2, P1416, DOI 10.1016/S0140-6736(86)92732-7
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Kong JA, 2002, J ALTERN COMPLEM MED, V8, P411, DOI 10.1089/107555302760253603
   Langevin Helene M, 2002, ANATOMICAL RECORD, V269, P257, DOI 10.1002/ar.10185
   Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp
   Langevin HM, 2001, J APPL PHYSIOL, V91, P2471, DOI 10.1152/jappl.2001.91.6.2471
   Lee G, 2002, NEUROSCI LETT, V325, P17, DOI 10.1016/S0304-3940(02)00214-8
   Lee GS, 2003, BRAIN RES BULL, V62, P161, DOI 10.1016/j.brainresbull.2003.09.007
   Li P, 1998, CIRCULATION, V97, P1186, DOI 10.1161/01.CIR.97.12.1186
   Li P, 2001, AUTON NEUROSCI-BASIC, V89, P38, DOI 10.1016/S1566-0702(01)00247-8
   Li P, 2006, AM J PHYSIOL-HEART C, V290, PH2535, DOI 10.1152/ajpheart.00972.2005
   Li Y, 2012, CAN MED ASSOC J, V184, P401, DOI 10.1503/cmaj.110551
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Lu Gwei-Djen, 1980, CELESTIAL LANCETS: A HISTORY AND RATIONALE OF ACUPUNCTURE AND MOXA, V0, P0
   LUX G, 1994, GUT, V35, P1026, DOI 10.1136/gut.35.8.1026
   Lytle C D, 1996, J ALTERN COMPLEMENT MED, V2, P253, DOI 10.1089/acm.1996.2.253
   Macklin EA, 2006, HYPERTENSION, V48, P838, DOI 10.1161/01.HYP.0000241090.28070.4c
   MAN PL, 1972, DIS NERV SYST, V33, P730
   Manni L, 2005, REPROD BIOL ENDOCRIN, V3, P0, DOI 10.1186/1477-7827-3-21
   MARK LC, 1973, JAMA-J AM MED ASSOC, V225, P1532, DOI 10.1001/jama.1973.03220400058020
   MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Meng Xianze, 2011, FRONT MED, V5, P134, DOI 10.1007/s11684-011-0135-9
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   MOORE ME, 1976, ANN INTERN MED, V84, P381, DOI 10.7326/0003-4819-84-4-381
   Napadow V, 2007, PAIN, V130, P254, DOI 10.1016/j.pain.2006.12.003
   Napadow V, 2007, HUM BRAIN MAPP, V28, P159, DOI 10.1002/hbm.20261
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Park HJ, 2002, NEUROSCI LETT, V319, P141, DOI 10.1016/S0304-3940(01)02582-4
   Park MB, 2004, J NEUROIMMUNOL, V151, P40, DOI 10.1016/j.jneuroim.2004.02.003
   PEETS JM, 1978, NATURE, V273, P675, DOI 10.1038/273675a0
   Pfab F, 2012, ALLERGY, V67, P566, DOI 10.1111/j.1398-9995.2012.02789.x
   Pfab F, 2010, ALLERGY, V65, P903, DOI 10.1111/j.1398-9995.2009.02284.x
   RICHTER A, 1991, EUR HEART J, V12, P175, DOI 10.1093/oxfordjournals.eurheartj.a059865
   Sato T, 1996, JPN J PHYSIOL, V46, P131, DOI 10.2170/jjphysiol.46.131
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Soh KS, 2012, PRIMO VASCULAR SYSTEM: ITS ROLE IN CANCER AND REGENERATION, V0, PP3, DOI 10.1007/978-1-4614-0601-3_1
   Soh KS, 2009, J ACUPUNCT MERIDIAN, V2, P93, DOI 10.1016/S2005-2901(09)60041-8
   Song Le, 2006, ZHONGGUO ZHEN JIU, V26, P362
   Stener-Victorin E, 2004, BIOL REPROD, V70, P329, DOI 10.1095/biolreprod.103.022368
   Sung HJ, 2004, PROTEOMICS, V4, P2805, DOI 10.1002/pmic.200300821
   Takano T, 2012, J PAIN, V13, P1215, DOI 10.1016/j.jpain.2012.09.012
   TERENIUS L, 1975, ACTA PHYSIOL SCAND, V94, P74, DOI 10.1111/j.1748-1716.1975.tb05863.x
   Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C
   Tjen-A-Looi SC, 2006, AM J PHYSIOL-HEART C, V290, PH2543, DOI 10.1152/ajpheart.01329.2005
   Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004
   Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A
   Vickers AJ, 2004, BRIT MED J, V328, P744, DOI 10.1136/bmj.38029.421863.EB
   VOLL R, 1980, AM J ACUPUNCTURE, V8, P97
   VOLL R, 1975, AMERICAN JOURNAL OF ACUPUNCTURE, V3, P7
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wan Y, 2001, PAIN, V91, P5, DOI 10.1016/S0304-3959(00)00416-4
   Wang LP, 2011, PAIN, V152, P1864, DOI 10.1016/j.pain.2011.04.006
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Wang Y, 2005, EXP NEUROL, V192, P156, DOI 10.1016/j.expneurol.2004.11.003
   WATKINS LR, 1982, SCIENCE, V216, P1185, DOI 10.1126/science.6281891
   White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005
   WILLER JC, 1984, BRAIN, V107, P1095, DOI 10.1093/brain/107.4.1095
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Witt CM, 2006, ARTHRITIS RHEUM-US, V54, P3485, DOI 10.1002/art.22154
   Wu QF, 2010, J PHARMACEUT BIOMED, V51, P698, DOI 10.1016/j.jpba.2009.09.042
   Zeng F, 2012, AM J GASTROENTEROL, V107, P1236, DOI 10.1038/ajg.2012.53
   Zhang RX, 2004, BRAIN RES, V1020, P12, DOI 10.1016/j.brainres.2004.05.067
   Zhou W, 2005, J APPL PHYSIOL, V98, P872, DOI 10.1152/japplphysiol.01079.2004
   ZHU Z-X, 1981, AMERICAN JOURNAL OF ACUPUNCTURE, V9, P203
NR 117
TC 168
Z9 197
U1 4
U2 77
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0074-7742
EI 2162-5514
J9 INT REV NEUROBIOL
JI Int. Rev. Neurobiol.
PD JUN 15
PY 2013
VL 111
IS 
BP 1
EP 23
DI 10.1016/B978-0-12-411545-3.00001-8
PG 23
WC Integrative & Complementary Medicine; Clinical Neurology; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA BJP95
UT WOS:000329548500002
PM 24215915
DA 2026-01-16
ER

PT J
AU Chen, H
   Liu, TY
   Kuai, L
   Zhu, J
   Wu, CJ
   Liu, LM
AF Chen, Hao
   Liu, Tang-Yi
   Kuai, Le
   Zhu, Ji
   Wu, Cai-Jun
   Liu, Lu-Ming
TI Electroacupuncture treatment for pancreatic cancer pain: A randomized controlled trial
SO PANCREATOLOGY
LA English
DT Article
DE Pancreatic cancer; Pain; Electroacupuncture
ID clinical-trials; acupuncture; care; efficacy; future; world
AB Background: Pancreatic cancer is often accompanied by severe abdominal or back pain. It's the first study to evaluate the analgesic effect of electroacupuncture on pancreatic cancer pain. A randomized controlled trial compared electroacupuncture with control acupuncture using the placebo needle. Methods: Sixty patients with pancreatic cancer pain were randomly assigned to the electroacupuncture group (n = 30) and the placebo control group (n = 30). Patients were treated on Jiaji (Ex-B2) points T8-T12 bilaterally for 30 min once a day for 3 days. Pain intensity was assessed with numerical rated scales (NRS) before the treatment (Baseline), after 3 treatments, and 2 days follow-up. Results: Baseline characteristics were similar in the two groups. After 3 treatment, pain intensity on NRS decreased compared with Baseline (-1.67, 95% confidence interval [CI] -1.46 to -1.87) in the electroacupuncture group; there was little change (-0.13, 95% CI 0.08 to -0.35) in control group; the difference between two groups was statistically significant (P < 0.001). Follow-up also found a significant reduction in pain intensity in the electroacupuncture group compared with the control group (P < 0.001). Conclusions: Electroacupuncture was an effective treatment for relieving pancreatic cancer pain. Copyright (C) 2013, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.
C1 [Chen, Hao; Zhu, Ji; Wu, Cai-Jun; Liu, Lu-Ming] Fudan Univ, Shanghai Canc Ctr, Dept Integrat Oncol, Shanghai 200433, Peoples R China.
   [Liu, Tang-Yi; Kuai, Le] Shanghai Univ Tradit Chinese Med, Coll Acupuncture & Tuina, Shanghai 200032, Peoples R China.
C3 Fudan University; Shanghai University of Traditional Chinese Medicine
RP Kuai, L (corresponding author), Shanghai Univ Tradit Chinese Med, Coll Acupuncture & Tuina, 1200 Cai Lun Rd, Shanghai 200032, Peoples R China.
EM happykuai2004@msn.com
FU National Natural Science Foundation of China (NSFC) [81202751]; Shanghai Science and Technology Committee [12401905600]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Cabioglu MT, 2008, AM J CHINESE MED, V36, P473, DOI 10.1142/S0192415X08005916
   Caraceni A, 2010, EUR J PAIN, V14, P441, DOI 10.1016/j.ejpain.2009.07.004
   CHERNY NI, 1994, CA-CANCER J CLIN, V44, P262, DOI 10.3322/canjclin.44.5.263
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   de Leon-Casasola O A, 2000, CANCER CONTROL, V7, P142
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005
   Foley K M, 1988, J PAIN SYMPTOM MANAGE, V3, P176, DOI 10.1016/0885-3924(88)90028-0
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Hariharan D, 2008, HPB, V10, P58, DOI 10.1080/13651820701883148
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P149
   Koide N, 2006, CLIN CANCER RES, V12, P2419, DOI 10.1158/1078-0432.CCR-05-1852
   Koorstra JBM, 2008, PANCREATOLOGY, V8, P110, DOI 10.1159/000123838
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lindsay TH, 2005, PAIN, V119, P233, DOI 10.1016/j.pain.2005.10.019
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Negus SS, 2006, J PHARMACOL EXP THER, V319, P507, DOI 10.1124/jpet.106.106377
   Oliveira-Cunha M, 2012, PANCREAS, V41, P428, DOI 10.1097/MPA.0b013e3182327a03
   Park Jongbae, 2002, ACUPUNCT MED, V20, P168
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Smith P, 2007, J DENT, V35, P259, DOI 10.1016/j.jdent.2006.09.004
   Stjernsward J, 1996, J PAIN SYMPTOM MANAG, V12, P65, DOI 10.1016/0885-3924(96)00109-1
   Zhou Y, 2007, J ACUPUNCT TUINA SCI, V5, P162, DOI 10.1007/s11726-007-0162-x
NR 28
TC 57
Z9 69
U1 1
U2 45
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1424-3903
EI 1424-3911
J9 PANCREATOLOGY
JI Pancreatology
PD NOV-DEC 15
PY 2013
VL 13
IS 6
BP 594
EP 597
DI 10.1016/j.pan.2013.10.007
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 270JC
UT WOS:000328313700008
PM 24280575
DA 2026-01-16
ER

PT J
AU Gatti, A
   Gentili, M
   Iorno, V
   Mammucari, M
   Tufaro, G
   Lazzari, M
   Sabato, AF
AF Gatti, Antonio
   Gentili, Marta
   Iorno, Vittorio
   Mammucari, Massimo
   Tufaro, Giuseppe
   Lazzari, Marzia
   Sabato, Alessandro Fabrizio
TI Beyond the Traditional Definition of Breakthrough Pain: An Observational Study
SO ADVANCES IN THERAPY
LA English
DT Article
DE Breakthrough pain; Chronic pain; Gender; Non-oncological pain; Observational study; Oncological pain; Pain severity
ID cancer-pain; prevalence
AB Breakthrough pain (BTP) is traditionally defined as a transitory pain flare in opioid-treated patients with chronic background pain. This definition has, however, been challenged in recent years. This study aimed to analyze BTP prevalence in different pain conditions. This was a prospective, noninterventional, observational study conducted from June to September 2011 in two Italian pain treatment reference centres. Consecutive patients aged > 18 years with oncological or non-oncological pain were eligible for this study; background pain was acute/ subacute (< 3 months) or chronic (> 3 months). The characteristics of pain were evaluated by means of a structured interview by physicians, and patients were asked to complete a dedicated clinical study form. The following outcomes were assessed: chronic pain duration (in patients with chronic pain), BTP prevalence, and number and severity of daily BTP episodes. All outcomes were assessed in four populations of patients with: (a) chronic oncological pain; (b) chronic non-oncological pain; (c) non-chronic oncological pain; (d) nonchronic non-oncological pain. The correlation between BTP and gender was also investigated. Of 1,270 patients with chronic pain, 1,086 had non-oncological pain (85.5%). Most patients (68.6%) with non-oncological pain were female (P = 0.001). Pain duration was significantly longer in non-oncological pain versus oncological pain groups (P = 0.002). BTP prevalence was lower in non-oncological patients (P < 0.001). No differences were reported in terms of number and severity of daily BTP episodes. BTP was more frequent in females with non-oncological pain (P = 0.04). Females had a significantly higher pain severity (P = 0.02) than males. BTP is frequently reported in patients who do not have BTP according to the traditional definition. BTP frequency and severity is similar in oncological and non-oncological pain.
C1 [Gatti, Antonio; Tufaro, Giuseppe; Lazzari, Marzia; Sabato, Alessandro Fabrizio] Univ Roma Tor Vergata, Tor Vergata Polyclin, Emergency Care Crit Care Med Pain Med & Anesthesi, Rome, Italy.
   [Gentili, Marta] Patient Assoc Vivere Senza Dolore, I-20154 Milan, Italy.
   [Iorno, Vittorio] Osped Maggiore Policlin Ca Granda, Fdn IRCCS, Milan, Italy.
   [Mammucari, Massimo] Primary Care ASL RM F, Rome, Italy.
C3 University of Rome Tor Vergata; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Gentili, M (corresponding author), Patient Assoc Vivere Senza Dolore, Piazza EL Morselli 1, I-20154 Milan, Italy.
EM presidenza@viveresenzadolore.it
CR Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa
   Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018
   Coluzzi P H, 1998, AM J HOSP PALLIAT CARE, V15, P13, DOI 10.1177/104990919801500105
   Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004
   Gatti A, 2012, ADV THER, V29, P464, DOI 10.1007/s12325-012-0022-z
   Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250
   Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035
   MCQUAY HJ, 1994, CANCER SURV, V21, P17
   PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W
   Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003
   Portenoy Russell K, 2010, J OPIOID MANAG, V6, P97
   Portenoy Russell K, 2010, J OPIOID MANAG, V6, P109
   Silverman SL, 2009, AM J MED, V122, P114, DOI 10.1016/j.amjmed.2008.09.030
   Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000
   Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001
   Webster Lynn R, 2008, AM J MANAG CARE, V14, P0
   Zeppetella Giovambattista, 2009, CURR OPIN SUPPORT PALLIAT CARE, V3, P1, DOI 10.1097/SPC.0b013e3283260658
NR 19
TC 9
Z9 14
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 
J9 ADV THER
JI Adv. Ther.
PD MAR 15
PY 2013
VL 30
IS 3
BP 298
EP 305
DI 10.1007/s12325-013-0013-8
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 109PM
UT WOS:000316380500007
PM 23444055
DA 2026-01-16
ER

PT J
AU Zhang, R
   Lao, L
   Ren, K
   Berman, BM
AF Zhang, Ruixin
   Lao, Lixing
   Ren, Ke
   Berman, Brian M
TI Mechanisms of acupuncture-electroacupuncture on persistent pain.
SO Anesthesiology
LA English
DT Review
AB In the last decade, preclinical investigations of electroacupuncture mechanisms  on persistent tissue injury (inflammatory), nerve injury (neuropathic), cancer,  and visceral pain have increased. These studies show that electroacupuncture  activates the nervous system differently in health than in pain conditions,  alleviates both sensory and affective inflammatory pain, and inhibits  inflammatory and neuropathic pain more effectively at 2 to 10 Hz than at 100 Hz.  Electroacupuncture blocks pain by activating a variety of bioactive chemicals  through peripheral, spinal, and supraspinal mechanisms. These include opioids,  which desensitize peripheral nociceptors and reduce proinflammatory cytokines  peripherally and in the spinal cord, and serotonin and norepinephrine, which  decrease spinal N-methyl-D-aspartate receptor subunit GluN1 phosphorylation.  Additional studies suggest that electroacupuncture, when combined with low  dosages of conventional analgesics, provides effective pain management which can  forestall the side effects of often-debilitating pharmaceuticals.
C1 From the Center for Integrative Medicine, School of Medicine, University of Maryland, Baltimore, Maryland (R.Z., L.L., and B.M.B.)
   and Department of Neuraland Pain Sciences, Dental School, University of Maryland, Baltimore, Maryland(K.R.).
NR 0
TC 0
SN 1528-117
EI 0003-302
J9 Anesthesiology
PD DEC 11
PY 2013
VL 120
IS 2
BP 482
EP 503
DI 10.1097/ALN.0000000000000101
PG 21
WC Acupuncture Points; Acupuncture Therapy; methods; Animals; Chronic Pain; etiology; Disease Models, Animal; Electroacupuncture; methods; Humans; Inflammation; complications; Neoplasms; complications; Neuralgia; drug therapy; Sensation; Spinal Cord; physiopathology; Visceral Pain; drug therapy
UT PubMed:24322588
PM 24322588
DA 2013-12-11
ER

PT J
AU Franconi, G
   Manni, L
   Schröder, S
   Marchetti, P
   Robinson, N
AF Franconi, Giovanna
   Manni, Luigi
   Schröder, Sven
   Marchetti, Paolo
   Robinson, Nicola
TI A systematic review of experimental and clinical acupuncture in
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect that  can be very disabling and can limit or delay the dose of chemotherapy that can be  administered. Acupuncture may be effective for treating peripheral neuropathy.  The aim of this study was to review the available literature on the use of  acupuncture for CIPN. The systematic literature search was performed using  MEDLINE, Google Scholar, Cochrane Database, CINHAL, and ISI Proceedings. Hand  searching was conducted, and consensus was reached on all extracted data. Only  papers in the English language were included, irrespective of study design. From  3989 retrieved papers, 8 relevant papers were identified. One was an experimental  study which showed that electroacupuncture suppressed CIPN pain in rats. In  addition, there were 7 very heterogeneous clinical studies, 1 controlled  randomised study using auricular acupuncture, 2 randomized controlled studies  using somatic acupuncture, and 3 case series/case reports which suggested a  positive effect of acupuncture in CIPN. Conclusions. Only one controlled  randomised study demonstrated that acupuncture may be beneficial for CIPN. All  the clinical studies reviewed had important methodological limitations. Further  studies with robust methodology are needed to demonstrate the role of acupuncture  for treating CIPN resulting from cancer treatment.
C1 Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD AUG 29
PY 2013
VL 2013
IS 
BP 516916
EP 516916
DI 10.1155/2013/516916
PG 0
UT PubMed:23983788
PM 23983788
DA 2013-08-29
ER

PT J
AU Hübner, J
AF Huebner, J.
TI Update 2013 on complementary oncology
SO ONKOLOGE
LA German
DT Article
DE Complementary oncology; Vitamin D; Selenium; Acupuncture; Mistleto
ID cell lung-cancer; quality-of-life; breast-cancer; prostate-cancer; double-blind; induced xerostomia; clinical-trial; neck-cancer; folic-acid; vitamin-c
AB In 2012 several studies and reviews on the question of prevention of tumerous diseases with nutritional supplements were published. There are still no indications for the use of antioxidants in healthy people. Folic acid and Vitamin B12 even may induce tumor growth. The data underline the significance of Vitamin D in primary and secondary prevention. Selenium levels below as well as above normal are associated with a higher risk of cancer. Omega-3 fatty acids have a potential as anti-inflammatory agents. The results of two studies are indicative for pomegranate extract reducing growth in prostate cancer but in both studies a control group without extract was lacking. So far no study on mistletoe has been published which proves positive effects on survival or side effects of cancer therapy. Chinese medical herbs may contain interesting substances. As knowledge on the side effects and interactions is missing they should not be used outside studies. For acupuncture many studies have been published but the quality in general is low so that no conclusions can be drawn concerning pain, fatigue and xerostomia. Systematic reviews have cited positive results for nausea and emesis. No studies are available which show results demonstrating the efficacy of homeopathy in cancer patients.
C1 Goethe Univ Frankfurt, Dr Senckenberg Chronomed Inst, D-60590 Frankfurt, Germany.
C3 Goethe University Frankfurt
RP Hübner, J (corresponding author), Goethe Univ Frankfurt, Dr Senckenberg Chronomed Inst, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM Huebner@med.uni-frankfurt.de
CR Attia A, 2012, J NEURO-ONCOL, V109, P357, DOI 10.1007/s11060-012-0901-9
   Bar-Sela G, 2012, EUR J CANCER, V0, P0, DOI DOI 10.1016/i
   Barton DL, 2012, SUPPORT CARE CANC, V0, P0
   Chajès V, 2012, CANCER EPIDEM BIOMAR, V21, P319, DOI 10.1158/1055-9965.EPI-11-0896
   Cho JH, 2008, J ALTERN COMPLEM MED, V14, P523, DOI 10.1089/acm.2007.0793
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chua ME, 2012, PROSTATE CANCER-US, V2012, P0, DOI 10.1155/2012/826254
   Clapin HF, 2012, NUTR CANCER, V64, P937, DOI 10.1080/01635581.2012.715718
   Cortés-Jofré M, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002141.pub2
   Crowther M, 2009, BONE MARROW TRANSPL, V44, P413, DOI 10.1038/bmt.2009.41
   Cruciani RA, 2012, J CLIN ONCOL, V30, P3864, DOI 10.1200/JCO.2011.40.2180
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Fedirko V, 2012, CANCER EPIDEM BIOMAR, V21, P582, DOI 10.1158/1055-9965.EPI-11-1065
   Fife J, 2011, COLORECTAL DIS, V13, P132, DOI 10.1111/j.1463-1318.2009.02089.x
   Gabius HJ, 2001, CANCER INVEST, V19, P114, DOI 10.1081/CNV-100000146
   Gaglio D, 2011, MOL SYST BIOL, V7, P0, DOI 10.1038/msb.2011.56
   Gibson RJ, 2013, SUPPORT CARE CANCER, V21, P313, DOI 10.1007/s00520-012-1644-z
   Guo L, 2012, MED ONCOL, V29, P1656, DOI 10.1007/s12032-011-0068-9
   Hankey GJ, 2012, STROKE, V43, P1572, DOI 10.1161/STROKEAHA.111.641613
   Harris HR, 2012, BREAST CANCER RES TR, V134, P1269, DOI 10.1007/s10549-012-2139-9
   Horneber MA, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003297.pub2
   Hurst R, 2012, AM J CLIN NUTR, V96, P111, DOI 10.3945/ajcn.111.033373
   Hurst R, 2010, AM J CLIN NUTR, V91, P923, DOI 10.3945/ajcn.2009.28169
   Johansson M, 2008, CANCER EPIDEM BIOMAR, V17, P279, DOI 10.1158/1055-9965.EPI-07-0657
   Kassab S, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004845.pub2
   Kennedy DA, 2011, CANCER EPIDEMIOL, V35, P2, DOI 10.1016/j.canep.2010.11.004
   Kim KC, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-172
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   Kucuktulu E, 2013, SUPPORT CARE CANCER, V21, P1071, DOI 10.1007/s00520-012-1627-0
   Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P4208, DOI 10.4161/cc.10.24.18487
   McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392
   Melzer J, 2009, FORSCH KOMPLEMENTMED, V16, P217, DOI 10.1159/000226249
   Mikirova N, 2012, J TRANSL MED, V10, P0, DOI 10.1186/1479-5876-10-189
   Modan-Moses D, 2012, PEDIATR RES, V72, P620, DOI 10.1038/pr.2012.131
   MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Monti DA, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0029794
   Murphy RA, 2011, CANCER-AM CANCER SOC, V117, P1775, DOI 10.1002/cncr.25709
   OSullivan EM, 2010, ACUPUNCT MED, V28, P191, DOI 10.1136/aim.2010.002733
   Oberbaum M, 2001, CANCER, V92, P684, DOI 10.1002/1097-0142(20010801)92:3<684::AID-CNCR1371>3.0.CO;2-#
   Ostermann T, 2012, EXPLORE-NY, V8, P277, DOI 10.1016/j.explore.2012.06.005
   Paller CJ, 2013, PROSTATE CANCER P D, V16, P50, DOI 10.1038/pcan.2012.20
   Pantuck AJ, 2006, CLIN CANCER RES, V12, P4018, DOI 10.1158/1078-0432.CCR-05-2290
   Pérol D, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-603
   Pilz S, 2013, ANTI-CANCER AGENT ME, V13, P107, DOI 10.2174/187152013804487407
   Rosen GP, 2013, PEDIATR BLOOD CANCER, V60, P949, DOI 10.1002/pbc.24349
   Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515
   Song YQ, 2012, J NATL CANCER I, V104, P1562, DOI 10.1093/jnci/djs370
   Steinbrecher A, 2012, CANCER EPIDEM BIOMAR, V19, P2958
   Sultan J, 2012, BRIT J SURG, V99, P346, DOI 10.1002/bjs.7799
   Thies A, 2005, TOXICOLOGY, V207, P105, DOI 10.1016/j.tox.2004.09.009
   van der Rhee H, 2013, EUR J CANCER, V49, P1422, DOI 10.1016/j.ejca.2012.11.001
   Wang WS, 2007, ONCOLOGIST, V12, P312, DOI 10.1634/theoncologist.12-3-312
   Wong RKW, 2003, INT J RADIAT ONCOL, V57, P472, DOI 10.1016/S0360-3016(03)00572-8
   Worthington HV, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000978.pub5
   Yeh CH, 2012, J ALTERN COMPLEM MED, V18, P334, DOI 10.1089/acm.2011.0102
   Zeller T, 2013, J CANCER RES CLIN, V139, P357, DOI 10.1007/s00432-012-1336-6
NR 59
TC 1
Z9 2
U1 0
U2 22
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0947-8965
EI 1433-0415
J9 ONKOLOGE
JI Onkologe
PD NOV 15
PY 2013
VL 19
IS 11
BP 970
EP +
DI 10.1007/s00761-013-2541-x
PG 8
WC Oncology
SC Oncology
GA 247EY
UT WOS:000326599800009
DA 2026-01-16
ER

PT J
AU Franconi, G
   Manni, L
   Schröder, S
   Marchetti, P
   Robinson, N
AF Franconi, Giovanna
   Manni, Luigi
   Schroeder, Sven
   Marchetti, Paolo
   Robinson, Nicola
TI A Systematic Review of Experimental and Clinical Acupuncture in Chemotherapy-Induced Peripheral Neuropathy
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID low-frequency electroacupuncture; spinal dorsal-horn; mechanical allodynia; neurotrophic factor; gene-expression; cold allodynia; messenger-rna; pain; growth; rat
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect that can be very disabling and can limit or delay the dose of chemotherapy that can be administered. Acupuncture may be effective for treating peripheral neuropathy. The aim of this study was to review the available literature on the use of acupuncture for CIPN. The systematic literature search was performed using MEDLINE, Google Scholar, Cochrane Database, CINHAL, and ISI Proceedings. Hand searching was conducted, and consensus was reached on all extracted data. Only papers in the English language were included, irrespective of study design. From 3989 retrieved papers, 8 relevant papers were identified. One was an experimental study which showed that electroacupuncture suppressed CIPN pain in rats. In addition, there were 7 very heterogeneous clinical studies, 1 controlled randomised study using auricular acupuncture, 2 randomized controlled studies using somatic acupuncture, and 3 case series/case reports which suggested a positive effect of acupuncture in CIPN. Conclusions. Only one controlled randomised study demonstrated that acupuncture may be beneficial for CIPN. All the clinical studies reviewed had important methodological limitations. Further studies with robust methodology are needed to demonstrate the role of acupuncture for treating CIPN resulting from cancer treatment.
C1 [Franconi, Giovanna] Univ Roma Tor Vergata, Dept Syst Med, I-00133 Rome, Italy.
   [Manni, Luigi] CNR, Inst Translat Pharmacol, I-00133 Rome, Italy.
   [Schroeder, Sven] Univ Med Ctr Hamburg Eppendorf, HanseMerkur Ctr Tradit Chinese Med, D-20246 Hamburg, Germany.
   [Marchetti, Paolo] Univ Roma La Sapienza, St Andrea Hosp, I-00189 Rome, Italy.
   [Marchetti, Paolo] IDI IRCCS, I-00167 Rome, Italy.
   [Robinson, Nicola] London S Bank Univ, Fac Hlth & Social Care, London SE1 0AA, England.
C3 University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Farmacologia Traslazionale (IFT-CNR); University of Hamburg; University Medical Center Hamburg-Eppendorf; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Istituto Dermopatico dell'Immacolata (IDI); London South Bank University
RP Franconi, G (corresponding author), Univ Roma Tor Vergata, Dept Syst Med, I-00133 Rome, Italy.
EM giovanna.franconi@uniroma2.it
CR Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Aloe L, 2000, AUTON NEUROSCI-BASIC, V86, P84, DOI 10.1016/S1566-0702(00)00247-2
   Aloe L, 2009, NEUROSCI LETT, V449, P173, DOI 10.1016/j.neulet.2008.11.003
   ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Beal MW, 2000, ALTERN THER HEALTH M, V6, P33
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Cavaletti G, 2004, ANN ONCOL, V15, P1439, DOI 10.1093/annonc/mdh348
   Cavaletti G, 2006, CURR DRUG SAF, V1, P35, DOI 10.2174/157488606775252656
   Cohen Andrea J, 2005, INTEGR CANCER THER, V4, P131, DOI 10.1177/1534735405276419
   De Santis S, 2000, CLIN CANCER RES, V6, P90
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dong ZQ, 2005, NEUROSCI LETT, V376, P143, DOI 10.1016/j.neulet.2004.11.044
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Fusumada Kazutoshi, 2007, OKAJIMAS FOLIA ANATOMICA JAPONICA, V84, P1, DOI 10.2535/ofaj.84.1
   GELDOF AA, 1995, J CANCER RES CLIN, V121, P657, DOI 10.1007/BF01218523
   Head KA, 2006, ALTERN MED REV, V11, P294
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Kim SK, 2005, EUR J PHARMACOL, V523, P64, DOI 10.1016/j.ejphar.2005.08.030
   Ko J, 2002, J BIOCHEM MOL BIOL, V35, P420
   Lau WK, 2008, NEUROSCIENCE, V155, P463, DOI 10.1016/j.neuroscience.2008.06.016
   LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916
   Liang XB, 2003, NEUROREPORT, V14, P1177, DOI 10.1097/00001756-200306110-00015
   Liang XB, 2002, MOL BRAIN RES, V108, P51, DOI 10.1016/S0169-328X(02)00513-2
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049
   Mannerås L, 2008, ENDOCRINOLOGY, V149, P3559, DOI 10.1210/en.2008-0053
   Manni L, 2011, DIABETOLOGIA, V54, P1900, DOI 10.1007/s00125-011-2117-5
   Manni L, 2010, AUTON NEUROSCI-BASIC, V157, P9, DOI 10.1016/j.autneu.2010.03.020
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Nori SL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/652735
   Özsoy M, 1999, INT J STD AIDS, V10, P629, DOI 10.1258/0956462991913088
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001
   Podratz JL, 2011, NEUROBIOL DIS, V41, P661, DOI 10.1016/j.nbd.2010.11.017
   Power R, 2002, PRIMARY CARE, V29, P361, DOI 10.1016/S0095-4543(01)00013-6
   Robinson N, 2012, J ETHNOPHARMACOL, V140, P604, DOI 10.1016/j.jep.2012.01.052
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Silva JRT, 2011, J PAIN, V12, P51, DOI 10.1016/j.jpain.2010.04.008
   Somers DL, 2009, J PAIN, V10, P221, DOI 10.1016/j.jpain.2008.08.008
   Sung HJ, 2004, PROTEOMICS, V4, P2805, DOI 10.1002/pmic.200300821
   Tian YP, 2011, TIANJIN J TCM, V28, P212
   Ulett GA, 1998, SOUTHERN MED J, V91, P1115, DOI 10.1097/00007611-199812000-00004
   Ventura C, 2005, EVID-BASED COMPL ALT, V2, P277, DOI 10.1093/ecam/neh100
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Wei GW, 2000, ACUPUNCTURE ELECTRO, V25, P81, DOI 10.3727/036012900816356208
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wu B, 1992, J TRADIT CHIN MED, V12, P10
   Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133
   Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Zhang C, 2010, J TRADIT CHIN MED, V30, P13, DOI 10.1016/S0254-6272(10)60003-9
   Zhang ZJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/429412
NR 62
TC 39
Z9 49
U1 0
U2 27
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2013
VL 2013
IS 
BP 
EP 
DI 10.1155/2013/516916
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 194MJ
UT WOS:000322637100001
PM 23983788
DA 2026-01-16
ER

PT J
AU Paley, C
AF Paley, Carole
TI Acupuncture for the treatment of cancer pain: a systematic review. Response to authors
SO SUPPORTIVE CARE IN CANCER
LA English
DT Letter
C1 Airedale NHS Fdn Trust, Keighley, W Yorkshire, England.
RP Paley, C (corresponding author), Airedale NHS Fdn Trust, Keighley, W Yorkshire, England.
EM carolepaley2@btinternet.com
CR Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
NR 1
TC 0
Z9 0
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAY 15
PY 2013
VL 21
IS 5
BP 1217
EP 1217
DI 10.1007/s00520-012-1704-4
PG 1
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 117OK
UT WOS:000316962600002
PM 23306936
DA 2026-01-16
ER

PT J
AU Wang, CJ
   Tan, W
   Huang, XH
   Fu, TT
   Lin, JZ
   Bu, JM
   Wei, GJ
   Du, Y
AF Wang, Changjun
   Tan, Wei
   Huang, Xuhui
   Fu, Tingting
   Lin, Juze
   Bu, Junmin
   Wei, Guojian
   Du, Yu
TI Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE Analgesics; Liver neoplasms; Pain; Acupuncture points; Randomized controlled trail
ID scales; ladder
AB OBJECTIVE: To observe the curative effect of an acupoint application with a Dingqi analgesic patch on moderate to severe pain caused by liver cancer. METHODS: Forty patients with moderate to severe pain caused by liver cancer were randomly divided into a treatment group (TG) and a control group (CG). Patients with moderate pain were given 100 mg qd of a sustainably released tablet of tramadol hydrochloride; patients with-severe pain were given 4.2 mg q3d of the fentanyl transdermal system. The ashi points Ganshu (BL 18), Danshu (BL 19) and Qimen (LR 14) were chosen for the acupoint application intervention. CG patients were given a sham patch and TG patients were given a Dingqi analgesic patch. A visual analogue scale (VAS) was used before treatment and after 1, 3, 6, 9 and 12 days of treatment. The Karnofsky score was measured before treatment and after 12 days of treatment. Any main adverse reactions (e.g. nausea, constipation, dizziness and headache) were recorded after 6 and 12 days of treatment. Any skin side effects (i.e. skin irritation and allergic reactions) were recorded. RESULTS: The VAS in TG was significantly lower than that in CG after 3, 6, 9 and 12 days of treatment (P<0.05). There was no significant difference in the Karnofsky score before treatment and after 12 days of treatment between CG and TG. There were also no significant differences in the main adverse reactions or skin side effects after 6 and 12 days of treatment between CG and TG (P>0.05). CONCLUSION: The Dingqi analgesic patch can enhance the analgesic effect of tramadol and fentanyl. (C) 2013 JTCM. All rights reserved.
C1 [Wang, Changjun; Tan, Wei; Huang, Xuhui; Fu, Tingting; Lin, Juze; Bu, Junmin; Wei, Guojian; Du, Yu] Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Geriatr Inst, Dept Tradit Chinese Med, Guangzhou 510080, Guangdong, Peoples R China.
C3 Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital
RP Wang, CJ (corresponding author), Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Geriatr Inst, Dept Tradit Chinese Med, Guangzhou 510080, Guangdong, Peoples R China.
EM gzwchj@126.com
FU Administration of Traditional Chinese Medicine of Guangdong Province, China [2010431]
CR Ai F, 2010, ZHONGCAOYAO, V41, P201
   AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005
   Unknown -, 2009, MED LETT DRUGS THER, V51, P29
   Chang YunPing Chang YunPing, 2012, DRUGS AND CLINIC, V27, P52
   Chen S, 2012, GUANG MING ZHONG YI, V27, P1841
   Chinese Medical Association, 2005, GUID CLIN PRACT CANC, V0, P322
   Csupor D, 2011, PHARM BIOL, V49, P1097, DOI 10.3109/13880209.2011.595011
   Forbes K, 2011, CLIN ONCOL-UK, V23, P379, DOI 10.1016/j.clon.2011.04.016
   Fu Ying Fu Ying, 2011, ZHONGCAOYAO = CHINESE TRADITIONAL AND HERBAL DRUGS, V42, P1229
   Ge Hong-Yan, 2012, ZHONGGUO ZHEN JIU, V32, P602
   Han Zhifeng, 2011, ZHONGGUO ZHONG YAO ZA ZHI, V36, P41
   Han ZY, 2007, ZHONG YI YAO GUAN LI, V15, P142
   Huang CF, 2011, AM J CHINESE MED, V39, P981, DOI 10.1142/S0192415X11009354
   Huang QF, 2011, ZHEN JIU TUI NA YI X, V9, P346
   Li XL, 2006, XIN ZHONG YI, V38, P71
   Liu YQ, 2011, ZHONG GUO TENG TONG, V17, P314
   Mo YF, 2011, HUNAN ZHONG YI YAO D, V31, P40
   Mo YF, 2008, ZHONG GUO MIN ZU MIN, V0, P25
   Peng Jin, 2012, ZHONG XI YI JIE HE XUE BAO, V10, P39
   Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428
   Pu ZY, 2005, JI LIN ZHONG YI YAO, V25, P21
   Qin YY, 2011, GUANG MING ZHONG YI, V26, P1121
   Qiu YB, 2011, ZHONG GUO LIAO YANG, V20, P435
   Ripamonti CI, 2009, CLIN J PAIN, V25, P386, DOI 10.1097/AJP.0b013e3181929b4f
   Shao YZ, 2010, LIAONING ZHONG YI ZA, V37, P352
   Sun H, 2008, HUBEI ZHONG YI ZA ZH, V30, P32
   Sun LH, 2002, JIANGXI ZHONG YI XUE, V14, P19
   Swarm R, 2010, J NATL COMPR CANC NE, V8, P1046, DOI 10.6004/jnccn.2010.0076
   Tang WJ, 2012, SHI YONG ZHONG XI YI, V12, P23
   Tassinari D, 2011, PALLIATIVE MED, V25, P410, DOI 10.1177/0269216311405090
   Wang SH, 2011, ZHONG YI ZA ZHI, V52, P962
   Wang XP, 2010, SHANGHAI ZHEN JIU ZA, V29, P506
   Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x
   Xie Hong-Liang, 2010, ZHONGGUO ZHEN JIU, V30, P567
   Yang YZ, 2011, LIAONING ZHONG YI ZA, V38, P1192
   Yuan J, 2009, ZHONG YAO CAI, V32, P1442
   Zeng JG, 2011, ZHONG GUO YAO WU JIN, V0, P82
   Zhang SH, 2003, ZHONG YI ZA ZHI, V44, P648
   Zhang YM, 2009, XI BEI YAO XUE ZA ZH, V24, P399
   Zhao JF, 2011, ZHONG GUO YAO FANG, V22, P661
NR 40
TC 4
Z9 7
U1 1
U2 13
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD APR 15
PY 2013
VL 33
IS 2
BP 176
EP 180
DI 10.1016/S0254-6272(13)60121-1
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 124CI
UT WOS:000317441000005
PM 23789213
DA 2026-01-16
ER

PT J
AU Chen, H
   Liu, TY
   Kuai, L
   Zhu, J
   Wu, CJ
   Liu, LM
AF Chen, Hao
   Liu, Tang-Yi
   Kuai, Le
   Zhu, Ji
   Wu, Cai-Jun
   Liu, Lu-Ming
TI Electroacupuncture treatment for pancreatic cancer pain: a randomized controlled
SO Pancreatology : official journal of the International Association of
LA English
DT Journal Article
DE Electroacupuncture; Pain; Pancreatic cancer
AB BACKGROUND: Pancreatic cancer is often accompanied by severe abdominal or back  pain. It's the first study to evaluate the analgesic effect of electroacupuncture  on pancreatic cancer pain. A randomized controlled trial compared  electroacupuncture with control acupuncture using the placebo needle. METHODS:  Sixty patients with pancreatic cancer pain were randomly assigned to the  electroacupuncture group (n = 30) and the placebo control group (n = 30).  Patients were treated on Jiaji (Ex-B2) points T8-T12 bilaterally for 30 min once  a day for 3 days. Pain intensity was assessed with numerical rated scales (NRS)  before the treatment (Baseline), after 3 treatments, and 2 days follow-up.  RESULTS: Baseline characteristics were similar in the two groups. After 3  treatment, pain intensity on NRS decreased compared with Baseline (-1.67, 95%  confidence interval [CI] -1.46 to -1.87) in the electroacupuncture group; there  was little change (-0.13, 95% CI 0.08 to -0.35) in control group; the difference  between two groups was statistically significant (P < 0.001). Follow-up also  found a significant reduction in pain intensity in the electroacupuncture group  compared with the control group (P < 0.001). CONCLUSIONS: Electroacupuncture was  an effective treatment for relieving pancreatic cancer pain.
C1 Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
NR 0
TC 0
SN 1424-391
EI 
J9 Pancreatology
PD NOV 28
PY 2013
VL 13
IS 6
BP 594
EP 7
DI 10.1016/j.pan.2013.10.007
PG -587
WC Adolescent; Adult; Aged; Analgesics; therapeutic use; Disease Progression; Electroacupuncture; methods; Female; Humans; Liver Neoplasms; secondary; Male; Middle Aged; Pain Management; Pain Measurement; Pain, Intractable; etiology; Pancreatic Neoplasms; complications; Survival Analysis; Young Adult
UT PubMed:24280575
PM 24280575
DA 2013-11-28
ER

PT J
AU Miller, MC
AF Miller, Matthew C.
TI Complementary and Integrative Treatments Expanding the Continuum of Care
SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Complementary and alternative medicine; CAM; Integrative medicine; CIM; Otolaryngology; Traditional medicine; Acupuncture; Homeopathy natural products; Supplements
ID alternative medicine use; traditional chinese medicine; low-back-pain; cancer-patients; united-states; physicians attitudes; advising patients; acupuncture; therapy; head
AB This article is an introduction to the concepts of complementary, alternative, and integrative medicine. It discusses the scope and prevalence of complementary and integrative medicine (CIM) use among otolaryngology patients. Specific types of CIM are characterized in the context of their origins, philosophic and historical bases, scientific evidence, and applicability to the practice of otolaryngology. The author's intent is to provide a framework for discussing CIM with patients and integrating it into treatment paradigms in an evidence-based manner.
C1 Dept Otolaryngol Head & Neck Surg, Rochester, NY 14642 USA.
RP Miller, MC (corresponding author), Dept Otolaryngol Head & Neck Surg, Box 629,601 Elmwood Ave, Rochester, NY 14642 USA.
EM Matthew_miller@urmc.rochester.edu
CR Andersen BL, 2004, J CLIN ONCOL, V22, P3570, DOI 10.1200/JCO.2004.06.030
   Unknown -, 2002, WHO TRADITIONAL MED, V0, P0
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Blom M, 1996, ORAL ONCOL, V32B, P182
   Borsa PA, 1998, J ATHL TRAINING, V33, P150
   Bronfort Gert, 2004, SPINE J, V4, P335, DOI 10.1016/j.spinee.2003.06.002
   Carlson LE, 2003, PSYCHOSOM MED, V65, P571, DOI 10.1097/01.PSY.0000074003.35911.41
   Cassileth BR, 2004, ONCOLOGIST, V9, P80, DOI 10.1634/theoncologist.9-1-80
   CHENG R, 1980, INT J NEUROSCI, V10, P95, DOI 10.3109/00207458009160487
   Chopra A, 2002, MED CLIN N AM, V86, P75, DOI 10.1016/S0025-7125(03)00073-7
   Cohen Andrea J, 2005, INTEGR CANCER THER, V4, P131, DOI 10.1177/1534735405276419
   Collacott EA, 2000, JAMA-J AM MED ASSOC, V283, P1322, DOI 10.1001/jama.283.10.1322
   Davis GE, 2006, HEAD NECK-J SCI SPEC, V28, P926, DOI 10.1002/hed.20420
   DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508
   Dy GK, 2004, J CLIN ONCOL, V22, P4810, DOI 10.1200/JCO.2004.03.121
   Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010
   Eisenberg DM, 2002, ANN INTERN MED, V137, P965, DOI 10.7326/0003-4819-137-12-200212170-00010
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Ernst E, 2007, J ROY SOC MED, V100, P330, DOI 10.1258/jrsm.100.7.330
   Ernst E, 2003, EUR J CANCER, V39, P2273, DOI 10.1016/S0959-8049(03)00604-X
   Ernst E, 2002, BRIT J CLIN PHARMACO, V54, P577, DOI 10.1046/j.1365-2125.2002.01699.x
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Gouveia LO, 2009, SPINE, V34, PE405, DOI 10.1097/BRS.0b013e3181a16d63
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Homola S, 2006, CLIN ORTHOP RELAT R, V0, PP236, DOI 10.1097/01.blo.0000200258.95865.87
   Hsiao AF, 2006, J ALTERN COMPLEM MED, V12, P1003, DOI 10.1089/acm.2006.12.1003
   Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126
   Johnson SM, 2001, ACAD MED, V76, P821, DOI 10.1097/00001888-200108000-00016
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Kawakita K, 2006, J PHARMACOL SCI, V100, P443, DOI 10.1254/jphs.CRJ06004X
   Kennedy J, 2008, EVID-BASED COMPL ALT, V5, P451, DOI 10.1093/ecam/nem045
   Khatri Deepali, 2007, DIABETES RES CLIN PRACT, V78, Pe9, DOI 10.1016/j.diabres.2007.05.002
   Lafferty WE, 2004, CANCER-AM CANCER SOC, V100, P1522, DOI 10.1002/cncr.20105
   Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9
   Manheimer E, 2009, J ALTERN COMPLEM MED, V15, P1001, DOI 10.1089/acm.2008.0414
   Milazzo S, 2006, EUR J CANCER, V42, P282, DOI 10.1016/j.ejca.2005.09.025
   Milden SP, 2004, BEHAV MED, V30, P73, DOI 10.3200/BMED.30.2.73-84
   Miller Matthew C, 2010, EAR NOSE THROAT J, V89, P0
   Misra R, 2010, J ALTERN COMPLEM MED, V16, P843, DOI 10.1089/acm.2009.0517
   Molassiotis A, 2006, EUR J CANCER CARE, V15, P19, DOI 10.1111/j.1365-2354.2005.00615.x
   Nahin Richard L, 2009, NATL HEALTH STAT REPORT, V0, P1
   NANSEL D, 1995, J MANIP PHYSIOL THER, V18, P379
   Nidich SI, 2009, AM J HYPERTENS, V22, P1326, DOI 10.1038/ajh.2009.184
   Patwardhan B, 2005, EVID-BASED COMPL ALT, V2, P465, DOI 10.1093/ecam/neh140
   Pilkington K, 2011, J ALTERN COMPLEM MED, V17, P647, DOI 10.1089/acm.2010.0138
   Raimond K, 2003, INT J RADIAT ONCOL, V57, P472
   Riddle GNE, 2004, CAN FAM PHYSICIAN, V50, P871
   Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005
   Rubinstein SM, 2011, SPINE, V36, PE825, DOI 10.1097/BRS.0b013e3182197fe1
   Schmidt K, 2004, ANN ONCOL, V15, P733, DOI 10.1093/annonc/mdh174
   Shakeel M, 2007, INT J PEDIATR OTORHI, V71, P1725, DOI 10.1016/j.ijporl.2007.07.009
   Shakeel M, 2010, AM J OTOLARYNG, V31, P252, DOI 10.1016/j.amjoto.2009.02.016
   Sivasankaran S, 2006, CLIN CARDIOL, V29, P393, DOI 10.1002/clc.4960290905
   Smith MJ, 2002, MED CLIN N AM, V86, P173, DOI 10.1016/S0025-7125(03)00079-8
   Solberg EE, 2004, MED SCI MONITOR, V10, P0
   Stehlin I, 1996, FDA CONSUMER LINE ED, V30, P0
   Swenson Rand, 2003, J AM ACAD ORTHOP SURG, V11, P228
   Talmi YP, 2005, LARYNGOSCOPE, V115, P1505, DOI 10.1097/01.mlg.0000172205.31559.8d
   Thompson Trevor D B, 2006, BMC COMPLEMENT ALTERN MED, V6, P37
   van der Weg F, 2003, SWISS MED WKLY, V133, P233
   Wahner-Roedler DL, 2006, EVID-BASED COMPL ALT, V3, P495, DOI 10.1093/ecam/nel036
   Warrick PD, 1999, ARCH OTOLARYNGOL, V125, P573, DOI 10.1001/archotol.125.5.573
   Waterbrook AL, 2010, J EMERG MED, V39, P569, DOI 10.1016/j.jemermed.2008.01.007
   Weiger WA, 2002, ANN INTERN MED, V137, P889, DOI 10.7326/0003-4819-137-11-200212030-00010
   Wolsko PM, 2004, J GEN INTERN MED, V19, P43, DOI 10.1111/j.1525-1497.2004.21019.x
   Wu APW, 2007, FAM MED, V39, P195
   Yates JS, 2005, SUPPORT CARE CANCER, V13, P806, DOI 10.1007/s00520-004-0770-7
   Yu Y, 1997, JPN J PHYSIOL, V47, P173, DOI 10.2170/jjphysiol.47.173
NR 69
TC 3
Z9 3
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0030-6665
EI 1557-8259
J9 OTOLARYNG CLIN N AM
JI Otolaryngol. Clin. N. Am.
PD JUN 15
PY 2013
VL 46
IS 3
BP 261
EP +
DI 10.1016/j.otc.2012.12.003
PG 17
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 175JL
UT WOS:000321226900001
PM 23764808
DA 2026-01-16
ER

PT J
AU Chen, HY
   Li, SG
   Cho, WCS
   Zhang, ZJ
AF Chen, Hai-Yong
   Li, Shi-Guang
   Cho, William C. S.
   Zhang, Zhang-Jin
TI The role of acupoint stimulation as an adjunct therapy for lung cancer: a systematic review and meta-analysis
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
DE Acupuncture; Chinese medicine; Lung cancer; Systematic review; Meta-analysis
ID acupuncture treatment; alternative medicine; interferon-gamma; cell-activity; complementary; interleukin-2; enhancement; carcinoma; efficacy; th17
AB Background: Lung cancer is the leading cause of death in cancer patients. Clinical studies showed that a variety of acupoint stimulations have been extensively used for lung cancer patients, including needle insertion, injection with herbal extraction, plaster application, and moxibustion. However, the role of acupoint stimulation in lung cancer treatment was not fully reviewed. Methods: In the present study, we conducted a systematic review and meta-analysis on the role of acupoint stimulation in lung cancer treatment by electronic and manual searching in seven databases, including Ovid (Ovid MEDLINE, AMED, CAB Abstracts, EMBASE), EBSCOhost research databases (Academic Search premier, MEDLINE, CIHAHL Plus), PreQuest (British Nursing Index, ProQuest Medical Library, ProQuest Dissertations & Theses A&I, PsycINFO), and ISI web of knowledge (Web of Science, BIOSIS Citation Index, Biological Abstracts, Chinese Science Citation Database), CNKI, Wanfang Data, and CQVIP. Results: Our study showed that acupoint stimulation has strong immunomodulatory effect for lung cancer patients as demonstrated by the significant increase of IL-2, T cell subtypes (CD3+ and CD4+, but not CD8+ cells), and natural killer cells. Further analysis revealed that acupoint stimulation remarkably alleviates the conventional therapy-induced bone marrow suppression (hemoglobin, platelet, and WBC reduction) in lung cancer patients, as well as decreases nausea and vomiting. The pooled studies also showed that acupoint stimulation can improve Karnofsky performance status, immediate tumor response, quality of life (EORCT-QLQ-C30), and pain control of cancer patients. Conclusions: Acupoint stimulation is found to be effective in lung cancer treatment, further confirmatory evaluation via large scale randomized trials is warranted.
C1 [Chen, Hai-Yong; Zhang, Zhang-Jin] Univ Hong Kong, Li Ka Shing Fac Med, Sch Chinese Med, Pokfulam, Hong Kong, Peoples R China.
   [Li, Shi-Guang] Shenzhen Hosp TCM, Dept Oncol & Hematol, Shenzhen, Guangdong, Peoples R China.
   [Cho, William C. S.] Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R China.
C3 University of Hong Kong
RP Cho, WCS (corresponding author), Queen Elizabeth Hosp, Dept Clin Oncol, 30 Gascoigne Rd, Kowloon, Hong Kong, Peoples R China.
EM williamcscho@gmail.com; Zhangzj@hku.hk
CR Bronte V, 2008, BLOOD, V112, P214, DOI 10.1182/blood-2008-04-149260
   Cai LH, 2011, NURS J CHIN PEOPLES, V28, P43
   CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923
   Cao HJ, 2013, MED ACUPUNCT, V25, P173, DOI 10.1089/acu.2012.0906
   Chen DL, 2008, THESIS GUANGZHOU U C, V0, P0
   Chen FR, 2009, NAT TRAD CHIN MED NU, V0, P91
   Chen HY, 2007, J ALTERN COMPLEM MED, V13, P669, DOI 10.1089/acm.2006.6400
   Chen LL, 1997, ZHONGGUO ZHEN JIU, V17, P197
   Chen WF, 2005, THESIS TIANJIN U TRA, V0, P0
   Cho JH, 2008, J ALTERN COMPLEM MED, V14, P523, DOI 10.1089/acm.2007.0793
   Cho WCS, 2009, EXPERT OPIN INV DRUG, V18, P617, DOI 10.1517/13543780902855308
   Cho WCS, 2009, CANCER INVEST, V27, P334, DOI 10.1080/07357900802392683
   Ding L, 2011, THESIS BEIJING U CHI, V0, P0
   Ding YW, 2011, GANSU J TCM, V24, P23
   Fan QL, 2009, J TRADIT CHIN MED, V32, P25
   Gu LM, 2010, J TRADIT CHIN MED, V26, P531
   Han XM, 2012, ADV MATER RES-SWITZ, V554-556, P1650, DOI 10.4028/www.scientific.net/AMR.554-556.1650
   He W, 2010, CLIN OBSERVATION ACU, V0, P0
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Huang J, 2012, J KUNMING MED U, V33, P48
   Huang Y, 2012, UTILIZING FUNCTIONAL MAGNETIC RESONANCE IMAGING (FMRI) TO EXPLORE THE CENTRAL MECHANISMS OF ACUPUNCTURE IN TREATING CERVICAL SPONDYLOSIS, V0, P0
   Jiang Yi, 2011, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V31, P1311
   Johnston MF, 2011, EVID-BASED COMPL ALT, V2011, P0
   Kim CK, 2005, J NEUROIMMUNOL, V168, P144, DOI 10.1016/j.jneuroim.2005.07.005
   Konno R, 2012, ACUPUNCTURE MOXIBUST, V0, P121
   Kou W, 2005, BRAIN BEHAV IMMUN, V19, P318, DOI 10.1016/j.bbi.2004.10.001
   Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730
   Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4
   Li SG, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0057604
   Li X, 2010, THESIS BEIJING U CHI, V0, P0
   Lin GH, 2011, GUANGZH CHIN AC ASS, V0, P30
   Lin GH, 2010, INT S AC MER RES REV, V0, P301
   Lin Q, 2011, THESIS GUANGZHOU U T, V0, P0
   刘红英, 2012, 中国中医药信息杂志 CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE, V19, P79
   Lou T, 2012, CHIN J TRADIT MED SC, V6, P516
   Lu Weidong, 2005, SEMIN ONCOL NURS, V21, P190, DOI 10.1016/j.soncn.2005.04.008
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   ORegan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   Ouyang J, 1992, ACUPUNCT RES, V17, P241
   Qiao ZB, 2004, J BEIJING U TCM CLIN, V11, P1
   Sagar SM, 2008, CURR TREAT OPTION ON, V9, P117, DOI 10.1007/s11864-008-0063-3
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Shi LL, 2003, SHANGHAI J ACUPUNCT, V22, P27
   Takahashi T, 2011, NEUROMODULATION, V14, P8, DOI 10.1111/j.1525-1403.2010.00295.x
   Tao YZ, 2012, MOD J INTEGR TRADIT, V21, P2961
   Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174
   Wang T, 2010, THESIS GUANGZHOU U C, V0, P0
   Wells M, 2007, CANCER NURS, V30, P45, DOI 10.1097/00002820-200701000-00008
   [徐天舒 Xu Tianshu], 2011, 南京中医药大学学报 JOURNAL OF NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V27, P418
   Xu YL, 2012, THESIS GUANGZHOU U C, V0, P0
   Xuan LH, 2003, J TRADIT CHIN MED, V38, P223
   Yamaguchi N, 2007, EVID-BASED COMPL ALT, V4, P447, DOI 10.1093/ecam/nel107
   Ye Fang, 2007, J TRADIT CHIN MED, V27, P19
   Yu Y, 1998, J NEUROIMMUNOL, V90, P176, DOI 10.1016/S0165-5728(98)00143-X
   Yu Y, 1997, JPN J PHYSIOL, V47, P173, DOI 10.2170/jjphysiol.47.173
   Zhang QF, 2010, INFLUENCE CSF TNF IL, V0, P0
   [张琼 Zhang Qiong], 2010, 中国全科医学 CHINESE GENERAL PRACTICE, V13, P2397
   Zhang R, 2012, ACUPUNCTURE MOXIBUST, V3, P291
   Zhang ZJ, 2010, J AFFECT DISORDERS, V124, P9, DOI 10.1016/j.jad.2009.07.005
   Zhao X, 2011, J. ACUPUNCT. TUINA SCI., V9, P331, DOI 10.1007/s11726-011-0545-x
   Zhao YJ, 2008, J ACUPUNCT MERIDIAN, V6, P363
   Zhong LLD, 2012, COMPLEMENT THER MED, V20, P240, DOI 10.1016/j.ctim.2012.02.004
   Zhou H, 2003, SHANGHAI J ACUPUNCT, V22, P34
   周珂, 2011, 广东医学 GUANGDONG MEDICAL JOURNAL, V32, P2124
NR 65
TC 43
Z9 53
U1 3
U2 53
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6882
EI 
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD DEC 17
PY 2013
VL 13
IS 
BP 
EP 
DI 10.1186/1472-6882-13-362
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 284XG
UT WOS:000329354800001
PM 24344728
DA 2026-01-16
ER

PT J
AU Bao, T
   Cai, L
   Giles, JT
   Gould, J
   Tarpinian, K
   Betts, K
   Medeiros, M
   Jeter, S
   Tait, N
   Chumsri, S
   Armstrong, DK
   Tan, M
   Folkerd, E
   Dowsett, M
   Singh, H
   Tkaczuk, K
   Stearns, V
AF Bao, Ting
   Cai, Ling
   Giles, Jon T
   Gould, Jeff
   Tarpinian, Karineh
   Betts, Kelly
   Medeiros, Michelle
   Jeter, Stacie
   Tait, Nancy
   Chumsri, Saranya
   Armstrong, Deborah K
   Tan, Ming
   Folkerd, Elizabeth
   Dowsett, Mitch
   Singh, Harvinder
   Tkaczuk, Kate
   Stearns, Vered
TI A dual-center randomized controlled double blind trial assessing the effect of
SO Breast cancer research and treatment
LA English
DT Journal Article
AB Up to 50 % of women receiving aromatase inhibitor (AI) complain of AI-associated  musculoskeletal symptoms (AIMSS) and 15 % discontinue treatment. We conducted a  randomized, sham-controlled trial to evaluate whether acupuncture improves AIMSS  and to explore potential mechanisms. Postmenopausal women with early stage breast  cancer, experiencing AIMSS were randomized to eight weekly real or sham  acupuncture sessions. We evaluated changes in the Health Assessment Questionnaire  Disability Index (HAQ-DI) and pain visual analog scale (VAS) following the  intervention compared to baseline. Serum estradiol, β-endorphin, and  proinflammatory cytokine concentrations were measured pre and post-intervention.  We enrolled 51 women of whom 47 were evaluable, including 23 randomized to real  and 24 to sham acupuncture. Baseline characteristics were balanced between groups  with the exception of a higher HAQ-DI score in the real acupuncture group (p =  0.047). We did not observe a statistically significant difference in reduction of  HAQ-DI (p = 0.30) or VAS (p = 0.31) between the two groups. Following eight  weekly treatments, we observed a statistically significant reduction of IL-17 (p  ≤ 0.009) in both groups. No significant modulation was seen in estradiol,  β-endorphin, or other proinflammatory cytokine concentrations in either group. We  did not observe a significant difference in AIMSS changes between real and sham  acupuncture. As sham acupuncture used in this study may not be equivalent to  placebo, further studies with a non-acupuncture arm may be required to establish  whether acupuncture is beneficial for the treatment of AIMSS.
C1 University of Maryland Greenebaum Cancer Center, Baltimore, MD 20201, USA. tbao@umm.edu
NR 0
TC 0
SN 1573-721
EI 0167-680
J9 Breast Cancer Res Treat
PD FEB 9
PY 2013
VL 138
IS 1
BP 167
EP 74
DI 10.1007/s10549-013-2427-z
PG -93
WC Acupuncture Therapy; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; adverse effects; Aromatase Inhibitors; adverse effects; Breast Neoplasms; blood; Female; Humans; Inflammation Mediators; blood; Middle Aged; Musculoskeletal Pain; chemically induced; Time Factors; Treatment Outcome; beta-Endorphin; blood
UT PubMed:23393007
PM 23393007
DA 2013-02-09
ER

PT J
AU Chen, HY
   Li, SG
   Cho, WC
   Zhang, ZJ
AF Chen, Hai-Yong
   Li, Shi-Guang
   Cho, William Cs
   Zhang, Zhang-Jin
TI The role of acupoint stimulation as an adjunct therapy for lung cancer: a
SO BMC complementary and alternative medicine
LA English
DT Journal Article
AB BACKGROUND: Lung cancer is the leading cause of death in cancer patients.  Clinical studies showed that a variety of acupoint stimulations have been  extensively used for lung cancer patients, including needle insertion, injection  with herbal extraction, plaster application, and moxibustion. However, the role  of acupoint stimulation in lung cancer treatment was not fully reviewed. METHODS:  In the present study, we conducted a systematic review and meta-analysis on the  role of acupoint stimulation in lung cancer treatment by electronic and manual  searching in seven databases, including Ovid (Ovid MEDLINE, AMED, CAB Abstracts,  EMBASE), EBSCOhost research databases (Academic Search premier, MEDLINE, CIHAHL  Plus), PreQuest (British Nursing Index, ProQuest Medical Library, ProQuest  Dissertations & Theses A&I, PsycINFO), and ISI web of knowledge (Web of Science,  BIOSIS Citation Index, Biological Abstracts, Chinese Science Citation Database),  CNKI, Wanfang Data, and CQVIP. RESULTS: Our study showed that acupoint  stimulation has strong immunomodulatory effect for lung cancer patients as  demonstrated by the significant increase of IL-2, T cell subtypes (CD3+ and CD4+,  but not CD8+ cells), and natural killer cells. Further analysis revealed that  acupoint stimulation remarkably alleviates the conventional therapy-induced bone  marrow suppression (hemoglobin, platelet, and WBC reduction) in lung cancer  patients, as well as decreases nausea and vomiting. The pooled studies also  showed that acupoint stimulation can improve Karnofsky performance status,  immediate tumor response, quality of life (EORCT-QLQ-C30), and pain control of  cancer patients. CONCLUSIONS: Acupoint stimulation is found to be effective in  lung cancer treatment, further confirmatory evaluation via large scale randomized  trials is warranted.
C1 School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, G/F, 10 Sassoon Road, Pokfulam, Hong Kong Special AdministrativeRegion, China. williamcscho@gmail.com.
NR 0
TC 0
SN 1472-688
EI 
J9 BMC Complement Altern Med
PD DEC 19
PY 2013
VL 13
IS 
BP 362
EP 362
DI 10.1186/1472-6882-13-362
PG 0
WC Acupuncture Points; Acupuncture Therapy; Antineoplastic Agents; adverse effects; CD3 Complex; blood; CD4 Antigens; blood; Combined Modality Therapy; Humans; Lung Neoplasms; blood; Lymphocyte Count; Nausea; complications; Vomiting; chemically induced
UT PubMed:24344728
PM 24344728
DA 2013-12-19
ER

PT J
AU Windmill, J
   Fisher, E
   Eccleston, C
   Derry, S
   Stannard, C
   Knaggs, R
   Moore, RA
AF Windmill, Jude
   Fisher, Emma
   Eccleston, Christopher
   Derry, Sheena
   Stannard, Cathy
   Knaggs, Roger
   Moore, R. Andrew
TI Interventions for the reduction of prescribed opioid use in chronic non-cancer pain
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID low-back-pain; treatment outcm; extended-release; analgesic medication; older-adults; double-blind; efficacy; rehabilitation; withdrawal; moderate
AB Background Patients with chronic non-cancer pain who are prescribed and are taking opioids can have a history of long term high dose opioid use without effective pain relief. In those without good pain relief, reduction of prescribed opioid dose may be the desired and shared goal of both patient and clinician. Simple unsupervised reduction of opioid use is clinically challenging, and very difficult to achieve and maintain. Objectives To investigate the effectiveness of different methods designed to achieve reduction or cessation of prescribed opioid use for the management of chronic non-cancer pain. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from inception to 8th April 2013, as well as bibliographies. Selection criteria Included studies had to be randomised controlled trials comparing opioid users receiving an intervention with a control group receiving treatment as usual, active control, or placebo. The aim of the study had to include a treatment goal of dose reduction or cessation of opioid medication. Data collection and analysis We sought data relating to prescribed opioid use, adverse events of opioid reduction, pain, and psychological and physical function. Main results Two studies provided information on 86 participants. One compared electroacupuncture with sham acupuncture for 20 minutes twice a week for six weeks; there was no difference between treatments. The other followed 11 weeks of cognitive behavioural therapy with either therapeutic interactive voice response through a computer for four months or usual treatment; the active group had a significant reduction in opioid use, while the usual care group had a significant increase. Authors' conclusions Both included studies were at significant risk of bias because of their small size, together with other important issues, including blinding. Because of this risk and the paucity of relevant studies, no conclusions can be drawn regarding the effectiveness of interventions for opioid withdrawal in chronic non-cancer pain.
C1 [Windmill, Jude; Derry, Sheena; Moore, R. Andrew] Univ Oxford, Oxford OX3 7LE, England.
   [Windmill, Jude; Derry, Sheena; Moore, R. Andrew] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford OX3 7LE, England.
   [Fisher, Emma; Eccleston, Christopher] Univ Bath, Ctr Pain Res, Bath BA2 7AY, Avon, England.
   [Stannard, Cathy] Frenchay Hosp, Macmillan Ctr, Pain Clin, Bristol BS16 1LE, Avon, England.
   [Knaggs, Roger] Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England.
C3 University of Oxford; University of Oxford; University of Bath; University of Nottingham
RP Windmill, J (corresponding author), Univ Oxford, Churchill Hosp, Oxford OX3 7LE, England.
EM jude_windmill@hotmail.com
FU AstraZeneca; Eli Lilly; Flynn Pharma; Furtura Medical; Grunenthal; GSK; Horizon Pharma; Lundbeck; Menarini; MSD; Pfizer; Reckitt Bensckiser; Sanofi Aventis; Urgo; Vifor Pharma
CR Amato L, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005031.pub4
   Unknown -, 2010, OPIOIDS PERSISTENT P, V0, P0
   Unknown -, 2013, PAIN REHABILITATION, V0, P0
   Unknown -, 2019, OP THER GUID ADH REP, V0, P0
   Atluri S, 2012, PAIN PHYSICIAN, V15, P0
   Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Braden JB, 2010, ARCH INTERN MED, V170, P1425, DOI 10.1001/archinternmed.2010.273
   Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008
   Crisostomo RA, 2008, AM J PHYS MED REHAB, V87, P527, DOI 10.1097/PHM.0b013e31817c124f
   Darchuk KM, 2010, PAIN MED, V11, P1352, DOI 10.1111/j.1526-4637.2010.00937.x
   Eccleston C, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007407.pub2
   Franklin GM, 2012, AM J IND MED, V55, P325, DOI 10.1002/ajim.21998
   Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528
   Gallagher AM, 2009, CLIN THER, V31, P1707, DOI 10.1016/j.clinthera.2009.08.022
   Gowing L, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002022.pub3
   Gowing L, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002021.pub3
   Hale ME, 2007, J PAIN, V8, P175, DOI 10.1016/j.jpain.2006.09.011
   Hooten WM, 2007, PAIN MED, V8, P8, DOI 10.1111/j.1526-4637.2007.00253.x
   Hooten WM, 2009, ANESTH ANALG, V108, P308, DOI 10.1213/ane.0b013e31818c7b99
   Information Centre 2012 NHS Information Centre, 2004, REP PRESCR DAT EXTR, V0, P0
   Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019
   Krymchantowski AV, 2003, CEPHALALGIA, V23, P982, DOI 10.1046/j.1468-2982.2003.00648.x
   Leong M, 2009, INTERN MED J, V39, P676, DOI 10.1111/j.1445-5994.2009.01982.x
   Manchikanti L, 2012, PAIN PHYSICIAN, V15, P0
   McDonough M, 2012, AUST PRESCR, V35, P20, DOI 10.18773/austprescr.2012.008
   Miller M, 2011, J AM GERIATR SOC, V59, P430, DOI 10.1111/j.1532-5415.2011.03318.x
   Moore RA, 2012, PAIN, V153, P265, DOI 10.1016/j.pain.2011.10.004
   Moore RA, 2005, ARTHRITIS RES THER, V7, PR1046, DOI 10.1186/ar1782
   Moore RA, 2014, PAIN PRACT, V14, P79, DOI 10.1111/papr.12050
   Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002
   Naylor MR, 2008, PAIN, V134, P335, DOI 10.1016/j.pain.2007.11.001
   Naylor MR, 2010, J PAIN, V11, P1410, DOI 10.1016/j.jpain.2010.03.019
   Noble M, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006605.pub2
   Paulozzi Leonard J, 2011, MORBIDITY AND MORTALITY WEEKLY REPORT, V60, P60
   Potter JS, 2010, J SUBST ABUSE TREAT, V38, PS80, DOI 10.1016/j.jsat.2009.12.007
   Roland CL, 2011, POSTGRAD MED, V123, P148, DOI 10.3810/pgm.2011.07.2314
   Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391
   Stannard C, 2012, BRIT J PAIN, V6, P7, DOI 10.1177/2049463712439131
   Steiner DJ, 2011, J PAIN SYMPTOM MANAG, V42, P903, DOI 10.1016/j.jpainsymman.2011.04.006
   Sullivan MD, 2010, PAIN, V150, P332, DOI 10.1016/j.pain.2010.05.020
   Townsend CO, 2008, PAIN, V140, P177, DOI 10.1016/j.pain.2008.08.005
   Weinstein SM, 2006, CLIN THER, V28, P86, DOI 10.1016/j.clinthera.2006.01.010
   Zheng Z, 2008, EUR J PAIN, V12, P671, DOI 10.1016/j.ejpain.2007.10.003
NR 45
TC 34
Z9 39
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2013
VL 0
IS 9
BP 
EP 
DI 10.1002/14651858.CD010323.pub2
PG 23
WC Medicine, General & Internal
SC General & Internal Medicine
GA 227QZ
UT WOS:000325129900027
PM 23996347
DA 2026-01-16
ER

PT J
AU Binmoeller, KF
   Shah, JN
   Bhat, YM
   Kane, SD
AF Binmoeller, Kenneth F
   Shah, Janak N
   Bhat, Yasser M
   Kane, Steve D
TI Suck-ligate-unroof-biopsy by using a detachable 20-mm loop for the diagnosis and
SO Gastrointestinal endoscopy
LA English
DT Journal Article
AB BACKGROUND: The diagnosis and therapy of subepithelial tumors (SETs) can be  challenging. OBJECTIVE: Proof-of-concept evaluation of the  suck-ligate-unroof-biopsy (SLUB) technique for small (<2 cm), non-pedunculated  SETs. DESIGN: Pilot feasibility study. SETTING: Tertiary-care referral center.  PATIENTS: Twenty-three patients (median age 60 years) meeting the inclusion  criteria after preliminary EUS. INTERVENTION: SET ligation was performed with a  detachable 20-mm loop deployed through an 18-mm diameter, soft, oblique,  transparent, cap attachment. The SLUB technique comprised (1) suction to draw the  SET into the cap; (2) ligation below the SET, confirmation by repeat EUS; (3)  unroofing of the overlying mucosa with a needle-knife; and (4) biopsy specimens  taken from the exposed tumor. MAIN OUTCOME MEASUREMENTS: Technical success,  histology and/or immunohistochemistry yield, adverse events, completeness of  resection. RESULTS: SLUB was attempted on 24 SETs and was technically successful  in all. Location was the stomach (n = 19), small bowel (n = 1), colon (n = 2),  and rectum (n = 2). Median size by EUS was 10 mm (range 6-15 mm). Biopsy  specimens provided an immunohistologic diagnosis in all cases: GI stromal tumor  (n = 5), leiomyoma (n = 8), carcinoid tumor (n = 5), Vanek's tumor (n = 2),  granuloma (n =1), and pancreatic heterotopia (n = 3). Follow-up endoscopy and EUS  in 13 patients showed well-healed scars with no residual tumor, including all 9  patients with premalignant neoplastic lesions. The only adverse event was  self-limited pain in 2 patients. LIMITATIONS: Single center, single operator,  small sample size. CONCLUSIONS: Loop ligation of small, non-pedunculated SETs is  feasible by using a cap attachment for suction. Unroofing after ligation is safe  and provides sufficient tissue for immunohistochemistry. Ligation combined with  unroofing appears to lead to complete ablation by ischemia and tumor enucleation.
C1 Paul May & Frank Stein Interventional Endoscopy Center, California Pacific Medical Center, San Francisco, California, USA.
   Paul May & Frank Stein Interventional Endoscopy Center, California Pacific Medical Center, San Francisco, California, USA.
   Paul May & Frank Stein Interventional Endoscopy Center, California Pacific Medical Center, San Francisco, California, USA.
   Paul May & Frank Stein Interventional Endoscopy Center, California Pacific Medical Center, San Francisco, California, USA.
NR 0
TC 0
SN 1097-677
EI 
J9 Gastrointest Endosc
PD NOV 19
PY 2013
VL 79
IS 5
BP 750
EP 5
DI 10.1016/j.gie.2013.09.028
PG -745
WC Biopsy; instrumentation; Carcinoid Tumor; diagnostic imaging; Choristoma; diagnostic imaging; Endoscopy, Gastrointestinal; instrumentation; Endosonography; Feasibility Studies; Female; Gastrointestinal Neoplasms; pathology; Gastrointestinal Stromal Tumors; diagnostic imaging; Granuloma; diagnostic imaging; Humans; Leiomyoma; diagnostic imaging; Ligation; Male; Middle Aged; Pancreas; Pilot Projects; Retrospective Studies; Second-Look Surgery; Suction
UT PubMed:24238309
PM 24238309
DA 2013-11-19
ER

PT J
AU Yoon, SY
   Yeo, JH
   Han, SD
   Bong, DJ
   Oh, B
   Roh, DH
AF Yoon, Seo-Yeon
   Yeo, Ji-Hee
   Han, Seung-Dae
   Bong, Dong-Jun
   Oh, Beomsoo
   Roh, Dae-Hyun
TI Diluted Bee Venom Injection Reduces Ipsilateral Mechanical Allodynia in Oxaliplatin-Induced Neuropathic Mice
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE bee venom; oxaliplatin; mechanical allodynia; alpha-2 adrenoceptor
ID acupoint stimulation; formalin test; peripheral neuropathy; acupuncture point; colorectal-cancer; pain model; apipuncture; activation; hyperalgesia; involvement
AB Oxaliplatin, which is used as one of anti-cancer drugs, commonly induces peripheral neuropathic pain. We have previously reported that an injection of diluted bee venom (DBV) produced a significant anti-nociceptive effects in several pain models of mice or rats. In this study, we evaluated time- and dose-dependent development of oxaliplatin-induced mechanical allodynia in bilateral hind paws of mice, and investigated the effect of DBV injection on this mechanical allodynia. DBV (0.1 mg/kg) was subcutaneously injected into the Zusanli acupoint 2 weeks after oxaliplatin (10 mg/kg) injection. One hour after DBV injection, we observed a significant reduction of mechanical allodynia in the ipsilateral hind paw, but not in the contralateral hind paw to DBV injection site. We subsequently examined whether this effect of DBV was related to the activation of peripheral nerves in DBV injected site, and then whether it was mediated by the activation of spinal cord alpha-2 adrenoceptors or opioid receptors. Subcutaneous pre-injection of 2% lidocaine (40 mg/kg) into the Zusanli acupoint completely blocked the anti-allodynic effect of DBV. Intrathecal pretreatment with yohimbine (25 mu g/mouse), an alpha-2 adrenoceptor antagonist, also prevented the anti-allodynic effect of DBV, whereas pretreatment with naloxone (20 mu g/mouse), an opioid receptor antagonist, did not block the effect of DBV. Taken together, these findings demonstrate that DBV injection into the Zusanli acupoint significantly reduces ipsilateral mechanical allodynia generated by oxaliplatin in mice, and also suggest that this anti-allodynic effect is dependent on the peripheral nerve activation in injected site and spinal cord alpha-2 adrenoceptors.
C1 [Yoon, Seo-Yeon] Korea Inst Sci & Technol, Ctr Neural Sci, Lab Mol Signal Transduct, Seoul 136791, South Korea.
   [Yeo, Ji-Hee; Han, Seung-Dae; Bong, Dong-Jun; Oh, Beomsoo; Roh, Dae-Hyun] Kyung Hee Univ, Sch Dent, Dept Maxillofacial Tissue Regenerat, Seoul 130701, South Korea.
   [Yeo, Ji-Hee; Han, Seung-Dae; Bong, Dong-Jun; Oh, Beomsoo; Roh, Dae-Hyun] Kyung Hee Univ, Sch Dent, Res Ctr Tooth & Periodontal Tissue Regenerat, Seoul 130701, South Korea.
C3 Korea Institute of Science & Technology (KIST); Kyung Hee University; Kyung Hee University
RP Roh, DH (corresponding author), Kyung Hee Univ, Sch Dent, Dept Maxillofacial Tissue Regenerat, Seoul 130701, South Korea.
EM dbroh@khu.ac.kr
FU Kyung Hee University [KHU-20120484]
CR Argyriou AA, 2008, CANCER TREAT REV, V34, P368, DOI 10.1016/j.ctrv.2008.01.003
   Attal N, 2009, PAIN, V144, P245, DOI 10.1016/j.pain.2009.03.024
   Binder A, 2007, EUR J CANCER, V43, P2658, DOI 10.1016/j.ejca.2007.07.030
   Chao Hui-Lin, 2013, ONCOL NURS FORUM, V40, PE61, DOI 10.1188/13.ONF.E61-E68
   Farquhar-Smith Paul, 2011, CURR OPIN SUPPORT PALLIAT CARE, V5, P1, DOI 10.1097/SPC.0b013e328342f9cc
   Fu S, 2006, INT J GYNECOL CANCER, V16, P1717, DOI 10.1111/j.1525-1438.2006.00654.x
   Gao YH, 2013, NEUROCHEM RES, V38, P1467, DOI 10.1007/s11064-013-1047-7
   Gokin AP, 2001, ANESTHESIOLOGY, V95, P1441, DOI 10.1097/00000542-200112000-00025
   Grothey A, 2010, ONCOLOGY-BASEL, V79, P389, DOI 10.1159/000323491
   Kaley TJ, 2009, BRIT J HAEMATOL, V145, P3, DOI 10.1111/j.1365-2141.2008.07558.x
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Kang SY, 2011, BRAIN RES BULL, V86, P412, DOI 10.1016/j.brainresbull.2011.08.012
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kroin JS, 2010, REGION ANESTH PAIN M, V35, P343, DOI 10.1097/AAP.0b013e3181e82df0
   Kwon YB, 2004, MOL CELLS, V17, P329
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Kwon YB, 2006, NEUROSCI RES, V55, P197, DOI 10.1016/j.neures.2006.03.003
   Lee JH, 2001, J VET MED SCI, V63, P251, DOI 10.1292/jvms.63.251
   Paice Judith A, 2009, SEMIN ONCOL NURS, V25, PS8, DOI 10.1016/j.soncn.2009.03.013
   Raez LE, 2010, CLIN LUNG CANCER, V11, P18, DOI 10.3816/CLC.2010.n.003
   Roh DH, 2006, J PAIN, V7, P500, DOI 10.1016/j.jpain.2006.02.002
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   SOMERFIELD SD, 1988, J RHEUMATOL, V15, P1878
   Stein A, 2012, EXPERT OPIN PHARMACO, V13, P125, DOI 10.1517/14656566.2012.643870
   Tofthagen C, 2011, CLIN J ONCOL NURS, V15, P182, DOI 10.1188/11.CJON.182-188
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Yajiri Y, 1997, NEUROSCIENCE, V76, P673, DOI 10.1016/S0306-4522(96)00291-6
   Yoon SY, 2012, NEUROSCIENCE, V221, P214, DOI 10.1016/j.neuroscience.2012.06.024
   Yoon SY, 2008, NEUROSCI LETT, V430, P163, DOI 10.1016/j.neulet.2007.10.035
   Yoon SY, 2013, J PAIN, V14, P205, DOI 10.1016/j.jpain.2012.11.002
   Yoon SY, 2009, J PAIN, V10, P253, DOI 10.1016/j.jpain.2008.09.002
NR 32
TC 17
Z9 20
U1 1
U2 12
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
EI 
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD NOV 15
PY 2013
VL 36
IS 11
BP 1787
EP 1793
DI 
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 244AQ
UT WOS:000326359900022
PM 23985901
DA 2026-01-16
ER

PT J
AU Rostock, M
   Jaroslawski, K
   Guethlin, C
   Ludtke, R
   Schröder, S
   Bartsch, HH
AF Rostock, M.
   Jaroslawski, K.
   Guethlin, C.
   Ludtke, R.
   Schroeder, S.
   Bartsch, H. H.
TI Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID clinical-trials; acupuncture; pain; prevention; management
AB Purpose. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting side effect of cytostatic drugs. Since there are no proven therapeutic procedures against CIPN, we were interested to define the role of electroacupuncture (EA) from which preliminary data showed promising results. Methods. In a randomized trial with a group sequential adaptive design in patients with CIPN, we compared EA (LV3, SP9, GB41, GB34, LI4, LI11, SI3, and HT3; n = 14) with hydroelectric baths (HB, n = 14), vitamin B1/B6 capsules (300/300mg daily; VitB, n = 15), and placebo capsules (n = 17). The statistical power in this trial was primarily calculated for proving EA only, so results of HB and VitB are pilot data. Results. CIPN complaints improved by 0.8 +/- 1.2 (EA), 1.7+ 1.7 (HB), 1.6+ 2.0 (VitB), and 1.3+ 1.3 points (placebo) on a 10-point numeric rating scale without significant difference between treatment groups or placebo. In addition no significant differences in sensory nerve conduction studies or quality of life (EORTC QLQ-C30) were found. Conclusions. The used EA concept, HB, and VitB were not superior to placebo. Since, contrary to our results, studies with different acupuncture concepts showed a positive effect on CIPN, the effect of acupuncture on CIPN remains unclear. Further randomized, placebo controlled studies seem necessary. This trial is registered with DRKS00004448.
C1 [Rostock, M.; Jaroslawski, K.; Bartsch, H. H.] Univ Freiburg, Tumor Biol Ctr, D-79106 Freiburg, Germany.
   [Rostock, M.] Univ Zurich Hosp, Inst Complementary Med, CH-8006 Zurich, Switzerland.
   [Rostock, M.] Univ Canc Ctr Hamburg, Hubertus Wald Tumor Ctr, D-20246 Hamburg, Germany.
   [Jaroslawski, K.; Guethlin, C.] Univ Med Ctr Freiburg, D-79106 Freiburg, Germany.
   [Guethlin, C.] Goethe Univ Frankfurt, Inst Gen Practice, D-60590 Frankfurt, Germany.
   [Ludtke, R.] Carstens Fdn Essen, D-45276 Essen, Germany.
   [Schroeder, S.] Univ Med Ctr Hamburg Eppendorf, Hanse Merkur Ctr Tradit Chinese Med, D-20246 Hamburg, Germany.
C3 University of Freiburg; University of Zurich; University Zurich Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg; Goethe University Frankfurt; University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Rostock, M (corresponding author), Univ Freiburg, Tumor Biol Ctr, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM m.rostock@uke.de
FU Fordergesellschaft Forschung Tumorbiologie, Freiburg, Germany; Karl and Veronica Carstens Foundation, Essen, Germany
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Ahn Andrew C, 2007, ACUPUNCT MED, V25, P11
   Albers J, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005228.pub2
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Ang CD, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004573.pub3
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   BAUER P, 1994, BIOMETRICS, V50, P1029, DOI 10.2307/2533441
   Brunelli B, 2004, J NEUROL SCI, V218, P59, DOI 10.1016/j.jns.2003.10.013
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dwan K, 2008, PLOS ONE, V3, P0, DOI 10.1371/journal.pone.0003081
   Galantino MLA, 1999, J ALTERN COMPLEM MED, V5, P135, DOI 10.1089/acm.1999.5.135
   Grober J, 1963, KLIN LEHRBUCH PHYS T, V0, P0
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Hui Kathleen K S, 2007, BMC COMPLEMENT ALTERN MED, V7, P33, DOI 10.1186/1472-6882-7-33
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Littner Y, 2005, ARCH PEDIAT ADOL MED, V159, P1036, DOI 10.1001/archpedi.159.11.1036
   Maurer W, 1995, BIOMETRIE CHEM PHARM, V6, P2
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   *NCI, 1999, CANC THER EV PROGR C, V0, P0
   Ocean AJ, 2004, SUPPORT CARE CANCER, V12, P619, DOI 10.1007/s00520-004-0657-7
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Phillips KD, 2004, J ALTERN COMPLEM MED, V10, P449, DOI 10.1089/1075553041323678
   Postma TJ, 2000, ANN ONCOL, V11, P509, DOI 10.1023/A:1008345613594
   Raffe MR, 1985, TEXTBOOK OF SMALL ANIMAL ORTHOPAEDICS, V0, P0
   Schroder S, 2008, JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE, V6, P312
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   STUX G, 1999, AKUPUNKTUR LEHRBUCH, V0, P0
   Unnebrink K, 2001, STAT MED, V20, P3931, DOI 10.1002/sim.1149
   Visovsky Constance, 2007, CLIN J ONCOL NURS, V11, P901
   Wang YF, 2005, CHINESE J ORG CHEM, V25, P8
   Weis J, 2006, RES REHABILITATION R, V0, P162
   Wickham Rita, 2007, CLIN J ONCOL NURS, V11, P361, DOI 10.1188/07.CJON.361-376
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
NR 39
TC 65
Z9 73
U1 1
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2013
VL 2013
IS 
BP 
EP 
DI 10.1155/2013/349653
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 215AH
UT WOS:000324181000001
PM 24066010
DA 2026-01-16
ER

PT J
AU Cassileth, BR
   Van Zee, KJ
   Yeung, KS
   Coleton, MI
   Cohen, S
   Chan, YH
   Vickers, AJ
   Sjoberg, DD
   Hudis, CA
AF Cassileth, Barrie R.
   Van Zee, Kimberly J.
   Yeung, K. Simon
   Coleton, Marci I.
   Cohen, Sara
   Chan, Yi H.
   Vickers, Andrew J.
   Sjoberg, Daniel D.
   Hudis, Clifford A.
TI Acupuncture in the treatment of upper-limb lymphedema Results of a Pilot Study
SO CANCER
LA English
DT Article
DE axillary lymphadenectomy; acupuncture; lymphedema intervention; breast carcinoma; manual lymph drainage; complex decongestive therapy
ID quality-of-life; breast-cancer patients; controlled-trials; arm lymphedema; survivors; women; multicenter; reliability; management; pain
AB BACKGROUND Current treatments for lymphedema after breast cancer treatment are expensive and require ongoing intervention. Clinical experience and our preliminary published results suggest that acupuncture is safe and potentially useful. This study evaluates the safety and potential efficacy of acupuncture on upper-limb circumference in women with lymphedema. METHODS Women with a clinical diagnosis of breast cancer-related lymphedema (BCRL) for 0.5-5 years and with affected arm circumference 2 cm larger than unaffected arm received acupuncture treatment twice weekly for 4 weeks. Affected and unaffected arm circumferences were measured before and after each acupuncture treatment. Response, defined as 30% reduction in circumference difference between affected/unaffected arms, was assessed. Monthly follow-up calls for 6 months thereafter were made to document any complications and self-reported lymphedema status. RESULTS Among 37 enrolled patients, 33 were evaluated; 4 discontinued due to time constraints. Mean reduction in arm circumference difference was 0.90 cm (95% CI, 0.72-1.07; P<.0005). Eleven patients (33%) exhibited a reduction of 30% after acupuncture treatment. Seventy-six percent of patients received all treatments; 21% missed 1 treatment, and another patient missed 2 treatments. During the treatment period, 14 of the 33 patients reported minor complaints, including mild local bruising or pain/tingling. There were no serious adverse events and no infections or severe exacerbations after 255 treatment sessions and 6 months of follow-up interviews. CONCLUSIONS Acupuncture for BCRL appears safe and may reduce arm circumference. Although these results await confirmation in a randomized trial, acupuncture can be considered for women with no other options for sustained arm circumference reduction. Cancer 2013;119:2455-2461. (c) 2013 American Cancer Society.
C1 [Cassileth, Barrie R.; Yeung, K. Simon; Coleton, Marci I.; Chan, Yi H.; Vickers, Andrew J.; Sjoberg, Daniel D.] Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA.
   [Van Zee, Kimberly J.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA.
   [Cohen, Sara; Hudis, Clifford A.] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA.
   [Sjoberg, Daniel D.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Cassileth, BR (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med Serv, 1429 1st Ave, New York, NY 10021 USA.
EM Cassileth@mskcc.org
FU Laurance S. Rockefeller Fund; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Ahmed RL, 2008, J CLIN ONCOL, V26, P5689, DOI 10.1200/JCO.2008.16.4731
   Alem M, 2008, ACUPUNCT MED, V26, P86, DOI 10.1136/aim.26.2.86
   Beaulac SM, 2002, ARCH SURG-CHICAGO, V137, P1253, DOI 10.1001/archsurg.137.11.1253
   Bland KL, 2003, AM J SURG, V186, P509, DOI 10.1016/j.amjsurg.2003.07.003
   BRADY MS, 1994, ANN SURG ONCOL, V1, P66, DOI 10.1007/BF02303543
   Cassileth BR, 2011, ACUPUNCT MED, V29, P170, DOI 10.1136/aim.2011.004069
   Chao J, 2009, COCHRANE DATABASE SY, V0, P0, DOI DOI 10.1016/j.bcp.2017.06.123
   Chen YW, 2008, AM J PHYS MED REHAB, V87, P33, DOI 10.1097/PHM.0b013e31815b6199
   Cormier JN, 2010, CANCER-AM CANCER SOC, V116, P5138, DOI 10.1002/cncr.25458
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   de Godoy JMP, 2002, LYMPHOLOGY, V35, P72
   Deltombe T, 2007, LYMPHOLOGY, V40, P26
   Franks PJ, 2006, WOUND REPAIR REGEN, V14, P110, DOI 10.1111/j.1743-6109.2006.00099.x
   Ganz PA, 1999, NEW ENGL J MED, V340, P383, DOI 10.1056/NEJM199902043400511
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Harris SR, 2001, CAN MED ASSOC J, V164, P191
   Hayes SC, 2012, CANCER-AM CANCER SOC, V118, P2237, DOI 10.1002/cncr.27467
   He JP, 1999, CLINICAL AND EXPERIMENTAL OBSTETRICS AND GYNECOLOGY, V26, P81
   Kanakura Y, 2002, AM J CHINESE MED, V30, P37, DOI 10.1142/S0192415X02000041
   Kim KH, 2010, MENOPAUSE, V17, P269, DOI 10.1097/gme.0b013e3181bfac3b
   Lee MS, 2011, CHIN J INTEGR MED, V17, P187, DOI 10.1007/s11655-011-0665-7
   Lee Sang-Hun, 2011, CURR UROL REP, V12, P288, DOI 10.1007/s11934-011-0186-0
   Lu WD, 2010, INTEGR CANCER THER, V9, P284, DOI 10.1177/1534735410378856
   McLaughlin SA, 2008, J CLIN ONCOL, V26, P5213, DOI 10.1200/JCO.2008.16.3725
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Mercado-Poe C, 2008, SOC INT ONC 5 INT C, V0, P0
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   National Cancer Institute, 2012, LYMPH PDQ DIAGN EV, V0, P0
   Paskett ED, 2007, CANCER EPIDEM BIOMAR, V16, P775, DOI 10.1158/1055-9965.EPI-06-0168
   Petrek JA, 2001, CANCER, V92, P1368, DOI 10.1002/1097-0142(20010915)92:6<1368::AID-CNCR1459>3.0.CO;2-9
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Poage E, 2008, CLIN J ONCOL NURS, V12, P951, DOI 10.1188/08.CJON.951-964
   Pyszel A, 2006, LYMPHOLOGY, V39, P185
   Sagen Å, 2009, ACTA ONCOL, V48, P1111, DOI 10.3109/02841860903061691
   Selfe TK, 2008, FAM COMMUNITY HEALTH, V31, P247, DOI 10.1097/01.FCH.0000324482.78577.0f
   Shah C, 2011, INT J RADIAT ONCOL, V81, P907, DOI 10.1016/j.ijrobp.2011.05.043
   Shiflett SC, 2011, BJOG-INT J OBSTET GY, V118, P100, DOI 10.1111/j.1471-0528.2010.02758.x
   Shih YCT, 2009, J CLIN ONCOL, V27, P2007, DOI 10.1200/JCO.2008.18.3517
   Taylor R, 2006, PHYS THER, V86, P205, DOI 10.1093/ptj/86.2.205
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang SM, 2008, ANESTH ANALG, V107, P811, DOI 10.1213/ane.0b013e3181804441
   Wang SM, 2007, J ALTERN COMPLEM MED, V13, P241, DOI 10.1089/acm.2006.6262
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
NR 49
TC 52
Z9 59
U1 0
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUL 1
PY 2013
VL 119
IS 13
BP 2455
EP 2461
DI 10.1002/cncr.28093
PG 7
WC Oncology
SC Oncology
GA 165FT
UT WOS:000320469400016
PM 23576267
DA 2026-01-16
ER

PT J
AU Lee, DG
   Lee, SH
   Hwang, SW
   Kim, ES
   Eoh, W
AF Lee, Dong-Geun
   Lee, Sun-Ho
   Hwang, Sang-Won
   Kim, Eun-Sang
   Eoh, Whan
TI Myositis ossificans in the paraspinal muscles of the neck after acupuncture: a
SO The spine journal : official journal of the North American Spine Society
LA English
DT Journal Article
DE Acupuncture; Cervical spine; Myositis ossificans
AB BACKGROUND CONTEXT: Although traumatic myositis ossificans (MO) has been reported  occasionally, MO of paraspinal muscles has been rarely seen in the cervical spine  after minor injury. This is difficult to distinguish from benign and malignant  soft lesions in cases of a lack of definite trauma history. PURPOSE: We report a  case of MO in the cervical paraspinal muscle after acupuncture and describe  methods for diagnosis and proper treatment, including classification, etiology,  and radiologic and histologic features. STUDY DESIGN: Case report. METHODS: A  26-year-old woman complained of posterior neck pain that had began 2 months  earlier and neck swelling after acupuncture. No abnormal finding existed on the  X-ray except soft tissue swelling. Magnetic resonance imaging was evaluated  because of constant neck pain. To obtain more accurate assessment, computed  tomography-guided biopsy was performed and a diagnosis of MO was made. RESULTS:  The patient was conservatively treated through rest and analgesics. Posterior  neck pain and swelling improved for a several months. The hyperdensity was  comparable with the bony density, and the size of the calcified lesion on X-ray  diminished until the last follow-up. CONCLUSIONS: Myositis ossificans that can  occur after acupuncture should be recognized as a possible cause of persistent  neck pain and swelling despite no definite trauma after thorough evaluation of  the neoplasm and infection.
C1 Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Gangnam-gu, Seoul, 135-710, Republic of Korea.
NR 0
TC 0
SN 1878-163
EI 
J9 Spine J
PD MAR 26
PY 2013
VL 13
IS 7
BP e9
EP e12
DI 10.1016/j.spinee.2013.02.012
PG 1
WC Acupuncture Therapy; adverse effects; Adult; Female; Humans; Myositis Ossificans; diagnosis; Neck Muscles; diagnostic imaging; Neck Pain; diagnostic imaging; Paraspinal Muscles; diagnostic imaging; Radiography
UT PubMed:23523436
PM 23523436
DA 2013-03-26
ER

PT J
AU Smeester, BA
   Al-Gizawiy, M
   O'Brien, EE
   Ericson, ME
   Triemstra, JL
   Beitz, AJ
AF Smeester, Branden A
   Al-Gizawiy, Mona
   O'Brien, Elaine E
   Ericson, Marna E
   Triemstra, Jennifer L
   Beitz, Alvin J
TI The effect of electroacupuncture on osteosarcoma tumor growth and metastasis:
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB Osteosarcoma is the most common malignant bone tumor found in children and  adolescents and is associated with many complications including cancer pain and  metastasis. While cancer patients often seek complementary and alternative  medicine (CAM) approaches to treat cancer pain and fatigue or the side effects of  chemotherapy and treatment, there is little known about the effect of acupuncture  treatment on tumor growth and metastasis. Here we evaluate the effects of six  different electroacupuncture (EA) regimens on osteosarcoma tumor growth and  metastasis in both male and female mice. The most significant positive effects  were observed when EA was applied to the ST-36 acupoint twice weekly (EA-2X/3)  beginning at postimplantation day 3 (PID 3). Twice weekly treatment produced  robust reductions in tumor growth. Conversely, when EA was applied twice weekly  (EA-2X/7), starting at PID 7, there was a significant increase in tumor growth.  We further demonstrate that EA-2X/3 treatment elicits significant reductions in  tumor lymphatics, vasculature, and innervation. Lastly, EA-2X/3 treatment  produced a marked reduction in pulmonary metastasis, thus providing evidence for  EA's potential antimetastatic capabilities. Collectively, EA-2X/3 treatment was  found to reduce both bone tumor growth and lung metastasis, which may be mediated  in part through reductions in tumor-associated vasculature, lymphatics, and  innervation.
C1 Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD NOV 15
PY 2013
VL 2013
IS 
BP 387169
EP 387169
DI 10.1155/2013/387169
PG 0
UT PubMed:24228059
PM 24228059
DA 2013-11-15
ER

PT J
AU Cassileth, BR
   Van, Zee KJ
   Yeung, KS
   Coleton, MI
   Cohen, S
   Chan, YH
   Vickers, AJ
   Sjoberg, DD
   Hudis, CA
AF Cassileth, Barrie R
   Van Zee, Kimberly J
   Yeung, K Simon
   Coleton, Marci I
   Cohen, Sara
   Chan, Yi H
   Vickers, Andrew J
   Sjoberg, Daniel D
   Hudis, Clifford A
TI Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study.
SO Cancer
LA English
DT Journal Article
AB BACKGROUND: Current treatments for lymphedema after breast cancer treatment are  expensive and require ongoing intervention. Clinical experience and our  preliminary published results suggest that acupuncture is safe and potentially  useful. This study evaluates the safety and potential efficacy of acupuncture on  upper-limb circumference in women with lymphedema. METHODS: Women with a clinical  diagnosis of breast cancer-related lymphedema (BCRL) for 0.5-5 years and with  affected arm circumference ≥2 cm larger than unaffected arm received acupuncture  treatment twice weekly for 4 weeks. Affected and unaffected arm circumferences  were measured before and after each acupuncture treatment. Response, defined as  ≥30% reduction in circumference difference between affected/unaffected arms, was  assessed. Monthly follow-up calls for 6 months thereafter were made to document  any complications and self-reported lymphedema status. RESULTS: Among 37 enrolled  patients, 33 were evaluated; 4 discontinued due to time constraints. Mean  reduction in arm circumference difference was 0.90 cm (95% CI, 0.72-1.07; P <  .0005). Eleven patients (33%) exhibited a reduction of ≥30% after acupuncture  treatment. Seventy-six percent of patients received all treatments; 21% missed 1  treatment, and another patient missed 2 treatments. During the treatment period,  14 of the 33 patients reported minor complaints, including mild local bruising or  pain/tingling. There were no serious adverse events and no infections or severe  exacerbations after 255 treatment sessions and 6 months of follow-up interviews.  CONCLUSIONS: Acupuncture for BCRL appears safe and may reduce arm circumference.  Although these results await confirmation in a randomized trial, acupuncture can  be considered for women with no other options for sustained arm circumference  reduction.
C1 Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. Cassileth@mskcc.org
NR 0
TC 0
SN 1097-014
EI 0008-543
J9 Cancer
PD APR 12
PY 2013
VL 119
IS 13
BP 2455
EP 61
DI 10.1002/cncr.28093
PG -2394
WC Acupuncture Therapy; adverse effects; Adult; Aged; Breast Neoplasms; therapy; Female; Follow-Up Studies; Humans; Lymphedema; etiology; Middle Aged; Patient Safety; Pilot Projects; Research Design; Surveys and Questionnaires; Treatment Outcome; Upper Extremity
UT PubMed:23576267
PM 23576267
DA 2013-04-12
ER

PT J
AU Windmill, J
   Fisher, E
   Eccleston, C
   Derry, S
   Stannard, C
   Knaggs, R
   Moore, RA
AF Windmill, Jude
   Fisher, Emma
   Eccleston, Christopher
   Derry, Sheena
   Stannard, Cathy
   Knaggs, Roger
   Moore, R Andrew
TI Interventions for the reduction of prescribed opioid use in chronic non-cancer
SO The Cochrane database of systematic reviews
LA English
DT Journal Article
AB BACKGROUND: Patients with chronic non-cancer pain who are prescribed and are  taking opioids can have a history of long term high dose opioid use without  effective pain relief. In those without good pain relief, reduction of prescribed  opioid dose may be the desired and shared goal of both patient and clinician.  Simple unsupervised reduction of opioid use is clinically challenging, and very  difficult to achieve and maintain. OBJECTIVES: To investigate the effectiveness  of different methods designed to achieve reduction or cessation of prescribed  opioid use for the management of chronic non-cancer pain. SEARCH METHODS: We  searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE,  and EMBASE from inception to 8th April 2013, as well as bibliographies. SELECTION  CRITERIA: Included studies had to be randomised controlled trials comparing  opioid users receiving an intervention with a control group receiving treatment  as usual, active control, or placebo. The aim of the study had to include a  treatment goal of dose reduction or cessation of opioid medication. DATA  COLLECTION AND ANALYSIS: We sought data relating to prescribed opioid use,  adverse events of opioid reduction, pain, and psychological and physical  function. MAIN RESULTS: Two studies provided information on 86 participants. One  compared electroacupuncture with sham acupuncture for 20 minutes twice a week for  six weeks; there was no difference between treatments. The other followed 11  weeks of cognitive behavioural therapy with either therapeutic interactive voice  response through a computer for four months or usual treatment; the active group  had a significant reduction in opioid use, while the usual care group had a  significant increase. AUTHORS' CONCLUSIONS: Both included studies were at  significant risk of bias because of their small size, together with other  important issues, including blinding. Because of this risk and the paucity of  relevant studies, no conclusions can be drawn regarding the effectiveness of  interventions for opioid withdrawal in chronic non-cancer pain.
C1 Pain Research and Nuffield Department of Clinical Neurosciences, University of Oxford, Churchill Hospital, Oxford, UK, OX3 7LE.
NR 0
TC 0
SN 1469-493
EI 
J9 Cochrane Database Syst Rev
PD SEP 3
PY 2013
VL 0
IS 9
BP CD010323
EP CD010323
DI 10.1002/14651858.CD010323.pub2
PG 1
WC Analgesics, Opioid; administration & dosage; Chronic Pain; drug therapy; Cognitive Behavioral Therapy; methods; Drug Tolerance; Electroacupuncture; methods; Humans; Observational Studies as Topic; Randomized Controlled Trials as Topic; Therapy, Computer-Assisted; methods
UT PubMed:23996347
PM 23996347
DA 2013-09-03
ER

PT J
AU Kasymjanova, G
   Grossman, M
   Tran, T
   Jagoe, RT
   Cohen, V
   Pepe, C
   Small, D
   Agulnik, J
AF Kasymjanova, G.
   Grossman, M.
   Tran, T.
   Jagoe, R. T.
   Cohen, V.
   Pepe, C.
   Small, D.
   Agulnik, J.
TI The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study
SO CURRENT ONCOLOGY
LA English
DT Article
DE Acupuncture; lung cancer; Edmonton Symptom Assessment System; ESAS; pain; integrative oncology clinics; narcotics
ID quality-of-life; visual analog scale; pain; chemotherapy; prevalence; depression; management; distress; medicine; fatigue
AB Background Most lung cancer patients experience multiple symptoms related either to the disease or its treatment. The commonly reported symptoms are pain, depression, anxiety, nausea, and poor well-being. The aim of the present study was to evaluate the effect of acupuncture as a potential treatment modality in symptomatic lung cancer patients. Methods This prospective observational study enrolled 33 lung cancer patients from the Peter Brojde Lung Cancer Centre between August 2010 and May 2012. All patients received 45-minute sessions of acupuncture, 1-2 times weekly for a minimum of 4 sessions. Symptom severity was assessed using the Edmonton Symptom Assessment System (esas) before and after completion of acupuncture. Results The study cohort included 30 patients with non-small- cell lung cancer and 3 with small-cell lung cancer. Mean age was 62 years (range: 36-88 years); 17 of the patients were women. Most of the patients had advanced-stage cancer (73%) and good performance status (Eastern Cooperative Oncology Group 0-1: 88%). Of these patients, 67% received anticancer treatment (chemotherapy or radiotherapy, or both) with acupuncture. Of the remaining 10 patients, 8 received acupuncture after a complete surgical resection of their tumour, and because of their advanced age, 2 received acupuncture and best supportive care. The median number of acupuncture sessions was 7 (interquartile range: 4-13 sessions). Statistically significant improvements in pain, appetite, nausea, nervousness, and well-being were observed. A clinically important improvement (2 points on the esas) was reported by 61% of patients for pain and by 33% for well-being. A significant positive correlation between improved well-being and the number of acupuncture sessions was observed. This correlation remained significant even after controlling for treatment and narcotic use. Receiver operating characteristic analysis demonstrated that a minimum of 6 acupuncture sessions are required for a 70% chance of a clinically important improvement in well-being. Conclusions The present study is the first to demonstrate that acupuncture may be an effective approach for improving symptoms-in particular, pain and well-being-in lung cancer patients. Acupuncture is a safe and minimally invasive procedure, and it is potentially useful even in patients undergoing anticancer treatment.
C1 [Kasymjanova, G.; Grossman, M.; Tran, T.; Cohen, V.; Pepe, C.; Small, D.; Agulnik, J.] Peter Brojde Lung Canc Ctr, Montreal, PQ, Canada.
   [Kasymjanova, G.; Grossman, M.; Jagoe, R. T.; Cohen, V.; Pepe, C.; Small, D.; Agulnik, J.] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada.
   [Jagoe, R. T.] McGill Canc Nutr Rehabil Clin, Montreal, PQ, Canada.
C3 Jewish General Hospital - Montreal; McGill University
RP Kasymjanova, G (corresponding author), McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Peter Brojde Lung Canc Ctr, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.
EM gkasymja@jgh.mcgill.ca
CR *AC PROD, 2007, ATL AC POINTS POINT, V0, P0
   Ahn AC, 2005, ALTERN THER HEALTH M, V11, P40
   Akin S, 2010, EUR J ONCOL NURS, V14, P400, DOI 10.1016/j.ejon.2010.01.003
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2023, J CLIN, V0, P0, DOI DOI 10.3322/CAAC.21772
   BEDARD G, 2012, J PAIN SYMPTOM MANAG, V0, P0
   Bonta IL, 2002, MED HYPOTHESES, V58, P221, DOI 10.1054/mehy.2001.1425
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Chang S, 2012, TAIWAN J OBSTET GYNE, V51, P506, DOI 10.1016/j.tjog.2012.09.004
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ferreira KASL, 2008, J PAIN SYMPTOM MANAG, V35, P604, DOI 10.1016/j.jpainsymman.2007.07.010
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Hopwood P, 2000, J CLIN ONCOL, V18, P893, DOI 10.1200/JCO.2000.18.4.893
   Kasymjanova G, 2009, J THORAC ONCOL, V4, P602, DOI 10.1097/JTO.0b013e31819e77e8
   Kelly AM, 1998, ACAD EMERG MED, V5, P1086, DOI 10.1111/j.1553-2712.1998.tb02667.x
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Laird BJA, 2011, J PAIN SYMPTOM MANAG, V42, P1, DOI 10.1016/j.jpainsymman.2010.10.261
   Larsson M, 2012, EUR J CANCER CARE, V21, P642, DOI 10.1111/j.1365-2354.2012.01346.x
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Maione P, 2005, J CLIN ONCOL, V23, P6865, DOI 10.1200/JCO.2005.02.527
   Molassiotis Alexander, 2006, COMPLEMENT THER CLIN PRACT, V12, P34, DOI 10.1016/j.ctcp.2005.09.007
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   ORegan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Pavao TS, 2010, NEUROSCI LETT, V484, P47, DOI 10.1016/j.neulet.2010.08.016
   Sagar SM, 2008, CURR TREAT OPTION ON, V9, P117, DOI 10.1007/s11864-008-0063-3
   Samuels N, 2003, HAREFUAH, V142, P316
   Samuels Noah, 2003, HAREFUAH, V142, P297
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Steinberg T, 2009, SUPPORT CARE CANCER, V17, P1493, DOI 10.1007/s00520-009-0614-6
   Zabora J, 2001, PSYCHO-ONCOL, V10, P19, DOI 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6
NR 39
TC 16
Z9 30
U1 1
U2 30
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1198-0052
EI 1718-7729
J9 CURR ONCOL
JI Curr. Oncol.
PD JUN 15
PY 2013
VL 20
IS 3
BP 152
EP 157
DI 10.3747/co.20.1312
PG 6
WC Oncology
SC Oncology
GA 158KR
UT WOS:000319969800020
PM 23737683
DA 2026-01-16
ER

PT J
AU Vinjamury, SP
   Li, JT
   Hsiao, E
   Huang, C
   Hawk, C
   Miller, J
   Huang, Y
AF Vinjamury, Sivarama Prasad
   Li, Ju-Tzu
   Hsiao, Eric
   Huang, Calen
   Hawk, Cheryl
   Miller, Judith
   Huang, Yuhong
TI Effects of acupuncture for cancer pain and quality of life - a case series.
SO Chinese medicine
LA English
DT Journal Article
AB BACKGROUND: Many cancer patients seek complementary and alternative medicine  (CAM) including acupuncture to manage their cancer-related symptoms or side  effects of treatments. Acupuncture is used to manage cancer pain and improve  quality of life (QoL). This study aimed to conduct a preliminary study on a case  series to evaluate the feasibility of acupuncture for treating cancer pain and to  collect preliminary data on the effectiveness of acupuncture in treating cancer  pain and improving QoL. METHODS: A semi-standardized acupuncture treatment  comprising one to three treatment sessions (20-30 minutes per session) per week  for 8 weeks was provided by four licensed acupuncturists, who had more than 5  years of clinical experience, at the University Health Center. The European  Organization for Research and Treatment of Cancer Quality of Life Questionnaire  (EORTC QLQ-C3) and a visual analogue scale (VAS) for pain rating were used as the  outcome measures to assess pain and QoL. Data were collected at baseline,  immediately after 2, 4, 6, and 8 weeks of treatment and at 4 weeks after  treatment completion (week 12). RESULTS: Two males and five females with a median  age of 66 years (range: 44-71 years) completed the study. For the VAS, the  percentage of improvement ranged between 18% and 95%. The baseline mean raw score  was reduced from 51 mm to 36 mm at the end of week 8 and to 23 mm at the end of  week 12. The percentage of overall QoL improvement ranged between 20% and 100%.  The mean raw score for QoL improved with time. The baseline score was increased  from 55 to 69 at the end of treatment (week 8) and to 73 after the follow-up  (week 12). CONCLUSIONS: This pilot study on a case series showed that acupuncture  might be beneficial for reducing pain and improving QoL in cancer patients.
C1 Department of Fundamental Principles, Southern California University of Health Sciences, California, USA. sivaramavinjamury@scuhs.edu.
NR 0
TC 0
SN 1749-854
EI 1749-854
J9 Chin Med
PD JUL 31
PY 2013
VL 8
IS 1
BP 15
EP 15
DI 10.1186/1749-8546-8-15
PG 0
UT PubMed:23895044
PM 23895044
DA 2013-07-31
ER

PT J
AU Street, RL
AF Street, Richard L., Jr.
TI How clinician-patient communication contributes to health improvement: Modeling pathways from talk to outcome
SO PATIENT EDUCATION AND COUNSELING
LA English
DT Article; Proceedings Paper
DE Physician-patient communication; Health outcomes; Communication measurement; Communication pathways
ID randomized controlled-trial; shared decision-making; centered communication; care; cancer; consultations; impact; intervention; acupuncture; delivery
AB Objective: Although researchers have long investigated relationships between clinician-patient communication and health outcomes, much of the research has produced null, inconsistent, or contradictory findings. This essay examines challenges in the study of how clinician-patient communication contributes to a patient's health and offers recommendations for future research. Discussion: Communication may directly impact outcomes, but more often it will have an indirect effect through its influence on intervening variables (e.g., patient understanding, clinician-patient agreement on treatment, adherence to treatment). For example, a patient communication skills intervention may not directly improve pain control for cancer patients. However, it may do so indirectly by activating patients to talk about cancer pain, which prompts the physician to change pain medication, which leads to better pain control. Additionally, communication measurement is complicated because relationships among communication behavior, meaning, and evaluation are complex. Conclusion: Researchers must do more to model pathways linking clinician-patient communication to the outcomes of interest, particularly pathways in which the communication effects are indirect or mediated through other variables. To better explicate how communication contributes to health outcomes, researchers must critically reflect on the assumptions they are making about communication process and choose measures consistent with those assumptions. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Street, Richard L., Jr.] Texas A&M Univ, Dept Commun, College Stn, TX 77843 USA.
   [Street, Richard L., Jr.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA.
C3 Texas A&M University System; Texas A&M University College Station; Baylor College of Medicine
RP Street, RL (corresponding author), Texas A&M Univ, Dept Commun, College Stn, TX 77843 USA.
EM r-street@tamu.edu
CR Agha Z, 2009, J MED INTERNET RES, V11, P0, DOI 10.2196/jmir.1193
   Unknown -, 2001, CROSSING THE QUALITY CHASM: A NEW HEALTH SYSTEM FOR THE 21ST CENTURY, V0, P0
   Arora NK, 2009, PATIENT EDUC COUNS, V77, P404, DOI 10.1016/j.pec.2009.10.004
   Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313
   Brown JB, 2001, WORKING PAPER SERIES, V0, P0
   de Haes H, 2009, PATIENT EDUC COUNS, V74, P287, DOI 10.1016/j.pec.2008.12.006
   Elwyn G, 2005, HEALTH EXPECT, V8, P34, DOI 10.1111/j.1369-7625.2004.00311.x
   Epstein RM, 2005, SOC SCI MED, V61, P1516, DOI 10.1016/j.socscimed.2005.02.001
   Epstein RM, 2007, PATIENT-CENTERED COMMUNICATION IN CANCER CARE: PROMOTING HEALING AND REDUCING SUFFERING, V0, P0
   Fogarty LA, 1999, J CLIN ONCOL, V17, P371, DOI 10.1200/JCO.1999.17.1.371
   Gallagher TH, 1997, J GEN INTERN MED, V12, P663, DOI 10.1046/j.1525-1497.1997.07137.x
   Glasgow RE, 2006, HEALTH PROMOT INT, V21, P245, DOI 10.1093/heapro/dal017
   Heisler M, 2003, J GEN INTERN MED, V18, P893, DOI 10.1046/j.1525-1497.2003.21132.x
   Jager AJ, 2012, J HEALTH COMMUN, V17, P294, DOI 10.1080/10810730.2012.712624
   KAPLAN SH, 1989, MED CARE, V27, PS110, DOI 10.1097/00005650-198903001-00010
   Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202
   Kravitz RL, 2012, J PAIN SYMPTOM MANAG, V43, P874, DOI 10.1016/j.jpainsymman.2011.05.020
   Kravitz RL, 2011, PAIN, V152, P1572, DOI 10.1016/j.pain.2011.02.047
   Kravitz RL, 2009, BMC CANCER, V9, P0, DOI 10.1186/1471-2407-9-319
   Krupat E, 2006, PATIENT EDUC COUNS, V62, P38, DOI 10.1016/j.pec.2005.04.015
   Lafata JE, 2011, AM J PREV MED, V41, P480, DOI 10.1016/j.amepre.2011.07.018
   LERMAN CE, 1990, J GEN INTERN MED, V5, P29, DOI 10.1007/BF02602306
   Mead N, 2000, PATIENT EDUC COUNS, V39, P71, DOI 10.1016/S0738-3991(99)00092-0
   ORTH JE, 1987, HEALTH PSYCHOL, V6, P29, DOI 10.1037/0278-6133.6.1.29
   Papathanassoglou EDE, 2012, BIOL RES NURS, V14, P431, DOI 10.1177/1099800412451312
   Rimal RN, 2001, HEALTH COMMUN, V13, P89, DOI 10.1207/S15327027HC1301_08
   Robinson JD, 2013, J CLIN ONCOL, V31, P351, DOI 10.1200/JCO.2012.44.2699
   ROST KM, 1991, DIABETES CARE, V14, P881, DOI 10.2337/diacare.14.10.881
   Roter D, 2002, PATIENT EDUC COUNS, V46, P243, DOI 10.1016/S0738-3991(02)00012-5
   Saba GW, 2006, ANN FAM MED, V4, P54, DOI 10.1370/afm.393
   Smith A, 2011, PATIENT EDUC COUNS, V82, P233, DOI 10.1016/j.pec.2010.04.001
   Stewart M, 2000, J FAM PRACTICE, V49, P796
   Street RL, 2012, PATIENT EDUC COUNS, V89, P245, DOI 10.1016/j.pec.2012.06.032
   Street RL, 2012, EXPERT REV PHARM OUT, V12, P167, DOI 10.1586/erp.12.3
   Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015
   STREET RL, 1992, MED CARE, V30, P976, DOI 10.1097/00005650-199211000-00002
   Street RL, 2001, HEALTH COMMUN, V13, P61, DOI 10.1207/S15327027HC1301_06
   Street RL, 1997, MED DECIS MAKING, V17, P298, DOI 10.1177/0272989X9701700306
   STREET RL, 1993, DIABETES CARE, V16, P714, DOI 10.2337/diacare.16.5.714
   Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225
   Ward MM, 2003, ARTHRIT RHEUM-ARTHR, V49, P810, DOI 10.1002/art.11467
   Williams GC, 1998, HEALTH PSYCHOL, V17, P269, DOI 10.1037/0278-6133.17.3.269
   Williams GC, 2004, HEALTH PSYCHOL, V23, P58, DOI 10.1037/0278-6133.23.1.58
   Wolf MS, 2007, PATIENT EDUC COUNS, V67, P293, DOI 10.1016/j.pec.2007.03.024
   Wunderlich T, 2010, PATIENT EDUC COUNS, V80, P358, DOI 10.1016/j.pec.2010.06.034
NR 45
TC 214
Z9 258
U1 1
U2 54
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0738-3991
EI 
J9 PATIENT EDUC COUNS
JI Patient Educ. Couns.
PD SEP 15
PY 2013
VL 92
IS 3
BP 286
EP 291
DI 10.1016/j.pec.2013.05.004
PG 6
WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary
SC Public, Environmental & Occupational Health; Social Sciences - Other Topics
GA 221KM
UT WOS:000324657800002
PM 23746769
DA 2026-01-16
ER

PT J
AU Deng, GE
   Rausch, SM
   Jones, LW
   Gulati, A
   Kumar, NB
   Greenlee, H
   Pietanza, MC
   Cassileth, BR
AF Deng, Gary E
   Rausch, Sarah M
   Jones, Lee W
   Gulati, Amitabh
   Kumar, Nagi B
   Greenlee, Heather
   Pietanza, M Catherine
   Cassileth, Barrie R
TI Complementary therapies and integrative medicine in lung cancer: Diagnosis and
SO Chest
LA English
DT Journal Article
AB BACKGROUND: Physicians are often asked about complementary therapies by patients  with cancer, and data show that the interest in and use of these therapies among  patients with cancer is common. Therefore, it is important to assess the current  evidence base on the benefits and risks of complementary therapies (modalities  not historically used in modern Western medicine). METHODS: A systematic  literature review was carried out and recommendations were made according to the  American College of Chest Physicians Evidence-Based Clinical Practice Guidelines  development methodology. RESULTS: A large number of randomized controlled trials,  systematic reviews, and meta-analyses, as well as a number of prospective cohort  studies, met the predetermined inclusion criteria. These trials addressed many  different issues pertaining to patients with lung cancer, such as symptoms of  anxiety, mood disturbance, pain, quality of life, and treatment-related side  effects. The available data cover a variety of interventions, including  acupuncture, nutrition, mind-body therapies, exercise, and massage. The body of  evidence supports a series of recommendations. An evidenced-based approach to  modern cancer care should integrate complementary therapies with standard cancer  therapies such as surgery, radiation, chemotherapy, and best supportive care  measures. CONCLUSIONS: Several complementary therapy modalities can be helpful in  improving the overall care of patients with lung cancer.
C1 Memorial Sloan-Kettering Cancer Center, New York, NY. 
   University of Florida College of Medicine, Jacksonville, FL.
   Duke Cancer Institute, Durham, NC.
   Memorial Sloan-Kettering Cancer Center, New York, NY.
   Moffitt Cancer Center and Research Institute, Tampa, FL.
   Columbia University, New York, NY.
   Memorial Sloan-Kettering Cancer Center, New York, NY.
   Memorial Sloan-Kettering Cancer Center, New York, NY.
EM dengg@mskcc.org
NR 0
TC 0
SN 1931-354
EI 
J9 Chest
PD MAY 10
PY 2013
VL 143
IS 5 Suppl
BP e420S
EP e436S
DI 10.1378/chest.12-2364
PG 1
WC Complementary Therapies; Evidence-Based Medicine; Humans; Integrative Medicine; Lung Neoplasms; psychology; Quality of Life
UT PubMed:23649450
PM 23649450
DA 2013-05-10
ER

PT J
AU Burnstock, G
AF Burnstock, G.
TI Purinergic signalling in the lower urinary tract
SO ACTA PHYSIOLOGICA
LA English
DT Review
DE acupuncture; ATP; bladder; cancer; prostate; ureter
ID p2x(3) receptor expression; prostate-cancer cells; atp release; human bladder; in-vitro; adenosine-triphosphate; extracellular nucleotides; botulinum neurotoxin; growth-stimulation; activation
AB The aim of this review is to describe the conceptual steps contributing to our current knowledge of purinergic signalling and to consider its involvement in the physiology and pathophysiology of the lower urinary tract. The voiding reflex involves ATP released as a cotransmitter with acetylcholine from parasympathetic nerves supplying the bladder and ATP released from urothelial cells during bladder distension to initiate the voiding reflex via P2X3 receptors on suburothelial low threshold sensory nerve fibres. This mechanosensory transduction pathway also participates, via high threshold sensory nerve fibres, in the initiation of pain in bladder and ureter. Treatment of prostate and bladder cancer with ATP is effective against the primary tumours in animal models and human cell lines, via P2X5 and P2X7 receptors, and also improves the systemic symptoms associated with advanced malignancy. Acupuncture is widely used for the treatment of urinary disorders, and a purinergic hypothesis is discussed for the underlying mechanism.
C1 UCL, Sch Med, Autonom Neurosci Ctr, London NW3 2PF, England.
C3 University of London; University College London; UCL Medical School
RP Burnstock, G (corresponding author), UCL, Sch Med, Autonom Neurosci Ctr, Rowland Hill St, London NW3 2PF, England.
EM g.burnstock@ucl.ac.uk
CR Abraham EH, 2003, CURR TOP MEMBR, V54, P415, DOI 10.1016/S1063-5823(03)01013-5
   Agteresch HJ, 2000, J NATL CANCER I, V92, P321, DOI 10.1093/jnci/92.4.321
   Agteresch HJ, 2000, EUR J CLIN PHARMACOL, V56, P49, DOI 10.1007/s002280050719
   Andersson KE, 2002, UROLOGY, V60, P13, DOI 10.1016/S0090-4295(02)01786-7
   Artim DE, 2007, FASEB J, V21, P0
   Baqi Y, 2009, PURINERG SIGNAL, V5, P91, DOI 10.1007/s11302-008-9103-5
   Birder LA, 2004, AM J PHYSIOL-RENAL, V287, PF1084, DOI 10.1152/ajprenal.00118.2004
   Bo XN, 1999, NEUROREPORT, V10, P1107, DOI 10.1097/00001756-199904060-00037
   Boissier S, 1997, CANCER RES, V57, P3890
   BURNSTOCK G, 1972, BRIT J PHARMACOL, V44, P451, DOI 10.1111/j.1476-5381.1972.tb07283.x
   Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0
   BURNSTOCK G, 1978, BRIT J PHARMACOL, V63, P125, DOI 10.1111/j.1476-5381.1978.tb07782.x
   BURNSTOCK G, 1976, NEUROSCIENCE, V1, P239, DOI 10.1016/0306-4522(76)90054-3
   Burnstock G, 2010, CELL DEATH DIS, V1, P0, DOI 10.1038/cddis.2009.11
   Burnstock G, 2009, ACTA PHYSIOL, V195, P415, DOI 10.1111/j.1748-1716.2009.01957.x
   Burnstock G, 2001, HANDB EXP PHARM, V151, P423
   BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1
   Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x
   BURNSTOCK G, 1972, PHARMACOL REV, V24, P509
   Burnstock G, 2001, TRENDS PHARMACOL SCI, V22, P182, DOI 10.1016/S0165-6147(00)01643-6
   Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3
   Burnstock G, 2009, ASPECTS PHARM PYELOU, V0, P77
   Burnstock G, 1978, CELL MEMBRAIN RECEPT, V0, P107
   Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006
   Burnstock G, 2009, MOL PAIN, V5, P0, DOI 10.1186/1744-8069-5-69
   Burnstock G, 2009, MED HYPOTHESES, V73, P470, DOI 10.1016/j.mehy.2009.05.031
   Calvert RC, 2008, PURINERG SIGNAL, V4, P377, DOI 10.1007/s11302-008-9123-1
   Chancellor MB, 2008, NAT CLIN PRACT UROL, V5, P319, DOI 10.1038/ncpuro1124
   CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0
   Chen L, 2004, CANCER LETT, V215, P239, DOI 10.1016/j.canlet.2004.05.023
   Chen XW, 2010, J NEUROSCI, V30, P2365, DOI 10.1523/JNEUROSCI.5462-09.2010
   Cheng Y, 2010, J UROLOGY, V183, P1082, DOI 10.1016/j.juro.2009.11.028
   Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519
   Dainty IA, 1995, BR J PHARM, V114, P0
   Donnelly-Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265
   Engberg S, 2009, J WOUND OSTOMY CONT, V36, P661, DOI 10.1097/WON.0b013e3181bd82dd
   FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562
   Feng LL, 2011, NEOPLASIA, V13, P206, DOI 10.1593/neo.101332
   Fernando KC, 1999, ARCH BIOCHEM BIOPHYS, V362, P197, DOI 10.1006/abbi.1998.1045
   Ford APDW, 2006, BRIT J PHARMACOL, V147, PS132, DOI 10.1038/sj.bjp.0706637
   Gever JR, 2006, PFLUG ARCH EUR J PHY, V452, P513, DOI 10.1007/s00424-006-0070-9
   Gever JR, 2010, BRIT J PHARMACOL, V160, P1387, DOI 10.1111/j.1476-5381.2010.00796.x
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Greig AVH, 2003, J INVEST DERMATOL, V121, P315, DOI 10.1046/j.1523-1747.2003.12379.x
   Harvey RA, 2002, J UROLOGY, V168, P1235, DOI 10.1016/S0022-5347(05)64632-0
   Heppner TJ, 2009, J PHYSIOL-LONDON, V587, P5275, DOI 10.1113/jphysiol.2009.178806
   HOYLE CHV, 1989, EUR J PHARMACOL, V174, P115, DOI 10.1016/0014-2999(89)90881-9
   Ito K, 2008, N-S ARCH PHARMACOL, V377, P483, DOI 10.1007/s00210-007-0197-z
   Jajoo S, 2009, NEOPLASIA, V11, P1132, DOI 10.1593/neo.09744
   Janssens R, 2001, BRIT J PHARMACOL, V132, P536, DOI 10.1038/sj.bjp.0703833
   Kaan TKY, 2010, J NEUROSCI, V30, P4503, DOI 10.1523/JNEUROSCI.6132-09.2010
   KASAKOV L, 1982, EUR J PHARMACOL, V86, P291, DOI 10.1016/0014-2999(82)90330-2
   Knight GE, 2002, AM J PHYSIOL-RENAL, V282, PF281, DOI 10.1152/ajprenal.00293.2000
   KOISO K, 1991, UROL INT, V46, P145, DOI 10.1159/000282120
   Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108
   KYPRIANOU N, 1989, BIOCHEM BIOPH RES CO, V165, P73, DOI 10.1016/0006-291X(89)91035-8
   Lawrence GW, 2010, J PHARMACOL EXP THER, V334, P1080, DOI 10.1124/jpet.110.169342
   LEE YH, 1992, J UROLOGY, V147, P16, DOI 10.1016/S0022-5347(17)37121-5
   LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0
   MACKENZIE I, 1982, NEUROSCIENCE, V7, P997, DOI 10.1016/0306-4522(82)90056-2
   MARTIKAINEN P, 1991, CANCER RES, V51, P4693
   Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026
   Martins JP, 2012, BRIT J PHARMACOL, V165, P183, DOI 10.1111/j.1476-5381.2011.01535.x
   McCarthy CJ, 2009, J UROLOGY, V181, P1459, DOI 10.1016/j.juro.2008.10.139
   Minelli A, 2006, PROSTATE, V66, P1425, DOI 10.1002/pros.20458
   Minelli A, 2009, PROSTATE, V69, P538, DOI 10.1002/pros.20900
   Miyake H, 1999, J UROLOGY, V162, P916, DOI 10.1097/00005392-199909010-00090
   Mochizuki T, 2009, J BIOL CHEM, V284, P21257, DOI 10.1074/jbc.M109.020206
   Mönkkönen H, 2008, ANTI-CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Moore KH, 2001, J NEUROSCI, V21, P0, DOI 10.1523/JNEUROSCI.21-18-j0002.2001
   Nandigama R, 2006, J BIOL CHEM, V281, P5686, DOI 10.1074/jbc.M510452200
   NERGARDH A, 1981, SCAND J UROL NEPHROL, V15, P103, DOI 10.3109/00365598109179584
   Nishiguchi J, 2004, EUR J NEUROSCI, V20, P474, DOI 10.1111/j.1460-9568.2004.03508.x
   Nucciarelli F, 2003, DRUG DEVELOP RES, V58, P390, DOI 10.1002/ddr.10183
   OReilly BA, 2002, J UROLOGY, V167, P157, DOI 10.1016/S0022-5347(05)65403-1
   OReilly BA, 2001, BJU INT, V87, P617, DOI 10.1046/j.1464-410x.2001.02179.x
   PALEA S, 1993, J UROLOGY, V150, P2007, DOI 10.1016/S0022-5347(17)35955-4
   Phelps PT, 2006, EUR J PHARMACOL, V536, P28, DOI 10.1016/j.ejphar.2006.02.046
   Ralevic V, 1998, PHARMACOL REV, V50, P413
   RAPAPORT E, 1983, J CELL PHYSIOL, V114, P279, DOI 10.1002/jcp.1041140305
   Rocha I, 2001, AUTON NEUROSCI-BASIC, V88, P6, DOI 10.1016/S1566-0702(00)00284-8
   Rong WF, 2000, J PHYSIOL-LONDON, V524, P891, DOI 10.1111/j.1469-7793.2000.00891.x
   Rong WF, 2004, NEUROPHARMACOLOGY, V47, P1093, DOI 10.1016/j.neuropharm.2004.08.003
   Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025
   Sauer H, 2002, J CELL SCI, V115, P3265
   Shabbir M, 2008, BJU INT, V102, P108, DOI 10.1111/j.1464-410X.2008.07578.x
   Shabbir M, 2008, BJU INT, V101, P352, DOI 10.1111/j.1464-410X.2007.07293.x
   Shabbir M, 2008, BJU INT, V101, P106, DOI 10.1111/j.1464-410X.2007.07286.x
   Shabbir M, 2009, INT J UROL, V16, P143, DOI 10.1111/j.1442-2042.2008.02207.x
   Shemon AN, 2006, J BIOL CHEM, V281, P2079, DOI 10.1074/jbc.M507816200
   SIBLEY GNA, 1984, J PHYSIOL-LONDON, V354, P431, DOI 10.1113/jphysiol.1984.sp015386
   Slater M, 2004, HISTOPATHOLOGY, V44, P206, DOI 10.1111/j.0309-0167.2004.01798.x
   Smith CP, 2005, NEUROCHEM INT, V47, P291, DOI 10.1016/j.neuint.2005.04.021
   Smith DJ, 1994, NEUROUROL URODYNAM, V13, P414
   Soe SHTE, 2009, MULT SCLER J, V15, P1376, DOI 10.1177/1352458509107020
   Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292
   Stella J, 2010, UROL ONCOL-SEMIN ORI, V28, P260, DOI 10.1016/j.urolonc.2009.01.035
   Sugaya K, 2009, BIOMED RES-TOKYO, V30, P287, DOI 10.2220/biomedres.30.287
   Sun Y, 2001, UROLOGY, V57, P131, DOI 10.1016/S0090-4295(01)01106-2
   Sun Y, 2004, J UROLOGY, V171, P448, DOI 10.1097/01.ju.0000099660.46774.3c
   Tapia-Vieyra JV, 2001, ARCH MED RES, V32, P175, DOI 10.1016/S0188-4409(01)00274-0
   Tempest HV, 2004, BJU INT, V93, P1344, DOI 10.1111/j.1464-410X.2004.04858.x
   Tong YQ, 2009, J ALTERN COMPLEM MED, V15, P905, DOI 10.1089/acm.2009.0062
   van der Weyden L, 2000, HYPERTENSION, V36, P1093, DOI 10.1161/01.HYP.36.6.1093
   Vanoverberghe K, 2003, CELL CALCIUM, V34, P75, DOI 10.1016/S0143-4160(03)00024-1
   Vlaskovska M, 2001, J NEUROSCI, V21, P5670, DOI 10.1523/JNEUROSCI.21-15-05670.2001
   Wang QF, 2004, ENDOCRINOLOGY, V145, P5568, DOI 10.1210/en.2004-0807
   Wasilenko WJ, 1997, PROSTATE, V30, P167
   Wei Q, 2011, BIOCHEM PHARMACOL, V82, P418, DOI 10.1016/j.bcp.2011.05.013
   White N, 2006, TRENDS PHARMACOL SCI, V27, P211, DOI 10.1016/j.tips.2006.02.004
   Yegutkin GG, 2008, BBA-MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024
   Yegutkin GG, 2011, EUR J IMMUNOL, V41, P1231, DOI 10.1002/eji.201041292
   Yoshida M, 2001, EXP GERONTOL, V36, P99, DOI 10.1016/S0531-5565(00)00175-3
   Young JS, 2008, J PHYSIOL-LONDON, V586, P5743, DOI 10.1113/jphysiol.2008.162040
   Yuping Wang, 2006, J TRADIT CHIN MED, V26, P106
   Zhang Y, 2010, CANCER LETT, V293, P189, DOI 10.1016/j.canlet.2010.01.010
NR 116
TC 33
Z9 41
U1 0
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1748-1708
EI 1748-1716
J9 ACTA PHYSIOL
JI Acta Physiol.
PD JAN 15
PY 2013
VL 207
IS 1
BP 40
EP 52
DI 10.1111/apha.12012
PG 13
WC Physiology
SC Physiology
GA 054JX
UT WOS:000312340900006
PM 23176070
DA 2026-01-16
ER

PT J
AU Deng, GE
   Rausch, SM
   Jones, LW
   Gulati, A
   Kumar, NB
   Greenlee, H
   Pietanza, MC
   Cassileth, BR
AF Deng, Gary E.
   Rausch, Sarah M.
   Jones, Lee W.
   Gulati, Amitabh
   Kumar, Nagi B.
   Greenlee, Heather
   Pietanza, M. Catherine
   Cassileth, Barrie R.
TI Complementary Therapies and Integrative Medicine in Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
SO CHEST
LA English
DT Article
ID quality-of-life; chemotherapy-induced nausea; preoperative pulmonary rehabilitation; cruciferous vegetable intake; brief hypnosis intervention; tai-chi-chuan; breast-cancer; alternative medicine; palliative care; nutritional support
AB Background: Physicians are often asked about complementary therapies by patients with cancer, and data show that the interest in and use of these therapies among patients with cancer is common. Therefore, it is important to assess the current evidence base on the benefits and risks of complementary therapies (modalities not historically used in modern Western medicine). Methods: A systematic literature review was carried out and recommendations were made according to the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines development methodology. Results: A large number of randomized controlled trials, systematic reviews, and meta-analyses, as well as a number of prospective cohort studies, met the predetermined inclusion criteria. These trials addressed many different issues pertaining to patients with lung cancer, such as symptoms of anxiety, mood disturbance, pain, quality of life, and treatment-related side effects. The available data cover a variety of interventions, including acupuncture, nutrition, mind-body therapies, exercise, and massage. The body of evidence supports a series of recommendations. An evidenced-based approach to modern cancer care should integrate complementary therapies with standard cancer therapies such as surgery, radiation, chemotherapy, and best supportive care measures. Conclusions: Several complementary therapy modalities can be helpful in improving the overall care of patients with lung cancer.
C1 [Deng, Gary E.; Gulati, Amitabh; Pietanza, M. Catherine; Cassileth, Barrie R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
   [Rausch, Sarah M.] Univ Florida, Coll Med, Jacksonville, FL USA.
   [Kumar, Nagi B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
   [Jones, Lee W.] Duke Canc Inst, Durham, NC USA.
   [Greenlee, Heather] Columbia Univ, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; State University System of Florida; University of Florida; H Lee Moffitt Cancer Center & Research Institute; Duke University; Columbia University
RP Deng, GE (corresponding author), Mem Sloan Kettering Canc Ctr, 1429 First Ave, New York, NY 10021 USA.
EM dengg@mskcc.org
FU Lung Cancer Research Foundation; Boehringer Ingelheim Pharmaceuticals, Inc.
CR Adams D, 2011, PEDIATRICS, V128, PE1575, DOI 10.1542/peds.2011-1091
   Adams J, 2003, MED J AUSTRALIA, V179, P297, DOI 10.5694/j.1326-5377.2003.tb05551.x
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Amin M, 2010, EUR ARCH OTO-RHINO-L, V267, P1291, DOI 10.1007/s00405-010-1223-1
   Unknown -, 2008, INT J YOGA, V0, P0, DOI DOI 10.4103/0973-6131.36789
   Arbane G, 2011, LUNG CANCER, V71, P229, DOI 10.1016/j.lungcan.2010.04.025
   Arthur HM, 2000, ANN INTERN MED, V133, P253, DOI 10.7326/0003-4819-133-4-200008150-00007
   Astin JA, 2004, CLIN J PAIN, V20, P27, DOI 10.1097/00002508-200401000-00006
   Aune D, 2009, ASIAN PAC J CANCER P, V10, P429
   Baldwin C, 2011, J HUM NUTR DIET, V24, P431, DOI 10.1111/j.1365-277X.2011.01189.x
   Banasik J, 2011, J AM ACAD NURSE PRAC, V23, P135, DOI 10.1111/j.1745-7599.2010.00573.x
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Barnes PM, 2008, NATL HLTH STAT REPOR, V0, P0, DOI DOI 10.1037/E623942009-001
   Bobbio A, 2008, EUR J CARDIO-THORAC, V33, P95, DOI 10.1016/j.ejcts.2007.10.003
   Boffetta P, 2010, JNCI-J NATL CANCER I, V102, P529, DOI 10.1093/jnci/djq072
   Bonadonna Ramita, 2003, HOLIST NURS PRACT, V17, P309
   Bor MV, 2010, AM J CLIN NUTR, V91, P571, DOI 10.3945/ajcn.2009.28082
   Bosaeus I, 2008, SUPPORT CARE CANCER, V16, P447, DOI 10.1007/s00520-007-0388-7
   Bruera E, 1997, BRIT MED J, V315, P1219, DOI 10.1136/bmj.315.7117.1219
   Büchner FL, 2010, CANCER EPIDEM BIOMAR, V19, P2278, DOI 10.1158/1055-9965.EPI-10-0489
   Carpenter CL, 2009, NUTR CANCER, V61, P492, DOI 10.1080/01635580902752270
   Carson JW, 2007, J PAIN SYMPTOM MANAG, V33, P331, DOI 10.1016/j.jpainsymman.2006.08.009
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Cassileth BR, 2004, ONCOLOGIST, V9, P80, DOI 10.1634/theoncologist.9-1-80
   Cesario A, 2007, LUNG CANCER, V57, P175, DOI 10.1016/j.lungcan.2007.02.017
   Cesario A, 2007, LUNG CANCER, V57, P118, DOI 10.1016/j.lungcan.2007.03.022
   Chan CLW, 2012, SUPPORT CARE CANCER, V20, P1121, DOI 10.1007/s00520-011-1378-3
   Chandwani Kavita D, 2010, J SOC INTEGR ONCOL, V8, P43
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011
   Chrystal Kathryn, 2003, N Z MED J, V116, P0
   Corbin Lisa, 2005, CANCER CONTROL, V12, P158
   Couch M, 2007, HEAD NECK-J SCI SPEC, V29, P401, DOI 10.1002/hed.20447
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cross AJ, 2007, PLOS MED, V4, P1973, DOI 10.1371/journal.pmed.0040325
   Dale HL, 2010, PSYCHO-ONCOLOGY, V19, P227, DOI 10.1002/pon.1598
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dosil-Díaz O, 2008, NUTRITION, V24, P407, DOI 10.1016/j.nut.2008.01.005
   Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   EPPLEY KR, 1989, J CLIN PSYCHOL, V45, P957, DOI 10.1002/1097-4679(198911)45:6<957::AID-JCLP2270450622>3.0.CO;2-Q
   Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004
   Ernst E, 2003, RHEUMATOLOGY, V42, P1101, DOI 10.1093/rheumatology/keg306
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Fearon KCH, 2003, GUT, V52, P1479, DOI 10.1136/gut.52.10.1479
   Fearon KCH, 2006, J CLIN ONCOL, V24, P3401, DOI 10.1200/JCO.2005.04.5724
   Fjorback LO, 2011, ACTA PSYCHIAT SCAND, V124, P102, DOI 10.1111/j.1600-0447.2011.01704.x
   Gansler T, 2008, CANCER-AM CANCER SOC, V113, P1048, DOI 10.1002/cncr.23659
   Gardani G, 2007, MINERVA MED, V98, P665
   Gonzalez CA, 2006, PUBLIC HEALTH NUTR, V9, P124, DOI 10.1079/PHN2005934
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Granger CL, 2011, LUNG CANCER, V72, P139, DOI 10.1016/j.lungcan.2011.01.006
   Guo R, 1995, J TRADIT CHIN MED, V15, P262
   Hamerman D, 2002, J GERONTOL A-BIOL, V57, PM511, DOI 10.1093/gerona/57.8.M511
   He JP, 1999, CLINICAL AND EXPERIMENTAL OBSTETRICS AND GYNECOLOGY, V26, P81
   Higdon JV, 2007, PHARMACOL RES, V55, P224, DOI 10.1016/j.phrs.2007.01.009
   Hilliard RE, 2005, EVID-BASED COMPL ALT, V2, P173, DOI 10.1093/ecam/neh076
   Hyodo I, 2005, J CLIN ONCOL, V23, P2645, DOI 10.1200/JCO.2005.04.126
   Ito Y, 2005, J EPIDEMIOL, V15, PS140, DOI 10.2188/jea.15.S140
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Jones LW, 2007, CANCER-AM CANCER SOC, V110, P590, DOI 10.1002/cncr.22830
   Jones LW, 2008, CANCER-AM CANCER SOC, V113, P3430, DOI 10.1002/cncr.23967
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kaufer D, 2009, NEUROLOGY, V73, P2052, DOI 10.1212/WNL.0b013e3181c6784a
   Kumar NB, 2010, CURR TREAT OPTION ON, V11, P107, DOI 10.1007/s11864-010-0127-z
   Kwekkeboom KL, 2010, J PAIN SYMPTOM MANAG, V39, P126, DOI 10.1016/j.jpainsymman.2009.05.022
   Lam TK, 2010, CANCER EPIDEM BIOMAR, V19, P2534, DOI 10.1158/1055-9965.EPI-10-0475
   Lang EV, 2008, J VASC INTERV RADIOL, V19, P897, DOI 10.1016/j.jvir.2008.01.027
   Lao LX, 2003, ALTERN THER HEALTH M, V9, P72
   Ledesma D, 2009, PSYCHO-ONCOLOGY, V18, P571, DOI 10.1002/pon.1400
   Lewis SZ, 2013, CHEST, V143, P41S, DOI 10.1378/chest.12-2344
   LI QS, 1994, CHINESE MED J-PEKING, V107, P289
   Lim WY, 2011, NUTR CANCER, V63, P850, DOI 10.1080/01635581.2011.589961
   Lin KY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/659876
   Linseisen J, 2007, INT J CANCER, V121, P1103, DOI 10.1002/ijc.22807
   Littman AJ, 2012, SUPPORT CARE CANCER, V20, P267, DOI 10.1007/s00520-010-1066-8
   Lu WD, 2010, INTEGR CANCER THER, V9, P284, DOI 10.1177/1534735410378856
   Maciver I, 1996, INFECT IMMUN, V64, P4618, DOI 10.1128/IAI.64.11.4618-4629.1996
   MacPherson H, 2001, ACUPUNCT MED, V19, P93
   Mansky P, 2006, INTEGR CANCER THER, V5, P192, DOI 10.1177/1534735406291590
   MARTIN GP, 1981, NEW ZEAL MED J, V93, P421
   Matchim Y, 2007, ONCOL NURS FORUM, V34, P1059, DOI 10.1188/07.ONF.1059-1066
   McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Montbriand MJ, 1998, CANCER NURS, V21, P36, DOI 10.1097/00002820-199802000-00005
   Montgomery GH, 2002, ANESTH ANALG, V94, P1639, DOI 10.1097/00000539-200206000-00052
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Montgomery GH, 2010, J CONSULT CLIN PSYCH, V78, P80, DOI 10.1037/a0017392
   Montgomery GH, 2009, HEALTH PSYCHOL, V28, P317, DOI 10.1037/a0013582
   Murphy RA, 2010, J NUTR, V140, P1602, DOI 10.3945/jn.110.123521
   Mustian Karen M, 2006, J SUPPORT ONCOL, V4, P139
   Mustian KM, 2004, SUPPORT CARE CANCER, V12, P871, DOI 10.1007/s00520-004-0682-6
   Navo MA, 2004, J CLIN ONCOL, V22, P671, DOI 10.1200/JCO.2004.04.162
   Neuhouser ML, 2003, CANCER EPIDEM BIOMAR, V12, P350
   Nilsson U, 2003, ANAESTHESIA, V58, P699, DOI 10.1046/j.1365-2044.2003.03189_4.x
   Nystrom E, 2008, ACUPUNCT MED, V26, P27, DOI 10.1136/aim.26.1.27
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Osborn RL, 2006, INT J PSYCHIAT MED, V36, P13, DOI 10.2190/EUFN-RV1K-Y3TR-FK0L
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Perkins P, 2008, PALLIATIVE MED, V22, P193, DOI 10.1177/0269216307087144
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Quist M, 2012, LUNG CANCER, V75, P203, DOI 10.1016/j.lungcan.2011.07.006
   Raghavendra RM, 2007, EUR J CANCER CARE, V16, P462, DOI 10.1111/j.1365-2354.2006.00739.x
   Raiasekaran M, 2005, PALLIATIVE MED, V19, P418, DOI 10.1191/0269216305pm1030oa
   Remen RN, 2008, HEMATOL ONCOL CLIN N, V22, P767, DOI 10.1016/j.hoc.2008.04.001
   Richardson J, 2007, EUR J CANCER CARE, V16, P402, DOI 10.1111/j.1365-2354.2006.00736.x
   Riesenberg H, 2010, SUPPORT CARE CANCER, V18, P877, DOI 10.1007/s00520-009-0727-y
   Rivadeneira DE, 1998, CA-CANCER J CLIN, V48, P69, DOI 10.3322/canjclin.48.2.69
   Satia JA, 2009, CANCER EPIDEM BIOMAR, V18, P1419, DOI 10.1158/1055-9965.EPI-09-0038
   Schmidt K, 2004, ANN ONCOL, V15, P733, DOI 10.1093/annonc/mdh174
   Schmidt K, 2002, COMPLEMENT THER MED, V10, P179, DOI 10.1016/S0965229902000742
   Schnur JB, 2008, ANESTH ANALG, V106, P440, DOI 10.1213/ane.0b013e31815edb13
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Shennan C, 2011, PSYCHO-ONCOLOGY, V20, P681, DOI 10.1002/pon.1819
   Shumay D M, 2001, J FAM PRACT, V50, P1067
   Sima Lei, 2009, ZHONGGUO ZHEN JIU, V29, P3
   Smith JE, 2005, J ADV NURS, V52, P315, DOI 10.1111/j.1365-2648.2005.03592.x
   Smith KB, 2009, PSYCHO-ONCOLOGY, V18, P465, DOI 10.1002/pon.1411
   Speed-Andrews AE, 2010, CANCER NURS, V33, P369, DOI 10.1097/NCC.0b013e3181cfb55a
   Spruit MA, 2006, LUNG CANCER, V52, P257, DOI 10.1016/j.lungcan.2006.01.003
   Stalpers LJA, 2005, INT J RADIAT ONCOL, V61, P499, DOI 10.1016/j.ijrobp.2004.06.005
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   Struijker-Boudier HAJ, 2008, HYPERTENSION, V51, P821, DOI 10.1161/HYPERTENSIONAHA.107.103234
   Szabo E, 2013, CHEST, V143, PE40, DOI 10.1378/chest.12-2348
   Tang L, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-162
   Tang NP, 2009, JPN J CLIN ONCOL, V39, P352, DOI 10.1093/jjco/hyp028
   Tasevska N, 2011, INT J CANCER, V128, P402, DOI 10.1002/ijc.25327
   Tasevska N, 2009, AM J CLIN NUTR, V89, P1884, DOI 10.3945/ajcn.2008.27272
   Taspinar A, 2010, EUR J ONCOL NURS, V14, P49, DOI 10.1016/j.ejon.2009.07.006
   Temel JS, 2009, J THORAC ONCOL, V4, P595, DOI 10.1097/JTO.0b013e31819d18e5
   Vadiraja HS, 2009, COMPLEMENT THER MED, V17, P274, DOI 10.1016/j.ctim.2009.06.004
   van der Meij BS, 2010, J NUTR, V140, P1774, DOI 10.3945/jn.110.121202
   Vapiwala N, 2006, CANCER J, V12, P467, DOI 10.1097/00130404-200611000-00006
   Verhoef Marja J, 2005, INTEGR CANCER THER, V4, P274, DOI 10.1177/1534735405282361
   Vickers Andrew J, 2006, BMC ANESTHESIOL, V6, P5, DOI 10.1186/1471-2253-6-5
   Vojacek J, 2010, J CARDIAC SURG, V25, P72, DOI 10.1111/j.1540-8191.2009.00938.x
   Weiger WA, 2002, ANN INTERN MED, V137, P889, DOI 10.7326/0003-4819-137-11-200212030-00010
   Wells M, 2007, CANCER NURS, V30, P45, DOI 10.1097/00002820-200701000-00008
   White Adrian, 2004, ACUPUNCT MED, V22, P122
   White Margaret A, 2003, INTEGR CANCER THER, V2, P217, DOI 10.1177/1534735403256411
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Wu XA, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-269
   Xu S, 1995, J TRADIT CHIN MED, V15, P189
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Yamashita H, 1999, J ALTERN COMPLEM MED, V5, P229, DOI 10.1089/acm.1999.5.229
   Yamashita H, 2001, COMPLEMENT THER MED, V9, P98, DOI 10.1054/ctim.2001.0446
   Yang WS, 2011, AM J CLIN NUTR, V94, P1575, DOI 10.3945/ajcn.111.020966
   Yang Yan, 2009, ZHONGGUO ZHEN JIU, V29, P955
   Yin Shi, 2006, ZHONGHUA ZHONGLIU ZAZHI, V28, P840
   You Q, 2009, INT J GYNECOL CANCER, V19, P567, DOI 10.1111/IGC.0b013e31819d8b48
NR 159
TC 120
Z9 142
U1 1
U2 58
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD MAY 15
PY 2013
VL 143
IS 5
BP E420
EP E436
DI 10.1378/chest.12-2364
PG 17
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AB1HL
UT WOS:000331542000019
PM 23649450
DA 2026-01-16
ER

PT J
AU Zhang, YP
   Ru, QJ
AF Zhang, Yue-Ping
   Ru, Qing-Jing
TI [Cases of postoperative pain of liver cancer after transcatheter arterial
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
C1 iamzhangyueping@sina.com
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 5
PY 2013
VL 33
IS 9
BP 778
EP 778
DI 
PG 0
WC Acupuncture Analgesia; Acupuncture, Ear; Adult; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; complications; Male; Pain, Postoperative; etiology
UT PubMed:24298763
PM 24298763
DA 2013-12-05
ER

PT J
AU Vinjamury, SP
   Li, JT
   Hsiao, E
   Huang, C
   Hawk, C
   Miller, J
   Huang, YH
AF Vinjamury, Sivarama Prasad
   Li, Ju-Tzu
   Hsiao, Eric
   Huang, Calen
   Hawk, Cheryl
   Miller, Judith
   Huang, Yuhong
TI Effects of acupuncture for cancer pain and quality of life - a case series
SO CHINESE MEDICINE
LA English
DT Article
ID alternative medicine; complementary; malignancy; reliability; survivors; efficacy; validity; qlq-c30; opioids
AB Background: Many cancer patients seek complementary and alternative medicine (CAM) including acupuncture to manage their cancer-related symptoms or side effects of treatments. Acupuncture is used to manage cancer pain and improve quality of life (QoL). This study aimed to conduct a preliminary study on a case series to evaluate the feasibility of acupuncture for treating cancer pain and to collect preliminary data on the effectiveness of acupuncture in treating cancer pain and improving QoL. Methods: A semi-standardized acupuncture treatment comprising one to three treatment sessions (20-30 minutes per session) per week for 8 weeks was provided by four licensed acupuncturists, who had more than 5 years of clinical experience, at the University Health Center. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C3) and a visual analogue scale (VAS) for pain rating were used as the outcome measures to assess pain and QoL. Data were collected at baseline, immediately after 2, 4, 6, and 8 weeks of treatment and at 4 weeks after treatment completion (week 12). Results: Two males and five females with a median age of 66 years (range: 44-71 years) completed the study. For the VAS, the percentage of improvement ranged between 18% and 95%. The baseline mean raw score was reduced from 51 mm to 36 mm at the end of week 8 and to 23 mm at the end of week 12. The percentage of overall QoL improvement ranged between 20% and 100%. The mean raw score for QoL improved with time. The baseline score was increased from 55 to 69 at the end of treatment (week 8) and to 73 after the follow-up (week 12). Conclusions: This pilot study on a case series showed that acupuncture might be beneficial for reducing pain and improving QoL in cancer patients.
C1 [Vinjamury, Sivarama Prasad; Li, Ju-Tzu; Hsiao, Eric; Miller, Judith] So Calif Univ Hlth Sci, Dept Fundamental Principles, Los Angeles, CA USA.
   [Huang, Calen] China Med Univ, Sch Med, Taichung, Taiwan.
   [Hawk, Cheryl] Logan Coll Chiropract Univ, Dept Res, Chesterfield, MO USA.
   [Huang, Yuhong] United Hlth Grp, Santa Ana, CA USA.
C3 China Medical University Taiwan; UnitedHealth Group Incorporated
RP Vinjamury, SP (corresponding author), So Calif Univ Hlth Sci, Dept Fundamental Principles, Los Angeles, CA USA.
EM sivaramavinjamury@scuhs.edu
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Abs R, 2000, J CLIN ENDOCR METAB, V85, P2215, DOI 10.1210/jc.85.6.2215
   Unknown -, 2012, NATL VITAL STAT REPO, V0, P0
   Unknown -, 2009, SEER CANC STAT REV 1, V0, P0
   Baldini Angee, 2012, PRIM CARE COMPANION CNS DISORD, V14, P0, DOI 10.4088/PCC.11m01326
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Chancellor J, 2012, VALUE HEALTH, V15, P106, DOI 10.1016/j.jval.2011.07.002
   Chapman S, 2012, NURS STAND, V26, P42
   Chapman S, 2011, CANC NURSING PRACTIC, V10, P28
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Dekkers OM, 2012, ANN INTERN MED, V156, P37, DOI 10.7326/0003-4819-156-1-201201030-00006
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Hanks GW, 1997, ACTA ANAESTH SCAND, V41, P154, DOI 10.1111/j.1399-6576.1997.tb04630.x
   Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1
   Klaschik E, 2005, SCHMERZ, V19, P395, DOI 10.1007/s00482-005-0425-8
   Lang DSP, 2012, INT J EVID-BASED HEA, V10, P86, DOI 10.1111/j.1744-1609.2012.00257.x
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Lu Weidong, 2007, J SOC INTEGR ONCOL, V5, P1, DOI 10.2310/7200.2006.035
   Lu WD, 2009, J ALTERN COMPLEM MED, V15, P745, DOI 10.1089/acm.2008.0589
   Luo HC, 1998, PSYCHIAT CLIN NEUROS, V52, PS338, DOI 10.1111/j.1440-1819.1998.tb03262.x
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P144, DOI 10.1016/S0885-3924(00)00228-1
   Mukaino Yoshito, 2005, ACUPUNCT MED, V23, P70
   Nicklasson M, 2007, QUAL LIFE RES, V16, P1019, DOI 10.1007/s11136-007-9210-8
   Oldenmenger WH, 2012, SUPPORT CARE CANCER, V20, P1639, DOI 10.1007/s00520-011-1254-1
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P8
   Palos GR, 2008, ONCOL NURS FORUM, V35, P13, DOI 10.1188/08.ONF.S1.13-19
   Sepúlveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2
   Tascilar M, 2006, ONCOLOGIST, V11, P732, DOI 10.1634/theoncologist.11-7-732
   Weiger WA, 2002, ANN INTERN MED, V137, P889, DOI 10.7326/0003-4819-137-11-200212030-00010
   Yamaguchi N, 2007, EVID-BASED COMPL ALT, V4, P447, DOI 10.1093/ecam/nel107
NR 32
TC 7
Z9 11
U1 0
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
EI 
J9 CHIN MED-UK
JI Chin. Med.
PD JUL 30
PY 2013
VL 8
IS 
BP 
EP 
DI 10.1186/1749-8546-8-15
PG 6
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA 195TE
UT WOS:000322725700001
PM 23895044
DA 2026-01-16
ER

PT J
AU Towler, P
   Molassiotis, A
   Brearley, SG
AF Towler, P
   Molassiotis, A
   Brearley, S G
TI What is the evidence for the use of acupuncture as an intervention for symptom
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
AB PURPOSE: This study aims to systematically appraise the evidence for the use of  acupuncture for symptom management in cancer and supportive care and to identify  recommendations for clinical practice and future research. METHODS: A systematic  search was carried out to identify reviews of the use of acupuncture in cancer  supportive and palliative care, using MEDLINE, EMBASE, CINAHL, Web of Science,  Cochrane Library, British Nursing Index, Index to Theses, Dissertations and  Theses (via Proquest) and NHS evidence. Search terms included: acupuncture,  cancer and symptoms. Data were extracted for analysis. Reviews were assessed for  quality using a five-item checklist but were not excluded from the review on  grounds of quality, in order to include a comprehensive scope of the subject.  RESULTS: Seventeen reviews were included in the review. Evidence was found for  the use of acupuncture for treatment-related nausea and vomiting. Benefit was  reported for other cancer-related symptoms, including pain, fatigue, hot flushes,  xerostomia, dyspnoea and anxiety. Reviewers found a paucity of rigorous trials  and heterogeneity of populations, interventions, controls and outcome measures,  which challenge the process of systematic review and meta-analysis. CONCLUSION:  Acupuncture should be considered for symptom management where there are limited  treatment options, using current peer-reviewed guidelines and clinical reasoning.  Much of the primary research reported in reviews is innovative and indicates  potential benefit for people with cancer-related symptoms. The complexity of  acupuncture as an intervention needs to be acknowledged in future research  designs and when reviewing research findings. An iterative approach using  adequate interventions, appropriate outcome measures and adherence to reporting  standards is required to evaluate the efficacy of acupuncture in cancer  supportive and palliative care.
C1 University of Manchester, Manchester, UK.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD JUL 23
PY 2013
VL 21
IS 10
BP 2913
EP 23
DI 10.1007/s00520-013-1882-8
PG -2890
WC Acupuncture Therapy; methods; Evidence-Based Medicine; Humans; Neoplasms; therapy; Palliative Care; methods
UT PubMed:23868190
PM 23868190
DA 2013-07-23
ER

PT J
AU MacPherson, H
   Tilbrook, HE
   Richmond, SJ
   Atkin, K
   Ballard, K
   Bland, M
   Eldred, J
   Essex, HN
   Hopton, A
   Lansdown, H
   Muhammad, U
   Parrott, S
   Torgerson, D
   Wenham, A
   Woodman, J
   Watt, I
AF MacPherson, Hugh
   Tilbrook, Helen E.
   Richmond, Stewart J.
   Atkin, Karl
   Ballard, Kathleen
   Bland, Martin
   Eldred, Janet
   Essex, Holly N.
   Hopton, Ann
   Lansdown, Harriet
   Muhammad, Usman
   Parrott, Steve
   Torgerson, David
   Wenham, Aniela
   Woodman, Julia
   Watt, Ian
TI Alexander Technique Lessons, Acupuncture Sessions or usual care for patients with chronic neck pain (ATLAS): study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Article
ID back-pain; initial validation; cost-effectiveness; cognitive-factors; chronic headache; massage ateam; exercise; disability; outcm; work
AB Background: Chronic neck pain is a common condition in the adult population. More research is needed to evaluate interventions aiming to facilitate beneficial long-term change. We propose to evaluate the effect of Alexander Technique lessons and acupuncture in a rigorously conducted pragmatic trial with an embedded qualitative study. Methods/Design: We will recruit 500 patients who have been diagnosed with neck pain in primary care, who have continued to experience neck pain for at least three months with 28% minimum cut-off score on the Northwick Park Neck Pain Questionnaire (NPQ). We will exclude patients with serious underlying pathology, prior cervical spine surgery, history of psychosis, rheumatoid arthritis, ankylosing spondylitis, osteoporosis, haemophilia, cancer, HIV or hepatitis, or with alcohol or drug dependency currently or in the last 12 months, or actively pursuing compensation or with pending litigation. The York Trials Unit will randomly allocate participants using a secure computer-based system. We will use block randomisation with allocation to each intervention arm being unambiguously concealed from anyone who might subvert the randomisation process. Participants will be randomised in equal proportions to Alexander Technique lessons, acupuncture or usual care alone. Twenty 30-minute Alexander Technique lessons will be provided by teachers registered with the Society of Teachers of the Alexander Technique and twelve 50-minute sessions of acupuncture will be provided by acupuncturists registered with the British Acupuncture Council. All participants will continue to receive usual GP care. The primary outcome will be the NPQ at 12 months, with the secondary time point at 6 months, and an area-undercurve analysis will include 3, 6 and 12 month time-points. Adverse events will be documented. Potential intervention effect modifiers and mediators to be explored include: self-efficacy, stress management, and the incorporation of practitioner advice about self-care and lifestyle. Qualitative material will be used to address issues of safety, acceptability and factors that impact on longer term outcomes. Discussion: This study will provide robust evidence on whether there are significant clinical benefits to patients, economic benefits demonstrating value for money, and sufficient levels of acceptability and safety.
C1 [MacPherson, Hugh; Tilbrook, Helen E.; Richmond, Stewart J.; Atkin, Karl; Bland, Martin; Eldred, Janet; Essex, Holly N.; Hopton, Ann; Lansdown, Harriet; Muhammad, Usman; Parrott, Steve; Torgerson, David; Wenham, Aniela; Woodman, Julia; Watt, Ian] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.
   [Ballard, Kathleen; Woodman, Julia] Soc Teachers Alexander Tech, London NW5 1RS, England.
   [Watt, Ian] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England.
C3 University of York - UK; University of York - UK; University of Hull
RP MacPherson, H (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.
EM hugh.macpherson@york.ac.uk
FU Arthritis Research UK [19702]; Arthritis Research UK's Musculoskeletal Pain Clinic Studies Group; Cancer Research UK; Versus Arthritis [19702] Funding Source: researchfish
CR ANDERSON KO, 1995, PAIN, V63, P77, DOI 10.1016/0304-3959(95)00021-J
   Bakker AB, 2008, J VOCAT BEHAV, V72, P400, DOI 10.1016/j.jvb.2007.11.007
   Binder AI, 2007, BMJ-BRIT MED J, V334, P527, DOI 10.1136/bmj.39127.608299.80
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Dziedzic K, 2005, ARTHRIT RHEUM-ARTHR, V53, P214, DOI 10.1002/art.21087
   Ferrari R, 2003, BEST PRACT RES CL RH, V17, P57, DOI 10.1016/S1521-6942(02)00097-9
   Gross A, 2010, MANUAL THER, V15, P315, DOI 10.1016/j.math.2010.04.002
   Gustavsson C, 2010, EUR J PAIN, V14, P0, DOI 10.1016/j.ejpain.2009.10.004
   Hewitt CE, 2006, CAN MED ASSOC J, V175, P347, DOI 10.1503/cmaj.051625
   Hollinghurst Sandra, 2008, BMJ, V337, Pa2656, DOI 10.1136/bmj.a2656
   HOUTMAN ILD, 1994, SCAND J WORK ENV HEA, V20, P139, DOI 10.5271/sjweh.1419
   Hsu C, 2010, J ALTERN COMPLEM MED, V16, P157, DOI 10.1089/acm.2009.0188
   Hurwitz EL, 2006, DISABIL REHABIL, V28, P1319, DOI 10.1080/09638280600641509
   Jones FP, 1997, FREEDOM CHANGE DEV S, V3rd, P0
   Kind P, 1996, QUALITY LIFE PHARMAC, V2, P191
   Korhonen T, 2003, OCCUP ENVIRON MED, V60, P475, DOI 10.1136/oem.60.7.475
   LEAK AM, 1994, BRIT J RHEUMATOL, V33, P469
   Linton JS, 2000, EUR J PAIN-LONDON, V4, P347, DOI 10.1053/eujp.2000.0190
   Little P, 2008, BMJ-BRIT MED J, V337, P0, DOI 10.1136/bmj.a884
   Maciocia Giovanni, 1989, FDN CHINESE MED, V0, P0
   MacPherscon H, 2008, COMPLEMENT THER MED, V16, P101, DOI 10.1016/j.ctim.2008.02.010
   MacPherson H, 2004, QUAL SAF HEALTH CARE, V13, P349, DOI 10.1136/qshc.2003.009134
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   MacPherson H, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-209
   MacPherson H, 2010, BMC GASTROENTEROL, V10, P0, DOI 10.1186/1471-230X-10-63
   Mitchell AM, 2008, RES NURS HEALTH, V31, P576, DOI 10.1002/nur.20284
   Moffett JAK, 2005, BRIT MED J, V330, P75, DOI 10.1136/bmj.38286.493206.82
   Moffett JK, 2006, RHEUMATOLOGY OXFORD, V45, P1514
   National Collaborating Centre for Mental Health, 1900, P1, V0, P0
   National Institute for Health and Clincal Excellence, 2009, LOW BACK PAIN EARL M, V0, P0
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Ratcliffe J, 2006, BRIT MED J, V333, P626, DOI 10.1136/bmj.38932.806134.7C
   Salter GC, 2006, BMC MUSCULOSKEL DIS, V7, P0, DOI 10.1186/1471-2474-7-99
   Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C
   Thompson DP, 2010, DISABIL REHABIL, V32, P1758, DOI 10.3109/09638281003734342
   Torgerson D, 1999, BMJ-BRIT MED J, V318, P1413, DOI 10.1136/bmj.318.7195.1413
   Trinh KV, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004870.pub3
   Vickers AJ, 2004, BRIT MED J, V328, P744, DOI 10.1136/bmj.38029.421863.EB
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
   Willich SN, 2006, PAIN, V125, P107, DOI 10.1016/j.pain.2006.06.006
   Witt CM, 2006, PAIN, V125, P98, DOI 10.1016/j.pain.2006.05.013
   Woby SR, 2007, EUR J PAIN, V11, P869, DOI 10.1016/j.ejpain.2007.01.005
   Wonderling D, 2004, BMJ-BRIT MED J, V328, P747, DOI 10.1136/bmj.38033.896505.EB
   Yardley L, 2010, FAM PRACT, V27, P198, DOI 10.1093/fampra/cmp093
NR 45
TC 18
Z9 18
U1 1
U2 61
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 10
PY 2013
VL 14
IS 
BP 
EP 
DI 10.1186/1745-6215-14-209
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 187OJ
UT WOS:000322128100001
PM 23841901
DA 2026-01-16
ER

PT J
AU Oh, B
   Kimble, B
   Costa, DS
   Davis, E
   McLean, A
   Orme, K
   Beith, J
AF Oh, B
   Kimble, B
   Costa, D S J
   Davis, E
   McLean, A
   Orme, K
   Beith, J
TI Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE COMPLEMENTARY MEDICINE; PAIN MANAGEMENT; PAIN RESEARCH; THERAPEUTICS
AB BACKGROUND: Aromatase inhibitors (AIs) are recommended as adjuvant hormone  treatment for postmenopausal women with early breast cancer. A substantial  proportion of women taking AIs experience joint pain and stiffness. Studies have  suggested that acupuncture may be effective in treating joint pain. OBJECTIVE: A  pilot study was conducted to evaluate the feasibility, safety and efficacy of  using acupuncture to treat AI-induced arthralgia. METHODS: A total of 32 patients  were randomised to receive either sham or real electroacupuncture (EA) twice  weekly for 6 weeks. Outcomes of joint pain, stiffness and physical function were  measured with the Western Ontario and McMaster Universities Osteoarthritis Index  (WOMAC), overall pain severity and interference with the BPI-SF and quality of  life (QOL) with the Functional Assessment of Cancer Therapy-General (FACT-G)  instrument. Hand strength was assessed by a grip test, and a serum marker of  inflammation (C reactive protein (CRP)) was also measured. All assessments were  performed at baseline, 6 weeks and 12 weeks, except for blood samples at baseline  and 6 weeks only. RESULTS: No serious adverse events were reported during or  after acupuncture treatments. There were no significant differences in outcome  measures. However, positive trends were observed in stiffness and physical  function at week 12 in favour of real EA. CONCLUSIONS: Findings suggest that  acupuncture is feasible and safe in patients with breast cancer with joint pain  caused by AI. A larger study with adequately powered to confirm these results and  detect clinically relevant effects is needed.
C1 Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD JUN 1
PY 2013
VL 31
IS 3
BP 264
EP 71
DI 10.1136/acupmed-2012-010309
PG -193
WC Activities of Daily Living; Adult; Aromatase; metabolism; Aromatase Inhibitors; adverse effects; Arthralgia; etiology; Breast Neoplasms; drug therapy; Electroacupuncture; Female; Humans; Middle Aged; Pilot Projects; Quality of Life; Range of Motion, Articular; Severity of Illness Index
UT PubMed:23722951
PM 23722951
DA 2013-06-01
ER

PT J
AU Collinge, W
   Kahn, J
   Walton, T
   Kozak, L
   Bauer-Wu, S
   Fletcher, K
   Yarnold, P
   Soltysik, R
AF Collinge, William
   Kahn, Janet
   Walton, Tracy
   Kozak, Leila
   Bauer-Wu, Susan
   Fletcher, Kenneth
   Yarnold, Paul
   Soltysik, Robert
TI Touch, Caring, and Cancer: randomized controlled trial of a multimedia caregiver education program
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Caregiver education; Oncology massage; Palliative care; Psychosocial oncology; Family caregivers
ID quality-of-life; breast-cancer; therapeutic massage; adjustment; reflexology; mastectomy; pain; nausea; women
AB A randomized controlled trial was conducted to evaluate outcomes of a multimedia instructional program for family caregivers in simple touch-based techniques to provide comfort to cancer patients at home. A multilingual 78-min DVD and 66-page manual were produced for homebased instruction. Content addresses attitudes and communication about touch in cancer, psychological preparation for giving and receiving touch, safety precautions, massage techniques for comfort and relaxation, acupressure for specific cancer-related symptoms, and practice in the home setting. Materials were produced in English, Spanish, and Chinese versions. A community-based multiethnic sample of 97 adult patient/caregiver dyads was randomized to experimental (massage) or attention control (reading) groups for 4 weeks. Massage dyads received the program and instructions to practice at least three times per week, while control caregivers read to their patients for the same frequency. Self-report instruments assessed change in symptom severity, quality of life, perceived stress, and caregiver attitudes. Significant reductions in all symptoms occurred for patients after both activities: 12-28 % reductions after reading vs. 29-44 % after massage. Massage caregivers showed significant gains in confidence, comfort, and self-efficacy using touch and massage as forms of caregiving. Multimedia instruction in touch and massage methods may offer family members a viable means of enhancing self-efficacy and satisfaction in caregiving while decreasing patient pain, depression, and other symptoms. Family members may be able to learn and apply safe and simple methods that increase patient comfort and reduce distress.
C1 [Collinge, William] Collinge & Associates, Eugene, OR 97405 USA.
   [Kahn, Janet] Integrat Consulting, Burlington, VT 05401 USA.
   [Walton, Tracy] Tracy Walton & Associates LLC, Cambridge, MA 02140 USA.
   [Kozak, Leila] VA Puget Sound Hlth Care Syst HSR&D, VAPSHCS, Ctr Excellence Outcomes Res Older Adults, Seattle, WA USA.
   [Bauer-Wu, Susan] Emory Univ, Woodruff Sch Nursing, Atlanta, GA 30306 USA.
   [Fletcher, Kenneth] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01606 USA.
   [Yarnold, Paul] Optimal Data Anal LLC, San Diego, CA 92106 USA.
C3 Emory University; University of Massachusetts System; University of Massachusetts Worcester
RP Collinge, W (corresponding author), Collinge & Associates, 3986 N Shasta Loop, Eugene, OR 97405 USA.
EM william@collinge.org
FU Multimedia Technology Health Communication SBIR/STTR Grants; Health Communication Informatics Research Branch; Behavioral Research Program; Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, USA;  [R44CA103606-3]
CR Unknown -, 1900, DOI 10.1177/1049909108322292, V0, P0
   BAIDER L, 1988, ISRAEL J MED SCI, V24, P631
   BAIDER L, 1984, INT J PSYCHIAT MED, V14, P265, DOI 10.2190/WVVE-D9CF-VN7F-L4D7
   Billhult Annika, 2007, CLIN NURS RES, V16, P85, DOI 10.1177/1054773806298488
   Billhult A, 2007, J ALTERN COMPLEM MED, V13, P53, DOI 10.1089/acm.2006.6049
   Campeau Marie-Pierre, 2007, J SOC INTEGR ONCOL, V5, P133, DOI 10.2310/7200.2007.018
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Collinge William, 2007, J SOC INTEGR ONCOL, V5, P147, DOI 10.2310/7200.2007.013
   Demmer Craig, 2004, J PALLIAT MED, V7, P510, DOI 10.1089/1096621041838335
   Field TM, 1998, J APPL GERONTOL, V17, P229, DOI 10.1177/073346489801700210
   GIVEN CW, 1992, RES NURS HEALTH, V15, P271, DOI 10.1002/nur.4770150406
   Grealish L, 2000, CANCER NURS, V23, P237, DOI 10.1097/00002820-200006000-00012
   Keller M, 1998, PSYCHOTHER PSYCH MED, V48, P358
   Kirschner-Hermanns R, 2002, CRIT REV ONCOL HEMAT, V43, P141, DOI 10.1016/S1040-8428(02)00026-4
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Listing M, 2010, ARCH WOMEN MENT HLTH, V13, P165, DOI 10.1007/s00737-009-0143-9
   Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508
   McCorkle R, 2001, CANCER CONTROL, V8, P36
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Northouse LL, 2000, SOC SCI MED, V50, P271, DOI 10.1016/S0277-9536(99)00281-6
   OMNEPONTEN M, 1993, EUR J CANCER, V29A, P1393, DOI 10.1016/0959-8049(93)90009-5
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Poulin MJ, 2010, PSYCHOL AGING, V25, P108, DOI 10.1037/a0018064
   Ross CSK, 2002, PALLIATIVE MED, V16, P544, DOI 10.1191/0269216302pm597xx
   Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006
   Smith MC, 2002, J NURS SCHOLARSHIP, V34, P257, DOI 10.1111/j.1547-5069.2002.00257.x
   Stephenson N, 2003, APPL NURS RES, V16, P284, DOI 10.1016/j.apnr.2003.08.003
   Stephenson N L, 2000, ONCOL NURS FORUM, V27, P67
   Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132
   Stringer J, 2008, PSYCHO-ONCOL, V17, P1024, DOI 10.1002/pon.1331
   Sturgeon M, 2009, J ALTERN COMPLEM MED, V15, P373, DOI 10.1089/acm.2008.0399
   Weinrich S P, 1990, APPL NURS RES, V3, P140, DOI 10.1016/S0897-1897(05)80135-1
   WELLISCH DK, 1978, AM J PSYCHIAT, V135, P543
   Wilkie D J, 2000, HOSP J, V15, P31
   Yarnold PR, 1997, STAT MED, V16, P1451, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1451::AID-SIM571>3.0.CO;2-F
   YARNOLD PR, 2005, OPTIMAL DATA ANALYSI, V0, P0
NR 38
TC 47
Z9 60
U1 0
U2 48
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAY 15
PY 2013
VL 21
IS 5
BP 1405
EP 1414
DI 10.1007/s00520-012-1682-6
PG 10
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 117OK
UT WOS:000316962600025
PM 23262808
DA 2026-01-16
ER

PT J
AU Deng, G
   Wong, WD
   Guillem, J
   Chan, Y
   Affuso, T
   Yeung, KS
   Coleton, M
   Sjoberg, D
   Vickers, A
   Cassileth, B
AF Deng, Gary
   Wong, W. Douglas
   Guillem, Jose
   Chan, Yi
   Affuso, Theresa
   Yeung, K. Simon
   Coleton, Marci
   Sjoberg, Daniel
   Vickers, Andrew
   Cassileth, Barrie
TI A Phase II, Randomized, Controlled Trial of Acupuncture for Reduction of Postcolectomy Ileus
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID major abdominal-surgery; mu-opioid antagonist; postoperative ileus; alvimopan; recovery; electroacupuncture; stimulation; efficacy
AB Postoperative ileus (POI) prolongs hospital stay and increases risk of postoperative complications. We conducted a randomized, sham-controlled trial to evaluate whether acupuncture reduces POI more effectively than sham acupuncture. Colon cancer patients undergoing elective colectomy were randomized to receive 30 min of true or sham acupuncture twice daily during their first 3 postoperative days. GI-3 (the later of the following two events: time that the patient first tolerated solid food, AND time that the patient first passed flatus OR a bowel movement) and GI-2 (the later of the following two events: time patient first tolerated solid food AND time patient first passed a bowel movement) were determined. Pain, nausea, vomiting, and use of pain medications were evaluated daily for the first 3 postoperative days. Ninety patients were randomized. Eighty-one received the allocated intervention: 39 in the true acupuncture group and 42 in the sham acupuncture group, all evaluated for the primary endpoint. The mean time to GI-3 was 149 h [standard deviation (SD) 71 h] and 146 (SD 62 h) after surgery for the acupuncture group and the sham acupuncture group (difference between means -2 h; 95 % confidence interval -31, 26; p = 0.9). No significant differences were found between groups for secondary endpoints. True acupuncture as provided in this study did not reduce POI more significantly than sham acupuncture. The study was limited by a standard deviation much larger than expected, suggesting that a study with a larger sample size might be required.
C1 [Deng, Gary; Chan, Yi; Affuso, Theresa; Yeung, K. Simon; Coleton, Marci; Cassileth, Barrie] Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA.
   [Wong, W. Douglas; Guillem, Jose] Mem Sloan Kettering Canc Ctr, Colorectal Surg Serv, New York, NY 10021 USA.
   [Sjoberg, Daniel; Vickers, Andrew] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Deng, G (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.
EM dengg@mskcc.org
FU National Institutes of Health [R21CA122199]; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Balestrini JL, 2005, SCAND J GASTROENTERO, V40, P734, DOI 10.1080/00365520510015719
   Chang CS, 2001, DIGESTION, V64, P184, DOI 10.1159/000048860
   Chen LL, 2003, AM J CHINESE MED, V31, P781, DOI 10.1142/S0192415X03001466
   Choi M, 2001, J VET SCI, V2, P221
   Chou JW, 2003, HEPATO-GASTROENTEROL, V50, P582
   Delaney CP, 2005, DIS COLON RECTUM, V48, P1114, DOI 10.1007/s10350-005-0035-7
   Delaney CP, 2005, DIS COLON RECTUM, V48, P1127
   Holte K, 2002, DRUGS, V62, P2603, DOI 10.2165/00003495-200262180-00004
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   LAO LX, 1995, ORAL SURG ORAL MED O, V79, P423, DOI 10.1016/S1079-2104(05)80121-0
   Liu J X, 1991, ZHONG XI YI JIE HE ZA ZHI, V11, P156
   LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Purkayastha S, 2008, ARCH SURG-CHICAGO, V143, P788, DOI 10.1001/archsurg.143.8.788
   Scott AM, 1996, SURGERY, V120, P688, DOI 10.1016/S0039-6060(96)80018-3
   Sugai GCM, 2004, PHYSIOL BEHAV, V82, P855, DOI 10.1016/j.physbeh.2004.07.003
   Tabosa A, 2002, BRAZ J MED BIOL RES, V35, P731, DOI 10.1590/S0100-879X2002000600015
   Wan Q, 2000, J TRADIT CHIN MED, V20, P134
   Wolff BG, 2004, ANN SURG, V240, P728, DOI 10.1097/01.sla.0000141158.27977.66
   Wolff BG, 2007, J AM COLL SURGEONS, V205, P43, DOI 10.1016/j.jamcollsurg.2007.02.026
   Zhao Q, 1991, ZHONG XI YI JIE HE Z, V11, P133
NR 22
TC 32
Z9 37
U1 0
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR 15
PY 2013
VL 20
IS 4
BP 1164
EP 1169
DI 10.1245/s10434-012-2759-7
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA 109TV
UT WOS:000316392600018
PM 23188543
DA 2026-01-16
ER

PT J
AU Ng, SSM
   Leung, WW
   Mak, TWC
   Hon, SSF
   Li, JCM
   Wong, CYN
   Tsoi, KKF
   Lee, JFY
AF Ng, Simon S. M.
   Leung, Wing Wa
   Mak, Tony W. C.
   Hon, Sophie S. F.
   Li, Jimmy C. M.
   Wong, Cherry Y. N.
   Tsoi, Kelvin K. F.
   Lee, Janet F. Y.
TI Electroacupuncture Reduces Duration of Postoperative Ileus After Laparoscopic Surgery for Colorectal Cancer
SO GASTROENTEROLOGY
LA English
DT Article
DE Colon Cancer; Therapy; Recovery Time; Gastrointestinal Motility
ID functional gastrointestinal disorders; randomized controlled-trial; colonic surgery; conscious rats; acupuncture; placebo; pain
AB BACKGROUND & AIMS: We investigated the efficacy of electroacupuncture in reducing the duration of postoperative ileus and hospital stay after laparoscopic surgery for colorectal cancer. METHODS: We performed a prospective study of 165 patients undergoing elective laparoscopic surgery for colonic and upper rectal cancer, enrolled from October 2008 to October 2010. Patients were assigned randomly to groups that received electroacupuncture (n = 55) or sham acupuncture (n = 55), once daily from postoperative days 1 - 4, or no acupuncture (n = 55). The acupoints Zusanli, Sanyinjiao, Hegu, and Zhigou were used. The primary outcome was time to defecation. Secondary outcomes included postoperative analgesic requirement, time to ambulation, and length of hospital stay. RESULTS: Patients who received electroacupuncture had a shorter time to defecation than patients who received no acupuncture (85.9 +/- 36.1 vs 122.1 +/- 53.5 h; P < .001) and length of hospital stay (6.5 +/- 2.2 vs 8.5 +/- 4.8 days; P = .007). Patients who received electroacupuncture also had a shorter time to defecation than patients who received sham acupuncture (85.9 +/- 36.1 vs 107.5 +/- 46.2 h; P = .007). Electroacupuncture was more effective than no or sham acupuncture in reducing postoperative analgesic requirement and time to ambulation. In multiple linear regression analysis, an absence of complications and electroacupuncture were associated with a shorter duration of postoperative ileus and hospital stay after the surgery. CONCLUSIONS: In a clinical trial, electroacupuncture reduced the duration of postoperative ileus, time to ambulation, and postoperative analgesic requirement, compared with no or sham acupuncture, after laparoscopic surgery for colorectal cancer. ClinicalTrials.gov number, NCT00464425.
C1 [Ng, Simon S. M.; Leung, Wing Wa; Mak, Tony W. C.; Hon, Sophie S. F.; Li, Jimmy C. M.; Wong, Cherry Y. N.; Tsoi, Kelvin K. F.; Lee, Janet F. Y.] Chinese Univ Hong Kong, Prince Wales Hosp, Div Colorectal Surg, Dept Surg, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital Hong Kong
RP Ng, SSM (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Div Colorectal Surg, Dept Surg, Room 64045,4-F Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM simonng@surgery.cuhk.edu.hk
FU Health and Health Services Research Fund, Food and Health Bureau, Hong Kong SAR Government [06070371]
CR Bonjer HJ, 2005, LANCET ONCOL, V6, P477, DOI 10.1016/S1470-2045(05)70221-7
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Bungard TJ, 1999, PHARMACOTHERAPY, V19, P416, DOI 10.1592/phco.19.6.416.31040
   Gouvas N, 2009, INT J COLORECTAL DIS, V24, P1119, DOI 10.1007/s00384-009-0703-5
   Guillou PJ, 2005, LANCET, V365, P1718, DOI 10.1016/S0140-6736(05)66545-2
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Holzer P, 2004, NEUROSCI LETT, V361, P192, DOI 10.1016/j.neulet.2003.12.004
   Iwa M, 2006, AM J PHYSIOL-GASTR L, V290, PG285, DOI 10.1152/ajpgi.00068.2005
   Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a
   Kehlet H, 2008, LANCET, V371, P791, DOI 10.1016/S0140-6736(08)60357-8
   Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003
   Lee SWH, 2011, ACUPUNCT MED, V29, P40, DOI 10.1136/aim.2010.003137
   Leung KL, 2004, LANCET, V363, P1187, DOI 10.1016/S0140-6736(04)15947-3
   Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0
   Liu J X, 1991, ZHONG XI YI JIE HE ZA ZHI, V11, P156
   Luo D, 2008, DIGEST DIS SCI, V53, P689, DOI 10.1007/s10620-007-9929-7
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Ouyang H, 2004, ALIMENT PHARM THER, V20, P831, DOI 10.1111/j.1365-2036.2004.02196.x
   Person B, 2006, CURR PROB SURG, V43, P6, DOI 10.1067/j.cpsurg.2005.10.003
   Reza MM, 2006, BRIT J SURG, V93, P921, DOI 10.1002/bjs.5430
   Tabosa A, 2002, BRAZ J MED BIOL RES, V35, P731, DOI 10.1590/S0100-879X2002000600015
   Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6
   Tan EK, 2007, ALIMENT PHARM THER, V25, P47, DOI 10.1111/j.1365-2036.2006.03150.x
   VINCENT C, 1995, J ROY SOC MED, V88, P199
   Vlug MS, 2009, COLORECTAL DIS, V11, P335, DOI 10.1111/j.1463-1318.2008.01679.x
   Wan Q, 2000, J TRADIT CHIN MED, V20, P134
   Wind J, 2006, BRIT J SURG, V93, P800, DOI 10.1002/bjs.5384
   Xu Hong-Yan, 2007, ZHONGGUO ZHEN JIU, V27, P103
   [张智龙 ZHANG Zhilong], 2007, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V27, P475
   Zhao Q, 1991, ZHONG XI YI JIE HE Z, V11, P133
NR 30
TC 135
Z9 169
U1 3
U2 83
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD FEB 15
PY 2013
VL 144
IS 2
BP 307
EP +
DI 10.1053/j.gastro.2012.10.050
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 086VL
UT WOS:000314716300024
PM 23142625
DA 2026-01-16
ER

PT J
AU Azad, A
   John, T
AF Azad, Arun
   John, Thomas
TI Do Randomized Acupuncture Studies in Patients With Cancer Need a Sham Acupuncture Control Arm?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
ID radiation-induced xerostomia; low-back-pain; controlled-trial; breast-cancer; auricular acupuncture; placebo-acupuncture; induced nausea; hot flashes; chemotherapy; electroacupuncture
C1 [Azad, Arun] Austin Hlth, Joint Austin Ludwig Oncol Unit, Melbourne, Vic, Australia.
   Austin Hlth, Ludwig Inst Canc Res, Melbourne, Vic, Australia.
C3 Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates; Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates; Austin Research Institute; Ludwig Institute for Cancer Research
RP Azad, A (corresponding author), Austin Hlth, Joint Austin Ludwig Oncol Unit, Melbourne, Vic, Australia.
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Bao T, 2011, J PAIN SYMPTOM MANAG, V41, P995, DOI 10.1016/j.jpainsymman.2010.08.012
   Blom M, 1996, ORAL ONCOL, V32B, P182
   Carpenter JS, 2002, CANCER NURS, V25, P104, DOI 10.1097/00002820-200204000-00005
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Cho JH, 2008, J ALTERN COMPLEM MED, V14, P523, DOI 10.1089/acm.2007.0793
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Enblom A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014766
   Gan TJ, 2004, ANESTH ANALG, V99, P1070, DOI 10.1213/01.ANE.0000130355.91214.9E
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Lu WD, 2009, J ALTERN COMPLEM MED, V15, P745, DOI 10.1089/acm.2008.0589
   Meng ZQ, 2012, EUR J CANCER, V48, P1692, DOI 10.1016/j.ejca.2011.12.030
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Roscoe JA, 2005, J PAIN SYMPTOM MANAG, V29, P376, DOI 10.1016/j.jpainsymman.2004.07.007
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Vickers Andrew J, 2005, BMC PALLIAT CARE, V4, P5, DOI 10.1186/1472-684X-4-5
   White AR, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000009.pub3
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Yeh CH, 2012, J ALTERN COMPLEM MED, V18, P334, DOI 10.1089/acm.2011.0102
NR 29
TC 13
Z9 14
U1 1
U2 28
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 1
PY 2013
VL 31
IS 16
BP 2057
EP 2058
DI 10.1200/JCO.2012.47.8750
PG 2
WC Oncology
SC Oncology
GA 154FP
UT WOS:000319657600032
PM 23610109
DA 2026-01-16
ER

PT J
AU Lu, W
   Rosenthal, DS
AF Lu, Weidong
   Rosenthal, David S
TI Acupuncture for cancer pain and related symptoms.
SO Current pain and headache reports
LA English
DT Review
AB Cancer pain is one of most prevalent symptoms in patients with cancer.  Acupuncture and related techniques have been suggested for the management of  cancer pain. The National Comprehensive Cancer Network guidelines for adult  cancer pain recommends acupuncture, as one of several integrative interventions,  in conjunction with pharmacologic intervention as needed. This review presents  the latest available evidence regarding the use of acupuncture for cancer pain.  It also provides "actionable" acupuncture protocols for specific cancer pain  conditions and related symptoms in order to provide more clinically relevant  solutions for clinicians and cancer patients with pain. These conditions include  postoperative cancer pain, postoperative nausea and vomiting, postsurgical  gastroparesis syndrome, opioid-induced constipation, opioid-induced pruritus,  chemotherapy-induced neuropathy, aromatase inhibitor-associated joint pain, and  neck dissection-related pain and dysfunction.
C1 Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. weidong_lu@dfci.harvard.edu
NR 0
TC 0
SN 1534-308
EI 1531-343
J9 Curr Pain Headache Rep
PD JAN 23
PY 2013
VL 17
IS 3
BP 321
EP 321
DI 10.1007/s11916-013-0321-3
PG 0
WC Acupuncture Therapy; methods; Analgesics, Opioid; administration & dosage; Antineoplastic Agents; administration & dosage; Female; Guidelines as Topic; Humans; Male; Nausea; chemically induced; Neoplasms; complications; Pain Management; methods; Pain, Intractable; drug therapy; Treatment Outcome; United States; Vomiting; chemically induced
UT PubMed:23338773
PM 23338773
DA 2013-01-23
ER

PT J
AU Bao, T
   Cai, L
   Giles, JT
   Gould, J
   Tarpinian, K
   Betts, K
   Medeiros, M
   Jeter, S
   Tait, N
   Chumsri, S
   Armstrong, DK
   Tan, M
   Folkerd, E
   Dowsett, M
   Singh, H
   Tkaczuk, K
   Stearns, V
AF Bao, Ting
   Cai, Ling
   Giles, Jon T.
   Gould, Jeff
   Tarpinian, Karineh
   Betts, Kelly
   Medeiros, Michelle
   Jeter, Stacie
   Tait, Nancy
   Chumsri, Saranya
   Armstrong, Deborah K.
   Tan, Ming
   Folkerd, Elizabeth
   Dowsett, Mitch
   Singh, Harvinder
   Tkaczuk, Kate
   Stearns, Vered
TI A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Acupuncture; Aromatase inhibitor; Musculoskeletal symptoms
ID joint symptoms; women; serum; associations; disability; antibody; therapy; il-17
AB Up to 50 % of women receiving aromatase inhibitor (AI) complain of AI-associated musculoskeletal symptoms (AIMSS) and 15 % discontinue treatment. We conducted a randomized, sham-controlled trial to evaluate whether acupuncture improves AIMSS and to explore potential mechanisms. Postmenopausal women with early stage breast cancer, experiencing AIMSS were randomized to eight weekly real or sham acupuncture sessions. We evaluated changes in the Health Assessment Questionnaire Disability Index (HAQ-DI) and pain visual analog scale (VAS) following the intervention compared to baseline. Serum estradiol, beta-endorphin, and proinflammatory cytokine concentrations were measured pre and post-intervention. We enrolled 51 women of whom 47 were evaluable, including 23 randomized to real and 24 to sham acupuncture. Baseline characteristics were balanced between groups with the exception of a higher HAQ-DI score in the real acupuncture group (p = 0.047). We did not observe a statistically significant difference in reduction of HAQ-DI (p = 0.30) or VAS (p = 0.31) between the two groups. Following eight weekly treatments, we observed a statistically significant reduction of IL-17 (p a parts per thousand currency sign 0.009) in both groups. No significant modulation was seen in estradiol, beta-endorphin, or other proinflammatory cytokine concentrations in either group. We did not observe a significant difference in AIMSS changes between real and sham acupuncture. As sham acupuncture used in this study may not be equivalent to placebo, further studies with a non-acupuncture arm may be required to establish whether acupuncture is beneficial for the treatment of AIMSS.
C1 [Bao, Ting; Cai, Ling; Betts, Kelly; Medeiros, Michelle; Tait, Nancy; Chumsri, Saranya; Tan, Ming; Singh, Harvinder; Tkaczuk, Kate] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 20201 USA.
   [Giles, Jon T.] Columbia Univ, Div Rheumatol, New York, NY 10032 USA.
   [Gould, Jeff; Tarpinian, Karineh; Jeter, Stacie; Armstrong, Deborah K.; Stearns, Vered] Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins Sch Med, Baltimore, MD 21231 USA.
   [Folkerd, Elizabeth; Dowsett, Mitch] Royal Marsden Hosp, Acad Dept Biochem, London SW3 6JJ, England.
C3 University System of Maryland; University of Maryland Baltimore; Columbia University; Johns Hopkins University; Johns Hopkins Medicine; Royal Marsden NHS Foundation Trust
RP Bao, T (corresponding author), Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 20201 USA.
EM tbao@umm.edu
FU ASCO Foundation Young Investigator's Award; Susan Komen Postdoctoral Fellowship Award; Breast Cancer Research Foundation; Maryland Affiliate of Susan G. Komen for the Cure Craft grant; Novartis; GSK; Merck; AstraZeneca; Pfizer; National Institute for Health Research [NF-SI-0512-10122] Funding Source: researchfish
CR Arican O, 2005, MEDIAT INFLAMM, V0, PP273, DOI 10.1155/MI.2005.273
   Berk DR, 2006, J GERONTOL A-BIOL, V61, P97, DOI 10.1093/gerona/61.1.97
   Bruce Bonnie, 2003, HEALTH QUAL LIFE OUTCOMES, V1, P20, DOI 10.1186/1477-7525-1-20
   Burstein HJ, 2007, BREAST, V16, P223, DOI 10.1016/j.breast.2007.01.011
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   CHEN XH, 1992, EUR J PHARMACOL, V211, P203
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cuzick J, 2008, LANCET, V371, P2156, DOI 10.1016/S0140-6736(08)60933-2
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Harris RE, 2005, J ALTERN COMPLEM MED, V11, P663, DOI 10.1089/acm.2005.11.663
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Henry NL, 2008, ONCOLOGY-NY, V22, P1401
   Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064
   Khan QJ, 2012, J CLIN ONCOL S, V30, P0
   Krishnan E, 2004, ARTHRITIS RHEUM-US, V50, P953, DOI 10.1002/art.20048
   Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997
   Liu MH, 2012, BREAST CANCER RES, V14, P0, DOI 10.1186/bcr3137
   Maciocia G, 2005, FOUNDATIONS OF CHINESE MEDICINE: A COMPREHENSIVE TEXT FOR ACUPUNCTURISTS AND HERBALISTS, V0, P0
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017
   Partridge AH, 2003, J CLIN ONCOL, V21, P602, DOI 10.1200/JCO.2003.07.071
   Rosu A, 2012, ROM J MORPHOL EMBRYO, V53, P73
   Singh S, 2012, BREAST CANCER RES TR, V132, P625, DOI 10.1007/s10549-011-1911-6
   Vas J, 2012, PAIN, V153, P1883, DOI 10.1016/j.pain.2012.05.033
   Wolfe F, 2005, J RHEUMATOL, V32, P583
   Wu MT, 2002, NEUROIMAGE, V16, P1028, DOI 10.1006/nimg.2002.1145
NR 29
TC 74
Z9 87
U1 1
U2 37
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB 15
PY 2013
VL 138
IS 1
BP 167
EP 174
DI 10.1007/s10549-013-2427-z
PG 8
WC Oncology
SC Oncology
GA 099CX
UT WOS:000315598200017
PM 23393007
DA 2026-01-16
ER

PT J
AU MacPherson, H
   Tilbrook, HE
   Richmond, SJ
   Atkin, K
   Ballard, K
   Bland, M
   Eldred, J
   Essex, HN
   Hopton, A
   Lansdown, H
   Muhammad, U
   Parrott, S
   Torgerson, D
   Wenham, A
   Woodman, J
   Watt, I
AF MacPherson, Hugh
   Tilbrook, Helen E
   Richmond, Stewart J
   Atkin, Karl
   Ballard, Kathleen
   Bland, Martin
   Eldred, Janet
   Essex, Holly N
   Hopton, Ann
   Lansdown, Harriet
   Muhammad, Usman
   Parrott, Steve
   Torgerson, David
   Wenham, Aniela
   Woodman, Julia
   Watt, Ian
TI Alexander Technique Lessons, Acupuncture Sessions or usual care for patients with
SO Trials
LA English
DT Journal Article
AB BACKGROUND: Chronic neck pain is a common condition in the adult population. More  research is needed to evaluate interventions aiming to facilitate beneficial  long-term change. We propose to evaluate the effect of Alexander Technique  lessons and acupuncture in a rigorously conducted pragmatic trial with an  embedded qualitative study. METHODS/DESIGN: We will recruit 500 patients who have  been diagnosed with neck pain in primary care, who have continued to experience  neck pain for at least three months with 28% minimum cut-off score on the  Northwick Park Neck Pain Questionnaire (NPQ). We will exclude patients with  serious underlying pathology, prior cervical spine surgery, history of psychosis,  rheumatoid arthritis, ankylosing spondylitis, osteoporosis, haemophilia, cancer,  HIV or hepatitis, or with alcohol or drug dependency currently or in the last 12  months, or actively pursuing compensation or with pending litigation.The York  Trials Unit will randomly allocate participants using a secure computer-based  system. We will use block randomisation with allocation to each intervention arm  being unambiguously concealed from anyone who might subvert the randomisation  process.Participants will be randomised in equal proportions to Alexander  Technique lessons, acupuncture or usual care alone. Twenty 30-minute Alexander  Technique lessons will be provided by teachers registered with the Society of  Teachers of the Alexander Technique and twelve 50-minute sessions of acupuncture  will be provided by acupuncturists registered with the British Acupuncture  Council. All participants will continue to receive usual GP care.The primary  outcome will be the NPQ at 12 months, with the secondary time point at 6 months,  and an area-under-curve analysis will include 3, 6 and 12 month time-points.  Adverse events will be documented. Potential intervention effect modifiers and  mediators to be explored include: self-efficacy, stress management, and the  incorporation of practitioner advice about self-care and lifestyle. Qualitative  material will be used to address issues of safety, acceptability and factors that  impact on longer term outcomes. DISCUSSION: This study will provide robust  evidence on whether there are significant clinical benefits to patients, economic  benefits demonstrating value for money, and sufficient levels of acceptability  and safety. TRIAL REGISTRATION: Current Controlled Trials ISRCTN15186354.
C1 Department of Health Sciences, University of York, York, UK. hugh.macpherson@york.ac.uk
NR 0
TC 0
SN 1745-621
EI 
J9 Trials
PD JUL 12
PY 2013
VL 14
IS 
BP 209
EP 209
DI 10.1186/1745-6215-14-209
PG 0
WC Acupuncture Therapy; economics; Area Under Curve; Chronic Pain; diagnosis; Clinical Protocols; Cost-Benefit Analysis; England; Health Care Costs; Humans; Neck Pain; diagnosis; Pain Measurement; Patient Selection; Physical Therapy Modalities; economics; Predictive Value of Tests; Qualitative Research; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome
UT PubMed:23841901
PM 23841901
DA 2013-07-12
ER

PT J
AU D'Alessandro, E
   de Brito, C
   Cecatto, R
   Saul, M
   Atta, JA
   Lin, CA
AF D'Alessandro, Eduardo
   de Brito, Christina
   Cecatto, Rebeca
   Saul, Maira
   Atta, Jose Antonio
   Lin, Chin An
TI Evaluation of acupuncture for cancer symptoms in a cancer institute in Brazil
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
ID electroacupuncture; complementary; xerostomia; efficacy; trials; pain
AB Introduction Acupuncture has been progressively included in the practice of mainstream medicine in recent decades. The State of Sao Paulo Cancer Institute is a public hospital established in 2008 and its acupuncture service follows the experience and model of several oncology centres in the USA, aiming to optimise the treatment of symptoms such as postoperative pain, oncological pain, neuropathic pain, nausea, vomiting, xerostomia and fatigue induced by chemotherapy. This paper describes the population given acupuncture treatment and the effects of the intervention on symptom management. Methods One hundred and eighty-three patients from our service were enrolled in the study. Baseline and final symptom intensity was recorded using a visual analogue score (VAS) ranging from 0 to 10 cm, with a higher score meaning higher symptom intensity. Results Fifty-four (29.50%) were receiving active treatment with chemotherapy and/or radiotherapy, 29 (15.85%) were receiving hormone therapy and 100 (54.65%) were considered to be in remission. The main symptoms were: oncological pain in 44 (24.04%), chemotoxicity in 34(18.6%), lumbar pain in 53 (28.96%) and chronic postoperative pain in 54(28.4%). The mean (SD) initial symptom score was 7.04 (1.8), which was reduced to 2.56 (2.75) after treatment (p<0.001), an improvement of 63.6% in control of the symptoms. Further analysis of the data showed that the effect was similar in different indications for acupuncture treatment. Conclusions Use of acupuncture may have improved symptom control in patients enrolled in this study.
C1 [D'Alessandro, Eduardo] Sao Paulo State Inst Canc, Dept Internal Med, BR-05403000 Sao Paulo, Brazil.
   [de Brito, Christina; Cecatto, Rebeca; Saul, Maira; Atta, Jose Antonio] Sao Paulo State Inst Canc, Dept Rehabil Med, BR-05403000 Sao Paulo, Brazil.
   [Atta, Jose Antonio] Univ Sao Paulo, Fac Med, Clin Hosp, Dept Internal Med, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo
RP D'Alessandro, E (corresponding author), Sao Paulo State Inst Canc, Av Dr Eneas de Carvalho Aguiar,255 Cerqueira Cesa, BR-05403000 Sao Paulo, Brazil.
EM e.g.dalessandro@gmail.com
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Cohen L, 2008, CURR CLIN ONCOL, V0, PP1, DOI 10.1007/978-1-59745-183-3
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.03.010
   Fonnebo V, 2007, BMC MED RES METHODOL, V7, P0, DOI 10.1186/1471-2288-7-7
   Garcia MK, 2009, HEAD NECK-J SCI SPEC, V31, P1360, DOI 10.1002/hed.21110
   Gartlehner G, 2006, J CLIN EPIDEMIOL, V59, P1040, DOI 10.1016/j.jclinepi.2006.01.011
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   MacPherson H, 2010, ACUPUNCT MED, V28, P83, DOI 10.1136/aim.2009.001370
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P292, DOI 10.1159/000234904
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
NR 15
TC 7
Z9 8
U1 0
U2 21
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD MAR 15
PY 2013
VL 31
IS 1
BP 23
EP 26
DI 10.1136/acupmed-2012-010206
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 109MC
UT WOS:000316371700006
PM 23117345
DA 2026-01-16
ER

PT J
AU Saramago, P
   Weatherly, H
   Manca, A
   Sculpher, MJ
   MacPherson, H
AF Saramago, P.
   Weatherly, H.
   Manca, A.
   Sculpher, M. J.
   MacPherson, H.
TI COMPARATIVE EFFECTIVENESS OF ACTIVE VERSUS SHAM ACUPUNCTURE VERSUS USUAL CARE IN THE MANAGEMENT OF CHRONIC, NON-CANCER PAIN IN PRIMARY CARE
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Saramago, P.; Weatherly, H.; Sculpher, M. J.; MacPherson, H.] Univ York, York YO10 5DD, N Yorkshire, England.
   [Manca, A.] Univ York, Heslington, England.
C3 University of York - UK; University of York - UK
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD NOV 15
PY 2013
VL 16
IS 7
BP A556
EP A557
DI 10.1016/j.jval.2013.08.1456
PG 2
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 242MY
UT WOS:000326247602060
DA 2026-01-16
ER

PT J
AU Garcia, MK
   McQuade, J
   Haddad, R
   Patel, S
   Lee, R
   Yang, P
   Palmer, JL
   Cohen, L
AF Garcia, M Kay
   McQuade, Jennifer
   Haddad, Robin
   Patel, Sonya
   Lee, Richard
   Yang, Peiying
   Palmer, J Lynn
   Cohen, Lorenzo
TI Systematic review of acupuncture in cancer care: a synthesis of the evidence.
SO Journal of clinical oncology : official journal of the American Society of
LA English
DT Journal Article
AB PURPOSE: Many cancer centers offer acupuncture services. To date, a comprehensive  systematic review of acupuncture in cancer care has not been conducted. The  purpose of this review was to evaluate the efficacy of acupuncture for symptom  management in patients with cancer. METHODS: Medline, Embase, CINAHL, Cochrane  (all databases), Scopus, and PubMed were searched from inception through December  2011 for prospective randomized clinical trials (RCT) evaluating acupuncture for  symptom management in cancer care. Only studies involving needle insertion into  acupuncture points were included. No language limitations were applied. Studies  were assessed for risk of bias (ROB) according to Cochrane criteria. Outcomes by  symptom were designated as positive, negative, or unclear. RESULTS: A total of  2,151 publications were screened. Of those, 41 RCTs involving eight symptoms  (pain, nausea, hot flashes, fatigue, radiation-induced xerostomia, prolonged  postoperative ileus, anxiety/mood disorders, and sleep disturbance) met all  inclusion criteria. One positive trial of acupuncture for chemotherapy-induced  nausea and vomiting had low ROB. Of the remaining studies, eight had unclear ROB  (four positive, three negative, and one with unclear outcomes). Thirty-three  studies had high ROB (19 positive, 11 negative, and three with both positive and  negative outcomes depending on the symptom). CONCLUSION: Acupuncture is an  appropriate adjunctive treatment for chemotherapy-induced nausea/vomiting, but  additional studies are needed. For other symptoms, efficacy remains undetermined  owing to high ROB among studies. Future research should focus on standardizing  comparison groups and treatment methods, be at least single-blinded, assess  biologic mechanisms, have adequate statistical power, and involve multiple  acupuncturists.
C1 University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0462, Houston, TX 77030, USA.
NR 0
TC 0
SN 1527-775
EI 0732-183
J9 J Clin Oncol
PD JAN 24
PY 2013
VL 31
IS 7
BP 952
EP 60
DI 10.1200/JCO.2012.43.5818
PG -892
WC Acupuncture Therapy; Antineoplastic Agents; administration & dosage; Anxiety; etiology; Evidence-Based Medicine; Fatigue; etiology; Hot Flashes; etiology; Humans; Intestinal Pseudo-Obstruction; etiology; Mood Disorders; etiology; Nausea; etiology; Neoplasms; complications; Observer Variation; Pain; etiology; Pain Management; methods; Radiotherapy; adverse effects; Randomized Controlled Trials as Topic; Sleep Wake Disorders; etiology; Treatment Outcome; Xerostomia; etiology
UT PubMed:23341529
PM 23341529
DA 2013-01-24
ER

